nct_id,brief_title,page_rank_score_brief_title,page_rank_score_brief_title_summary_combined
NCT01762020,Barrier Film vs. Standard Skin Care in Preventing Dermatitis in Women With Breast Cancer Receiving Radiation,0.0002488917053973833,0.00023331520492881467
NCT01728506,An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors,0.00033541082997543047,0.0003599988446807181
NCT01731769,Preventing Seroma Formation After Axillary Lymph Node Dissection for Breast Cancer by Early Vacuum Assisted Closure,0.0002777079586466657,0.0002469590888431395
NCT01785420,Pre Operative Trastuzumab in Operable Breast Cancer,0.000492637956478363,0.0004907001664612074
NCT01758445,Proton Radiation for Stage II/III Breast Cancer,0.00035062887905492,0.0003146212465176986
NCT01752907,Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim,0.00030620278828837614,0.0003249499225073207
NCT01788839,Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma,0.0002908786819887878,0.0002932004562927777
NCT01766297,Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer,0.00026230296743599965,0.0003165066970095992
NCT01784120,A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer,0.0003390277791004133,0.00028642370145354017
NCT01777958,HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy,0.0003601788084883346,0.00036734023984726755
NCT01777802,"Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy",0.00029737748499019463,0.0002006977976180787
NCT01727362,Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy,0.0003147254930321642,0.00039323815083876164
NCT01723774,PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,0.00025803138233746023,0.00030917418219650485
NCT01723592,The Ability of Orally Administered Lactobacillus Species to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy.,0.0002563909547477532,0.00029041372195388177
NCT01723943,Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients,0.0003179116635024527,0.0002830128390614945
NCT01767168,Study to Test the Value of a Pain Modulation Test in Predicting Persistent Postoperative Pain After Breast Cancer Surgery,0.00028150436512093996,0.0002833293909907325
NCT01776008,Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,0.00029987201741185946,0.0003323574576282308
NCT01791998,Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer,0.0002965311674785476,0.00028050954817641357
NCT01791985,AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL),0.00036109997455094627,0.00036624973488274095
NCT01736605,The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Tissue Reconstruction,0.00029821928552751766,0.0002901116943526802
NCT01736306,Biomarkers for Breast Cancer Risk in African American Women,0.00047907240132673805,0.0002846523765655406
NCT01755208,Light-Scattering Spectroscopy for Detection of Breast Cancer,0.00033465643631217217,0.0003301860992214525
NCT01795612,Adapted Physical Activity Effect on Aerobic Function and Fatigue at Home in Patients With Breast Cancer Treated in Adjuvant or Neoadjuvant Phase,0.0003054701824413359,0.00035539482874222776
NCT01740271,A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients,0.0003724099217932551,0.00035819051540782816
NCT01740323,Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy,0.0003479338237059433,0.000340823567308691
NCT01740427,A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2),0.00031893724418684234,0.0003338496816398832
NCT01741883,Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients,0.0003182899726129031,0.00038582629994110676
NCT01732939,Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer,0.00033741808451625454,0.0003579224624548822
NCT01729884,Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer,0.0003084778781041716,0.0003384223948279729
NCT01729832,Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer,0.0002966737827500374,0.00027866348046140293
NCT01737970,A Study to Correlate Ultrasound Elastography With Histopathology to Monitor the Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy,0.0003124861045306118,0.00040727043602292447
NCT01779206,ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer,0.00028492825021142135,0.0004089361719294408
NCT01779050,Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,0.00030737518710904693,0.00036380052580091844
NCT01789684,Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients,0.0002992718224090056,0.00022583751233945827
NCT01790399,IDENTIFICATION OF SENTINEL NODE(S) IN BREAST CANCER,0.00033408787551537255,0.00038638557214859217
NCT01792726,A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.,0.00027885907979125326,0.00026616984299394604
NCT01706016,Local Treatment by Thermic Destruction of Primitive Breast Cancer,0.00037067954556672597,0.00035575819862531435
NCT01724606,Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),0.00026347096531559533,0.0003352791861285579
NCT01724866,Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients,0.0003338048838283126,0.00036269918393595015
NCT01724242,Vaginal DHEA for Women After Breast Cancer,0.0003341890573346378,0.00025000626440342596
NCT01743573,"Effects on Physical Fitness, Immunity, and Quality of Life of Yoga Training in Breast Cancer Survivors.",0.00024750768031336267,0.00026700640357410016
NCT01771666,Pilot Indocyanine Greenâ„¢ Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer,0.0002440232811048538,0.00020324647097820915
NCT01708798,Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer,0.0002860141276130642,0.0003555515841349753
NCT01716247,Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer,0.0002937150915530162,0.0003071671303263127
NCT01797354,Impact of a Group Intervention on Breast Cancer Patient's Adjustment and Emotion Regulation at the End of Treatment,0.0003158382747522459,0.00032789583302800923
NCT01799031,Educational Intervention for Reducing Work Disability in Breast Cancer Survivors,0.0003336142873953629,0.0003458693882822503
NCT01764789,Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer,0.00031804641031841374,0.0003904610860902064
NCT01764802,Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer,0.0003686261597104539,0.0004080175194364814
NCT01780064,Psychosocial Support to Facilitate the Return to Employment of Women With Breast Cancer,0.00046854042245142495,0.0004176777083275576
NCT01753908,Broccoli Sprout Extract in Treating Patients With Breast Cancer,0.00035132704098508546,0.0003280988106673993
NCT01754519,Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery,0.0002853403126020945,0.00038970152710385357
NCT01772472,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),0.00034030742520120945,0.0003684946294105333
NCT01796444,Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node,0.0002634498211482629,0.0002925913290708739
NCT01796041,Intraoperative Imaging of Breast Cancer With Indocyanine Green,0.00033389761662379683,0.00024729068527580794
NCT01763931,DIG-HIF1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer,0.00048072891205396695,0.0004940033412727351
NCT01793948,Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer,0.00029031560626509214,0.00029830539866661937
NCT01775514,"A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics",0.0002959142527078764,0.00032282654853656894
NCT01775085,Group Interventions for Breast Cancer Survivors,0.000336021662230345,0.00030393063075789595
NCT01734499,The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors,0.0002865671539424316,0.0003066473166268298
NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,0.0002885167015792438,0.00035041003694978476
NCT01757327,LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer,0.0003552266619724183,0.0003602413793321398
NCT01781338,Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer,0.00028492825021142135,0.0004089361719294408
NCT01725386,An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer,0.000297479001012668,0.00036623043967076426
NCT01709370,"Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women",0.0002560616013077288,0.0003569056041235471
NCT01782274,Proteome-based Immunotherapy of Brain Metastases From Breast Cancer,0.00033726623893215837,0.0002645289688156496
NCT01742975,Efficacy Study of Ifabond in Breast Cancer Surgery,0.0004134109314189121,0.0002779194744183408
NCT01717131,Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node,0.0002634498211482629,0.00026114662019547296
NCT01745965,"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.",0.00030266841075464365,0.00023799507212049104
NCT01730833,"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer",0.00031802216318370944,0.00036602855377167675
NCT01738685,Intervention to Improve Self-Care of Symptoms in Breast Cancer Survivors on Adjuvant Endocrine Therapy,0.0002624849153774959,0.00019834923789301698
NCT01750073,Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,0.0003236619918136821,0.00037571301382211003
NCT01750164,Patient Derived Breast Cancer Xenografts,0.00035153703948022694,0.00038315910909499166
NCT01712815,PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer,0.00034044529778396105,0.00040383854461615676
NCT01712893,"Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer",0.00034062560943241675,0.0003046413894457209
NCT01783444,A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.,0.0002978289685168476,0.00033359401582660624
NCT01783756,"Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",0.0002626050815938648,0.00033220486200074233
NCT01702571,A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment,0.00031069525134510656,0.00037656351223409017
NCT02890316,Assessment of Fatigue During Radiotherapy for Breast Cancer With and Without Homeopathy Treatment,0.0002763103548200187,0.0003063080865111764
NCT02890082,"Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer",0.00024312902496473684,0.0002863526277263439
NCT02866994,Project Connect Online: An Internet-based Intervention for Women With Breast Cancer,0.00034066895146678673,0.00021964380266817655
NCT02895178,Lifestyles Of Health And Sustainability for Breast Cancer Survivors,0.0004705397055103936,0.00037273564771235143
NCT02895724,Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial,0.0002827195979881648,0.00037411949462367564
NCT02876640,Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer,0.0003235839069261928,0.000331779747589335
NCT02876627,Effect Aerobic Training on Women With Breast Cancer After Chemotherapy,0.00036398186416595915,0.00027654039625689495
NCT02876497,Study of Trans-tissular Migration of Macrophages Associated to Human Breast Cancer,0.00032305231578171636,0.000262148858479718
NCT02855775,Monoclonal Antibodies Elimination in Breast Cancer Patient,0.00031425945202650813,0.00034858427226767003
NCT02860000,"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",0.0003155585535244815,0.0003424324279411284
NCT02825810,Cervical Motor Control in Long-term Breast Cancer Survivors,0.0003339943804594855,0.0002869557916991224
NCT02896504,"Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients",0.0003134680124014576,0.0003617408450039683
NCT02836093,Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment,0.0003364731709825148,0.00038305971404517053
NCT02817724,Integral Strategy to Supportive Care in Breast Cancer Patients,0.0003519903524224871,0.00040931235770152384
NCT02817334,A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery in Breast Cancer,0.0002829549568688705,0.0002639576010653539
NCT02863146,Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer,0.00029704839721916534,0.00034405682009525156
NCT02844335,Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer,0.0002815167696474308,0.00040616368613990143
NCT02879513,Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy,0.00032558134465104194,0.000309982036001778
NCT02875626,Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer,0.0002541679708177668,0.0003313329171185071
NCT02875951,"Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer",0.000335823157715553,0.0004100988783935534
NCT02819921,Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen,0.000280260399478375,0.00035696564718774474
NCT02804308,Combined Training on Body Composition of Postmenopausal Women Undergoing Treatment for Breast Cancer,0.00028664326794187924,0.00022667202650394894
NCT02840344,Couples-Based Mindfulness for Young Breast Cancer Survivors,0.0004705417050958934,0.00024447543589686674
NCT02840890,Osteopathy and Prevention of Gastrointestinal Side Effects in Women Treated for Breast Cancer,0.00025421783228702066,0.0002642095553736731
NCT02802098,Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer,0.000272564779591772,0.0002753999497543545
NCT02802748,Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA),0.0003600486318759487,0.0003852958659718833
NCT02802826,Studying Tailored Exercise Prescriptions in Breast Cancer Patients,0.0003552600187271638,0.00036913048497430964
NCT02850419,Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients,0.00038061690634256764,0.0004337071888212586
NCT02850939,Improving Adherence to EHT Among Breast Cancer Patients,0.0006150176815075327,0.00032251777965515974
NCT02894398,"Efficacy/Quality of Life Study of Postmenop. Women With Advanced Breast Cancer, Treated With Letrozol and Palbociclib",0.00030337920386813125,0.0003729895120710702
NCT02834494,"Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave),",0.00033152655661181486,0.00032524294594368796
NCT02888366,A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer,0.0003229086720006605,0.0002633601000995098
NCT02859168,Myofascial Induction in Breast Cancer Survivors,0.0004691063296756671,0.00025024158675448604
NCT02816125,Effects of Omega-3 Fatty Acids on Risk Factors for Breast Cancer in Pre-menopausal Women,0.0002803330376867803,0.00018577201260938994
NCT02884284,Prospective and Retrospective Breast Cancer Database,0.0003338855827944646,0.0002479697935708807
NCT02808598,Breast Cancer Trials Education Program,0.0003400278477302595,0.00036700643619844717
NCT02807597,LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer,0.0003010103844193912,0.00030531237460882445
NCT02806817,ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism,0.00033389441605054227,0.0003287555019972579
NCT02806544,Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country,0.0002754261647404373,0.00030369395072760434
NCT02800317,RISAS Procedure in Node Positive Breast Cancer Following NAC,0.00029742211709086667,0.0002611372183413079
NCT02869607,Institut Paoli Calmettes Breast Cancer Database,0.000468959289267398,0.000531703526490283
NCT02848989,Qigong For PPSP In Breast Cancer Pain In Breast Cancer Survivors,0.00033583324595528566,0.0002403277677301684
NCT02803593,To Enhance Breast Cancer Survivorship of Asian Americans,0.0008984903380354321,0.0003790124213111939
NCT02858856,Clinical Trial of Deciten Granule on Immunity of Breast Cancer Patients,0.00031641155096181556,0.00040707881314280326
NCT02858934,Feasibility Study of Accelerated Preoperative Radiotherapy for Early Breast Cancer,0.00034835570185634383,0.0003345540789756075
NCT02830282,Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer,0.00027375349244500947,0.0003326476625500967
NCT02820961,Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,0.00027967524724101115,0.0003249106571868084
NCT02833766,Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer,0.0003223197700314325,0.0002894858943497253
NCT02833233,A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer,0.00030649785325450614,0.00043598851982466704
NCT02846389,Trial of Exercise to Reduce Cancer Related Fatigue in Breast Cancer,0.000262237109868704,0.0003034409891719552
NCT02846428,To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer,0.0003055255146789043,0.00033589849541999876
NCT02831582,Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer,0.0003001174543226376,0.00029926196620239933
NCT02831530,Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients,0.0003470847659549578,0.00039784147150160725
NCT02831439,A Statewide Intervention to Reduce Use of Unproven or Ineffective Breast Cancer Care,0.00047844215270982453,0.00034433234648196626
NCT02827370,CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer,0.00027493492824339047,0.0004219484950032738
NCT02861703,Online vs In-Person Lifestyle Intervention for Weight Management and Improved Quality of Life in Breast Cancer Survivors,0.00024848449429891136,0.0002654837688706491
NCT02861859,Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study,0.000342554044628045,0.00037695815324869807
NCT02898376,Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer,0.0002618214152363695,0.0002782491576371684
NCT02839668,The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC),0.0003147610862091466,0.00027192108852666105
NCT02897934,CWI and Discharge After Breast Cancer Surgery,0.00035314426160169403,0.0002322759385942654
NCT02829021,Dynamic Infrared Thermography in Breast Cancer Diagnostics,0.000341636229590435,0.0003393788149212944
NCT02829008,Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients,0.0003058863382559653,0.0002309030102220943
NCT02826512,"A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients",0.0003369168949821101,0.000283716752269703
NCT02838225,DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer,0.00038600093840558355,0.00045233858590604817
NCT02838823,Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer,0.0003163340256895632,0.00039799911761877286
NCT02838173,Serratus Plane Block for the Prevention of Chronic Pain After Breast Cancer Surgery,0.0002670072474321477,0.0003302082186338976
NCT02882581,"Metformin in Breast Cancer, Visualized With Positron Emission Tomography",0.0003399541051220903,0.00021620082085595723
NCT02867644,Conversational Hypnosis in Women Undergoing Imaging for Breast Cancer,0.0003387099854702154,0.0003212497598831492
NCT02810093,Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis,0.00027661035102555384,0.0002043335895080765
NCT02810873,Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer,0.0003205065169396646,0.0003013407162690577
NCT02810743,Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer,0.00047621775402300004,0.00037518635516265114
NCT02870699,Efficacy of EvonailÂ® Solution in the Prevention of Nail Damage Induced by Docetaxel in Patients With Breast Cancer.,0.0003220435648834394,0.0003286096914565773
NCT02878057,Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer,0.0003756032458185828,0.00035099498274144766
NCT02856503,Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors,0.0002526434858300304,0.00022475936248878911
NCT02889458,Hong Kong Breast Cancer Study,0.0005580027294853632,0.00031292531702950885
NCT02889874,EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer,0.00034913047687828877,0.00019695955160012953
NCT02805153,PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy,0.0003321759119235337,0.0004933297259833022
NCT02805205,PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia,0.0003051456242965016,0.000410828384911549
NCT02871167,Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation,0.00025527977775896934,0.00031778884620696485
NCT02871388,Addressing Modifiable Breast Cancer Risk Factors With Project CONECT,0.00027740478617519664,0.00019167943561978362
NCT02872103,Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,0.000301225770043335,0.0004451197488741617
NCT02872064,Treatment of Primary Breast Cancer Using PDT,0.0005240256729824867,0.0005151231325093867
NCT02824016,Evaluation of Hypothyroidism Incidence After Breast Cancer Supraclavicular Irradiation,0.00026679337125140145,0.0002468958993045534
NCT02865148,Behavioral Symptom Management Program for Breast Cancer in Singapore and The US,0.000281801580435234,0.0002732556347333884
NCT02893761,Bergonie Institute Breast Cancer Database,0.000468959289267398,0.0003244497630243825
NCT02862990,Evaluation of the Attitude of Pre Menopausal Women With Breast Cancer Faced With the Risk of Fertility Loss Caused by Chemotherapy,0.0002637893542468065,0.00031351362086903405
NCT02842658,Exercise Preconditioning and Breast Cancer Cardiotoxicity,0.00028143784586763906,0.00030116118771908766
NCT02842099,Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer,0.00028287874397473167,0.0004122040013136313
NCT02823015,Acute Pain Trajectories and Persistent Pain After Breast Cancer Surgery,0.0002934177620032404,0.00019104494793903542
NCT03101683,Radiotherapy After Mastectomy for Breast Cancer Patients at Increased Risk of Local Recurrence,0.00030875862060916715,0.0003500919567237109
NCT03104595,Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer,0.00027736591304998627,0.0003333416176017119
NCT03106350,Symptoms Experienced and Quality of Life in Breast Cancer Receiving Radiotherapy,0.00026403515743916953,0.0002755336936492207
NCT03102866,Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer,0.0003001148506452165,0.000349900479610132
NCT03105440,Innovation Oncological Rehabilitation: Applicability of the Different Techniques Physiotherapeutic Post Breast Cancer,0.0004695259990623425,0.0003168921997262382
NCT03105076,Impact of Decision Aids on Breast Cancer Surgery Choice: A Randomized Controlled Trial,0.000292611132666115,0.00025054305648004513
NCT03100981,Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer,0.0003354109056273408,0.00032280544402997756
NCT01557478,Melatonin as Adjuvant Therapy in Breast Cancer Patients,0.0003538883009661406,0.0004140554359412392
NCT01545648,Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer,0.00033533140869744364,0.00033809841376540714
NCT01582685,Exercise in Breast Cancer Survivors,0.0004754606381545852,0.00018870303025262758
NCT01582971,Home-Based Symptom Management Via Reflexology for Breast Cancer Patients,0.0003143258336990154,0.0003176875045658666
NCT01528826,Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial,0.0002591555164467881,0.0003436258466414026
NCT01528345,"Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",0.0003262266680078361,0.00026490097321362155
NCT01517945,Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence: An Intervention Development Study,0.0002707332540548893,0.00026616541693083915
NCT01592825,PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors,0.0002876616218595366,0.00033109790822096824
NCT01511276,The Effects of Equivalent Weight Loss With or Without Exercise Training on Breast Cancer Risk (SHAPE-2),0.0002830832281395709,0.0002493256978433545
NCT01580800,National Breast Cancer and Lymphedema Registry,0.00033805288625550115,0.0003030376382319474
NCT01560416,Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,0.00033765827518483186,0.00036188963040511017
NCT01577420,Reflexology: An Intervention for Advanced Breast Cancer,0.00030872917725367343,0.00027227852041293793
NCT01510964,The Involvement of Breast Cancer Patients During Oncological Consultations,0.0004313854709002358,0.0003404041732093868
NCT01599039,Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema,0.0002767606299522382,0.00026436564734428096
NCT01537536,Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer,0.00027836765755190427,0.000321795971780344
NCT01542203,Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer,0.00024677613107834895,0.0002562291462085062
NCT01542216,Evaluation of Nutrition and Metabolism in Breast Cancer Patients,0.0003212273155057156,0.00030482015880127896
NCT01569087,Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer,0.0003250140008601414,0.000328529969807587
NCT01520103,Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer,0.00031230479542412203,0.0003928935476129237
NCT01596530,Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment,0.00027264272243985297,0.00037517848745328807
NCT01596439,A Prospective Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive Function of Breast Cancer Patients,0.0003403437768064771,0.0004028767118232878
NCT01559194,Low Fat Versus Protein Sparing Diet for Weight Loss & Impact on Biomarkers Associated With Breast Cancer Risk,0.00024120435049786388,0.00027422282225133486
NCT01583426,Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto),0.00028873285840702345,0.0003611626498126602
NCT01555645,Stress Management in Breast Cancer Patients,0.0003539377351983161,0.0003183731469008943
NCT01521676,Predictive Clinical and Biological Parameters in Breast Cancer,0.0002793273457917946,0.00041701357163203927
NCT01521000,The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient,0.00030016885913429963,0.0003734213964018297
NCT01521741,Prospective Analysis of Symptoms and Lymphedema in Patients Following Treatment for Breast Cancer,0.00034198129039980543,0.0003408854549281207
NCT01506466,Weight Variation During Chemotherapy in Breast Cancer Patients,0.0003737451456968707,0.00033434942144519315
NCT01502592,"Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer",0.00026152653875872577,0.0003327411980925045
NCT01566721,A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer),0.00033110929983540363,0.00030122945888519473
NCT01566799,Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer,0.00031400258540641726,0.00033580729280398915
NCT01567137,MR Characterisation/Localisation of Breast Cancer,0.0008984903380354321,0.00020224742600016084
NCT01564368,DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy,0.00034058654968472627,0.00039183290422454046
NCT01562288,Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab,0.0003431914999484975,0.00040890011123384583
NCT01562873,Ruxolitinib in Patients With Breast Cancer,0.0004314793780674046,0.00032451494240079003
NCT01558258,A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors,0.0002835226372540512,0.0002946294414747191
NCT01546649,A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naÃ¯ve Patients With Premenopausal Breast Cancer,0.0003212123354866099,0.0003014713989528995
NCT01540955,Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors,0.0002840263538293971,0.0002890851080938362
NCT01540110,Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses,0.00031037020431212085,0.00031997227458867094
NCT01565499,Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer,0.00030932255367971276,0.0003623422030369975
NCT01565083,A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer,0.00031056074631116216,0.0002836471507183527
NCT01500577,A Prevention Trial in Subjects at High Risk for Breast Cancer,0.0003429898738854906,0.0002270258572406197
NCT01593020,Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2,0.0003023471076891213,0.0003131950603843691
NCT01591915,A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer,0.0002441632699358828,0.00031535481839269964
NCT01547741,Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer,0.0002803904248546991,0.00028935750019333804
NCT01563211,Predictive Model of Therapy Outcomes in Breast Cancer Patients,0.00038038156137627126,0.0003852024633832024
NCT01527487,Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer,0.00027475267033364,0.0003263248467185927
NCT01572883,Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer,0.0003149266581585399,0.00040264732033605186
NCT01572038,A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (PERUSE),0.00030036807808209756,0.0003285439662402481
NCT01508546,Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer,0.00029313814248376065,0.00025980764680609455
NCT01508572,VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer,0.00028160663413607937,0.0002677430442897855
NCT01553903,Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not,0.00030531742003925494,0.00035549996020831304
NCT01530607,"Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer",0.00026868408921082595,0.0002688761436456819
NCT01530373,Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients,0.00031449102599367495,0.0002891626788847512
NCT01561443,LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer,0.00029833878110401506,0.0003454646066267205
NCT01568346,Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy,0.0002605979328780354,0.00028889309626909917
NCT01597921,A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer,0.000295886741550421,0.0004192452752421847
NCT01597999,Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer,0.00025496944736582897,0.00030525602862149147
NCT01597193,Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer,0.00039814328260548795,0.00036148249015663717
NCT01598077,"A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer",0.00029095940787027036,0.00026513549567519463
NCT01581619,External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks,0.00027681751005062484,0.0003438145228871174
NCT01544504,Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy,0.00034031645350944773,0.0003379357531742546
NCT01554943,Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients,0.0003054912267282473,0.000271269668865202
NCT01589861,"Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer",0.0002864443480210845,0.0003259220890161063
NCT01589367,Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer,0.00026863245328372646,0.00023597583096911988
NCT01556243,Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer,0.0003629238239124959,0.0003494052024511626
NCT01552655,Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT,0.000283203871468168,0.00027403729663182797
NCT01503697,The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer,0.0003192232484312169,0.00029199531137135456
NCT01503190,The Immune System's Response to Young Women's Breast Cancer,0.0003424116730275141,0.0005528869037740448
NCT01503905,Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients,0.00034708213167139733,0.00037901603172591804
NCT01503034,Pregnant Women With a Breast Cancer Diagnosed Between 2000 and 2014,0.000341636229590435,0.000470571698877623
NCT01548209,Effects of a Dexmedetomidine on Quality of Recovery 40 and Postoperative Nausea and Vomiting in Breast Cancer Surgery,0.00026405536875482173,0.0002678152077117972
NCT01548677,Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer,0.0003989341533579574,0.0003269095238296755
NCT01594398,Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer,0.00029115527515704166,0.00028712876477533604
NCT01594177,Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy,0.0003377375985525789,0.0003982446572427886
NCT01594216,Ruxolitinib in Estrogen Receptor Positive Breast Cancer,0.00033569339521012214,0.00032456280600890786
NCT01501656,Epigenetic Testing for Breast Cancer Risk Stratification,0.0004689720877894939,0.00030867576993307504
NCT01539876,Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel,0.00032244476629855463,0.00036962705790276464
NCT01539317,Therapy to Prevent Sexual Pain in Breast Cancer Survivors,0.00030731785415285715,0.00024438420742509413
NCT01504789,Part II: Exercise in Hispanic Breast Cancer Survivors,0.0004754606381545852,0.0003907281672409582
NCT01513408,Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy,0.00024180038135791372,0.0003301256195478528
NCT01513356,Pharmacodynamic Study of BKM120 in Breast Cancer,0.0005580027294853632,0.00028757804019371183
NCT01513278,Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer,0.00027827861661819777,0.0003146668033971371
NCT01532232,Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix),0.00031341384884400975,0.0003153459284420494
NCT01532960,Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer,0.00029322732775422796,0.0003358325847906891
NCT02203552,Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer,0.00031333821499834614,0.0003274018737285657
NCT02203565,Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy,0.00036268819618344173,0.0003156359035004145
NCT02299635,A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations,0.00037549308972926353,0.00041046220812218865
NCT02235051,Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors,0.0002913996902913282,0.0002682077965708608
NCT02289365,Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients,0.0003520988525157166,0.00031838302960869185
NCT02257775,Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer,0.00038049595538679817,0.0003469437517269177
NCT02216786,A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer,0.0003031549286082788,0.00035818061456777275
NCT02291913,Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,0.00028584924439374956,0.0003589679951525419
NCT02251353,Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients,0.0003018615021452832,0.0002553620175965603
NCT02271828,Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy,0.0003277140847511432,0.00035236366634797844
NCT02255240,LEVEL UP: Video Games for Activity in Breast Cancer Survivors,0.00033674050686920143,0.00032647660948506867
NCT02222337,Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers,0.00047844215270982453,0.0002832902956265155
NCT02249208,Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide for Breast Cancer Patients After Neoadjuvant Treatment.,0.0003269922252228093,0.0003309917326809819
NCT02272335,Facilitating Adjustment in Low Income Black Women With Breast Cancer,0.00033551820123653827,0.00026544374294418244
NCT02215876,Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer,0.00028215273909789116,0.0003304320004149221
NCT02215083,L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer,0.0002912411341074566,0.0003178417125972644
NCT02270931,A Prospective Longitudinal Breast Cancer Study,0.0005580027294853632,0.0004333482554930002
NCT02270372,Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer,0.00031318379812295274,0.0003071019848841739
NCT02270580,Komen Breast Cancer Survivor Health Screening Promotion Project: Staying Healthy,0.0003356559843338843,0.0002563513571044597
NCT02286362,An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer,0.0003579052810997816,0.0003500633131107896
NCT02219789,Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,0.0003311896829452597,0.00038017688406740086
NCT02204098,Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,0.00030800017109374145,0.00030456904205127927
NCT02204462,FBnTP Imaging of Breast Cancer,0.0004759151026646897,0.00025707343441476227
NCT02225652,"A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.",0.00027760794479409466,0.0003747950806186421
NCT02275403,Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma,0.00025528840278255725,0.0003505737875014368
NCT02275871,Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer,0.000246364219722341,0.0002916129258637885
NCT02252887,"Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy",0.00027818824703498753,0.0003621692038961834
NCT02276404,Preoperative Relaxation Training and Acupuncture to Minimize Perioperative Symptoms in Breast Cancer Patients,0.0003176898003216073,0.00033762404979705956
NCT02229084,Vaccination of High Risk Breast Cancer Patients,0.0003561819543994293,0.00039348010164115836
NCT02243397,Molecular and Cellular Analysis of Breast Cancer,0.0003349249765172705,0.0003488168039014465
NCT02243163,Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy,0.00032571726996017823,0.0004008056168317086
NCT02206984,Endocrine Response in Women With Invasive Lobular Breast Cancer,0.0003424071183170279,0.00037885445967493676
NCT02278120,"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",0.0003089019140943517,0.00033747169410957943
NCT02278965,Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer,0.00026215229323075373,0.00030029434478108936
NCT02244593,FAST MRI Study in Breast Cancer Survivors,0.0005580027294853632,0.0003032887573856343
NCT02244580,"Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit ""MammaTyperTM""",0.0002536366850537658,0.00027046454914398266
NCT02290782,TARGIT-C(Consolidation) Prospective Phase IV Study of IORT in Patients With Small Breast Cancer,0.00039791208818038416,0.0003557437398192615
NCT02279108,Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer,0.0003200093591261254,0.0002626073413207578
NCT02227082,Olaparib and Radiotherapy in Inoperable Breast Cancer,0.00034769206010352576,0.00036043143248417356
NCT02297412,Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel,0.0003284099507092215,0.0003640793063001011
NCT02297438,A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4],0.00031845931687207024,0.0003338496816398832
NCT02297698,Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,0.0003065755909079789,0.00038311208671776764
NCT02297230,Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,0.00030199043279614574,0.000354751489441791
NCT02236000,A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,0.0002881512586152239,0.000324546466026175
NCT02236806,Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab,0.00030932854392113143,0.0003167017551426111
NCT02269813,PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe),0.0003541540347567701,0.0003674685719158388
NCT02269696,"The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients",0.0002973419307766511,0.00033690327786415654
NCT02296801,A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,0.0002992660253410851,0.00031408941676214214
NCT02266173,Observational Study of Pertuzumab Safety in Participants With Breast Cancer,0.0003268500321034185,0.00033110787662295145
NCT02266602,Intraoperative Radiation Therapy in Early Stage Breast Cancer,0.0003492518412452544,0.00035638803015352905
NCT02207335,Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer,0.0003334228715094608,0.0002842518213045012
NCT02207179,Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology,0.00033842717099000425,0.00028937914238699183
NCT02260531,Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases,0.0003262565091524138,0.0003887108564939236
NCT02250118,Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer,0.0002542776870351324,0.0003638563914244582
NCT02294565,VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer,0.0002972341019506603,0.0003115340319993461
NCT02273973,A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),0.0002866524207899521,0.00034904406014782554
NCT02261389,Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET,0.0002893472978679013,0.0002579228441666182
NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,0.00030572646662257986,0.00031979776876059097
NCT02240472,Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.,0.00023809270683008876,0.0002898561979177312
NCT02240199,Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain,0.0002520440044884289,0.00026183497786741683
NCT02240836,Energy Balance and Breast Cancer Aspects-II,0.00033351553510340407,0.0003004822764835807
NCT02224261,Effectiveness of Physical Therapy on Axillary Web Syndrome After Breast Cancer Surgery,0.0002531447354851449,0.0002386346915891369
NCT02284919,[18F]ISO-1 PET/CT in Breast Cancer,0.00047601038216696324,0.00035330186720948514
NCT02256670,Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial,0.0004790047762716148,0.0003353856928451839
NCT02212834,Surveillance Imaging Modalities for Breast Cancer Assessment,0.00028669050385400895,0.00031434481139692576
NCT02213991,Intraoperative Radiotherapy for Korean Patients With Breast Cancer,0.00043180276032129286,0.00045068815919994894
NCT02287675,Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer,0.0003527176500909294,0.00020659366074866185
NCT02295033,Randomized Boost Versus no Boost Irradiation of Early Breast Cancer,0.0003520907571379065,0.0003130922145589186
NCT02217033,"Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo",0.0002919441426719235,0.00031749887292050307
NCT02281812,Radiofrequency Ablation in Breast Cancer,0.0004688234712564752,0.0003200304472728438
NCT02246621,A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,0.0003036874266337992,0.0004481896224103184
NCT00590109,Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer,0.0004695274796878045,0.00027469444908256266
NCT00590785,"Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)",0.0003069852309513548,0.00025335035855290374
NCT00532285,Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer,0.000324281600383072,0.000337256339738752
NCT00541086,"Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery",0.0002968925203868887,0.00030082478510922323
NCT00591747,Strength Training for Older Breast Cancer Survivors,0.0004691056735212158,0.0003070403404339416
NCT00591851,Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility,0.0002945616373587075,0.0003630831285691589
NCT00518583,Phase II Study in Patients With Operable Breast Cancer,0.0004915603397778765,0.0004770268898970388
NCT00580333,"Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer",0.0002566090341426774,0.00031717967430327533
NCT00534755,Prospective & Retrospective Data Collection of Breast Cancer Cases From 2000 to Present,0.0002770648547288388,0.0002819264131985024
NCT00570323,Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,0.0002721248896133557,0.0003485217006685841
NCT00531973,A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging,0.0002791781801953736,0.00029643123745787286
NCT00542451,Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer,0.000274787200485109,0.00037599393285410546
NCT00516243,Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer,0.00026751305937981464,0.00030365625532376714
NCT00516698,Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer,0.0002471237800970643,0.00032525306627327204
NCT00561119,Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer,0.0002816727448657935,0.0003753907225267786
NCT00574587,"Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",0.0002787674625433962,0.00034420568947448975
NCT00574301,Percutaneous Removal and Margin Ablation for Breast Cancer,0.0003340298559349545,0.00020420952535535005
NCT00574145,Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer,0.0002907510772630744,0.0003554101465588857
NCT00501332,"Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy",0.0003152876328236685,0.0002610865424598721
NCT00539474,"""The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial""",0.0002515939974462569,0.0004600466958450828
NCT00587925,Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer,0.0003248502868233505,0.00033651162535502504
NCT00587340,A Survey of Sleep Problems in Survivors of Breast Cancer,0.0002774267864881068,0.0002784950139458765
NCT00510367,Primary Breast Cancer Occurring Concomitant With Pregnancy,0.00033420943728718283,0.00036572174866815287
NCT00502736,A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.,0.0003235394317448541,0.0002637117641647153
NCT00502684,Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery,0.00026429744340480976,0.0003727032551363396
NCT00572416,Fatigue in Breast Cancer: A Behavioral Sleep Intervention,0.00025860232246622075,0.0002374304394733462
NCT00584142,Mindfulness-based Stress Reduction in Breast Cancer Recovery,0.0002534896602345755,0.00031353467373259003
NCT00584753,Molecular Imaging of Breast Cancer With Breast PET/CT,0.0002845669484058623,0.0002567698801081278
NCT00581256,A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer,0.0002578165134879297,0.0003128930944224576
NCT00563407,Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation Therapy,0.0002981388405427317,0.00035451057436940923
NCT00563953,Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years,0.0003103773982471621,0.0004109813356680102
NCT00566085,New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer,0.0003606043574218945,0.00028802138676987477
NCT00566618,Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis,0.0002704292160784424,0.00033746729680194553
NCT00540852,Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy,0.00025766215522568867,0.0002756301864133349
NCT00540800,BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer,0.00033330904615420123,0.00034172735931865534
NCT00533364,Effect of SBG in Patients With Breast Cancer,0.0006150176815075327,0.000404946907020909
NCT00533338,Weight Gain Prevention for Breast Cancer Survivors,0.00033758247711002007,0.00032109820547427705
NCT00533663,Healing Touch During Chemotherapy Infusions for Women With Breast Cancer,0.00029869222487085396,0.0003253057092583194
NCT00533780,Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer,0.0003054261323351635,0.00024147966139263316
NCT00569049,Molecular Analysis of Breast Cancer,0.00047037320740989097,0.00031046585486975046
NCT00569543,Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Undergoing Treatment for Newly Diagnosed Breast Cancer,0.0002681569174067705,0.0002650446045425075
NCT00500383,Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS),0.0002812080598876203,0.00025200897251623087
NCT00537173,Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer,0.00030890221344782257,0.00029190556547400515
NCT00594477,Intensity Modulated Radiotherapy for Breast Cancer,0.00034769850487249214,0.0002779670545411919
NCT00511459,Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients,0.0003419284203889591,0.0003647891005484845
NCT00559754,A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.,0.0003432145855766478,0.0003049919701367374
NCT00559845,A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer.,0.0003450042676200559,0.00032448091680697445
NCT00559507,Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery,0.00032564378078460784,0.00030476438722104837
NCT00559858,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer,0.0003112078493905914,0.000283217326294321
NCT00582244,Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized Trial,0.0003168627713481537,0.0005000187206797848
NCT00582478,Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients,0.00035476668271884794,0.0004239548454334646
NCT00582322,Genetic Studies in Breast Cancer,0.00047081508236247505,0.00041946265694971425
NCT00582920,Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer,0.00026385766838693986,0.00028341929341124856
NCT00505271,Safety and Efficacy Study Using Rexin-G for Breast Cancer,0.0005580027294853632,0.0003211204662932265
NCT00573495,Multipeptide Vaccine for Advanced Breast Cancer,0.0003698741795285867,0.00038386800908758007
NCT00525161,Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer,0.00034595497728856885,0.00038152031957570324
NCT00525759,Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer,0.00030069260859164727,0.00032068187081353555
NCT00508794,Effects of Yoga in Breast Cancer Patients,0.00043260271346385075,0.00037142006905544476
NCT00508352,Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer,0.00030079345709384096,0.00027249825992239836
NCT00556218,Meditation and Cognitive Function in Women With Breast Cancer,0.0003353605219455964,0.00029788170245752
NCT00556374,Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy,0.0003569645043693079,0.0003487810681852714
NCT00546156,Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer,0.00025528081374318404,0.0003060243012928543
NCT00546104,Phase II Dasatinib Study in Advanced Breast Cancer,0.0003501032912580023,0.0006006191522766438
NCT00571987,Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation,0.0002751911198937011,0.0002903901057251299
NCT00551278,Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer,0.0003340616512796536,0.00039390731804796045
NCT00519545,Prayer as a Possible Adjuvant Treatment for Breast Cancer,0.0003707754310157175,0.0004063911561657528
NCT00519168,"Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival",0.0004691117046371407,0.00030192591419588027
NCT00589238,"Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery",0.00027735351938773176,0.00028426412149431797
NCT00513695,"Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer",0.0003154254629454207,0.000353739500066973
NCT00513292,Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery,0.00027127203270674814,0.00030317813398423904
NCT00513136,Fatigue Intervention Trial for Breast Cancer Survivors,0.00034444523874865157,0.00018613456566930265
NCT00555503,Registry of Mastectomy for Breast Cancer Risk Reduction,0.00027921113413881,0.00022835459272420623
NCT00555841,Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue,0.00047463635589376396,0.0003773799680039709
NCT00555386,"Soy, Selenium and Breast Cancer Risk",0.0003337081239929167,0.0002748598562702057
NCT00555477,Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure,0.00031802790490813364,0.0004455406190694473
NCT00550771,Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048),0.000303120784035926,0.00029407739933400663
NCT00588705,The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer,0.0003351738867954925,0.000260894960332257
NCT00588029,"Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer",0.0002637446521661703,0.0003173125757577376
NCT00524459,Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery,0.00027769858503742405,0.00027814076026507216
NCT00524277,Vaccine Therapy in Treating Patients With Breast Cancer,0.0004323173750780106,0.0003074146832412779
NCT00524849,Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis,0.00031484109034570965,0.0003657888001112576
NCT00544765,"Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer",0.00033806311410547625,0.00035689039804091106
NCT00544505,"Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)",0.00037343530512887646,0.0006482334466618243
NCT00544167,Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer,0.00028651171207372446,0.00034112213584086
NCT00544986,"A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer",0.00029101842829519774,0.00037333825345335517
NCT00535327,Test of Digital Breast Tomosynthesis vs. Regular Mammography in Detecting Breast Cancer in Women Undergoing Diagnostic Mammography,0.00025172544898646856,0.00024797645727272214
NCT00535067,Neuropathic Pain in Survivors of Breast Cancer,0.0004689680023862357,0.0003406007944010669
NCT00535678,Testing Digital Breast Tomosynthesis vs. Regular Mammogram in Detecting Breast Cancer in Women Having Screening Mammogram,0.00027868464663114226,0.0002155483783319166
NCT00535184,Test of Digital Breast Tomosynthesis vs. Common Mammography to Detect Breast Cancer for Women Undergoing Breast Biopsy,0.00025172544898646856,0.00024867866375611166
NCT00535509,Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel Â± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer,0.00028934490453532015,0.0003373117030779451
NCT00530569,Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy,0.00032268894964526657,0.00033056728259135384
NCT00530868,Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer,0.00026123791037087986,0.0003390868798710323
NCT00575978,Hydralazine as Demethylating Agent in Breast Cancer,0.0003335174087506511,0.00034231221427816753
NCT00558272,Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease,0.0002869839519602864,0.0003650805263914589
NCT00558545,"A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer",0.0003229333245662474,0.0003249877193586218
NCT00597454,An Access Delivery Model That Eliminates Barriers to Breast Cancer Care Delivery,0.000250824837521695,0.0002970951210107777
NCT00597597,"Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer",0.0002858042869745342,0.0002915881612648324
NCT00506064,Melatonin Postoperative Sleep Study in Breast Cancer Patients,0.00035170210317716756,0.00022866868902624422
NCT00567554,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",0.0002727926977848611,0.0003804157873665718
NCT00567606,Prevention of Osteoporosis in Breast Cancer Survivors,0.00033758529871801,0.000310546761857871
NCT00579800,"Newer Breast MRI Sequences for the Evaluation of Breast Cancer -FIESTA, Vibrant-DE and IDEAL: Feasibility Evaluation",0.0002890885730587981,0.0003259361506529497
NCT00599105,Angiogenesis in Early Breast Cancer for Prognosis Prediction,0.0003342767615560838,0.00039824291862809247
NCT00536939,"Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer",0.0002632125322159234,0.00036868896119577824
NCT00512993,Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy,0.00034568009411447425,0.0004213057152437036
NCT00527293,Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer,0.0002975635972107008,0.000315739909852001
NCT00527449,Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel,0.00027301237540565436,0.000417230659665935
NCT00504699,Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients,0.00031940124996802694,0.00029500244336245487
NCT00548899,Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer,0.00028176696960634397,0.0004157060341953063
NCT00562458,Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer,0.00030650377226935216,0.0003746038185115971
NCT00562718,Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery,0.0003404946743762776,0.0002975421982571446
NCT00538330,Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer,0.000358878372837862,0.0004272092781076633
NCT00538525,Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer,0.0003159680021259862,0.0004310500476505336
NCT00538343,RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases,0.000298243899060324,0.0004046785327335374
NCT00538395,Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer,0.0002910640884842692,0.00036410844033730886
NCT00576901,A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.,0.00035175725574572496,0.0003478631659999229
NCT02706964,Imaging the Patterns of Breast Cancer Early Metastases,0.0003405207381624728,0.00034823121171042757
NCT02762110,Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer,0.000285608751740387,0.0002222205948040036
NCT02742051,"A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer",0.00027998278417303913,0.00029136710144674077
NCT02742168,99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients,0.00035134750004964157,0.000398350504180842
NCT02786797,Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors,0.00037086753275506786,0.0003234693313287803
NCT02786875,"Diet, Exercise and Vitamin D in Breast Cancer Recurrence",0.00025761066781128313,0.00025959536563822006
NCT02779751,A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,0.00032379947894030196,0.0003214297184818022
NCT02763566,A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer,0.00039453067907617,0.00036120520136078104
NCT02704312,Dosimetric Comparison of Doses in Both Positions (Prone and Decubitus) for Patient With Breast Cancer,0.00031556354063589796,0.00030476733486966233
NCT02710058,Experience of Arab American Women With Breast Cancer: In-depth Interviews,0.0003337063614114562,0.00039765022278226235
NCT02791581,"Cardiovascular Injury, Exercise Intolerance and Fatigue After Adjuvant Chemotherapy for Stage I-III Breast Cancer",0.00025016606504453493,0.000303266206595037
NCT02723877,PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO),0.0002638492700790219,0.0002942228195598318
NCT02734290,Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,0.0002991337453748971,0.0003155473725406071
NCT02749019,Dual Integrin Î±vÎ²3 and GRPR Targeting PET Imaging in Breast Cancer Patients,0.0003208629066744582,0.00032414667072572164
NCT02794064,A Prototype Tri-modal Imaging Device for Breast Cancer,0.00046854042245142495,0.0003250199718161283
NCT02794493,Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer,0.00030857894279332236,0.0002705690997849624
NCT02740491,"Implementation of a ""Remission"" Consultation in the Management of Patients Treated for Localized Breast Cancer",0.000315117954947222,0.00036662311317091817
NCT02754427,Pilot Study for a Prospective Surveillance Program for Rehabilitation Following Surgery for Breast Cancer,0.0002909181846275521,0.00032789321489428726
NCT02797652,Clinical Application of CTDNA in Operable Breast Cancer Patients,0.00035410147757295883,0.0003482440211838939
NCT02797223,"""Impact of Chemotherapy-induced Alopecia on the Quality of Life of Women With Breast Cancer""",0.00030147115168125413,0.00027735888467582035
NCT02716792,A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer,0.00027564688966564226,0.0002595787248587444
NCT02716467,Effect of Intercessory Prayer in Patients With Breast Cancer in Radiotherapy Treatment: Clinical Trial,0.00035006843995307824,0.00033432535789443263
NCT02769104,Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer,0.0002943993903115364,0.0003997695117077861
NCT02712723,"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",0.0002767570167835301,0.0003536991780256658
NCT02712645,A Multicenter Breast Cancer Biospecimen Registry,0.000469531047119882,0.00030676089460245824
NCT02712437,Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer,0.00036336145212289927,0.00034148600989067124
NCT02748746,Early Detection of Lymphedema With Bio-Electrical Impedance Analysis in Patients After Breast Cancer Surgery,0.00031082394868030413,0.00032743857316310724
NCT02789657,BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,0.0003179081891610045,0.00039572104925994815
NCT02789332,Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency,0.00031939477073041864,0.0003052016488756258
NCT02744079,Comparison of Healthy Diets on Breast Cancer Markers,0.0002844646425851026,0.00020069226929780298
NCT02750826,Breast Cancer WEight Loss Study (BWEL Study),0.0005580027294853632,0.0003448694706708834
NCT02750241,Pink Warriorâ€”Support Group Toolkit for Breast Cancer Survivors,0.00033782201413915425,0.00030177231287595145
NCT02746666,Pharmacist's Influence on Breast Cancer Patient Quality of Life,0.0004352097190974083,0.00031546231655742727
NCT02732171,PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer,0.00028245221347476476,0.0003293468039490728
NCT02781805,Pilot Study of Bisphosphonates for Breast Cancer,0.0003939697676078667,0.0002884088027917764
NCT02781051,Increasing Physical Activity Among Breast Cancer Survivors With Depression,0.0002846326154547731,0.0003416309788897061
NCT02781259,Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer,0.0002498021527992141,0.00026284783623763125
NCT02730858,Palliative And Oncology Care Model In Breast Cancer,0.00033989180476455034,0.00030629597560380374
NCT02730091,"A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",0.0003304214987394773,0.0003546773362387953
NCT02725489,Pilot Study of Durvalumab (MEDI4736) in Combination With Vigilâ„¢ in Advanced Breast Cancer,0.000301506840327041,0.0002891580223233997
NCT02725541,Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,0.00036668097636384636,0.0003950617908974342
NCT02725658,Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI,0.00028669551892962253,0.00035002158445988403
NCT02725840,Breast Cancer Lung Late Effects,0.00046953491271344494,0.00025314894171691525
NCT02725606,"Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer",0.00039883257911403267,0.00040935836731483547
NCT02771795,A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC,0.0003324396074341824,0.0004247011513071668
NCT02771756,The Effect of Zhen Qi Shen Capsule Combined With Yu Yi Kang on Breast Cancer and Lung Cancer Patients With Chemotherapy,0.0003321785427214726,0.00040466681422000346
NCT02752659,Reliability and Validity of Self-measured Arm Circumference in Women With Breast Cancer,0.0003341852811293098,0.00022703430266214267
NCT02752893,Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts,0.0003053073922053537,0.000317036468447187
NCT02726477,Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema,0.00028298264723961226,0.0003444434226142655
NCT02776917,"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",0.00029886185855577144,0.00033018498168683986
NCT02702830,MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment,0.0003336229272404715,0.00035598364256344026
NCT02705859,Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study),0.0003452349421402237,0.0003753665164294704
NCT02780401,"Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission",0.00029892980899728737,0.00032667082237230663
NCT02780271,Diet and Physical Activity Changes Among Latina Breast Cancer Survivors,0.0002588908318026061,0.00021290877449558931
NCT02733601,Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria,0.0002873270854528719,0.00028350790492046523
NCT02707471,Improving Well-Being for Breast Cancer Patients,0.0004313890278224732,0.00041750059135631674
NCT02707835,Edema Control in Patients With Breast Cancer-comparison of Manual Lymph Drainage and Epidermis Fascia Taping,0.0002960796926192986,0.00026917099605681385
NCT02790580,Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients,0.00029004804225941233,0.00040971657643773296
NCT02790320,Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer,0.0002979542509630423,0.0004021385560322251
NCT02790021,Lymphaticovenous Anastomosis for Breast Cancer-related Lymphedema,0.00028298264723961226,0.0003565471870082287
NCT02708511,Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer,0.00030316111206681886,0.00035570416600141057
NCT02708680,Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,0.0003249315589939631,0.0003430799711865798
NCT02777164,A Study of the MIRA System for Evaluating Women at High Risk of Breast Cancer,0.00039937849343915134,0.0002590433100571989
NCT02773004,"Prospective Study Assessing EndoPredictÂ® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer",0.0003333523051185776,0.00037276599420648423
NCT02792114,T-Cell Therapy for Advanced Breast Cancer,0.00036856130423470313,0.00038737323338690306
NCT02761642,A Study of Recombinant Human Erythropoietin Beta (r-HuEPO) (NeoRecormon) in Anemic Participants With Breast Cancer Undergoing Chemotherapy,0.0002834086356241433,0.0003564504120688211
NCT02761616,A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer,0.00032354837726656776,0.0003465165732498005
NCT02751606,Nano MRI on 7 Tesla in Rectal and Breast Cancer,0.00046854042245142495,0.00031304361988831434
NCT02751528,"QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer",0.00030163706400276045,0.0004731004046272445
NCT02721147,Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer,0.0003285496786518983,0.00026895379901761536
NCT02770469,Culturally Tailored Educational and Support Program to Increase Quality of Life Among Korean Breast Cancer Survivors,0.0002593876474017768,0.00019539990196001012
NCT02770781,Feasibility Study of the Addition of a Personal Trainer to the Post-Treatment Regimen of Breast Cancer Survivors,0.00033653229527982236,0.00022666956874594057
NCT02718144,Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer,0.0002888575239649161,0.00040980231401866607
NCT02793076,Physical and Emotional Benefits of Group Dance Intervention for Breast Cancer Survivors,0.0002614090805779501,0.0003255136882183112
NCT02774915,Outcome of Pregnancy and Breast Cancer,0.0004691000605511326,0.00019612349619504987
NCT02768415,Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer,0.00028309790890931956,0.00037419970420644297
NCT02768714,Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy,0.00026862218582862635,0.0002193000769836528
NCT02798796,Brazilian Randomized Study - Impact of MRI for Breast Cancer,0.0003267557240662409,0.000477754578610805
NCT02753686,Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy Â± Targeted Therapy,0.0002873511001245878,0.0003180070818183398
NCT02778685,"Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",0.0002925398775648684,0.00035465275451534366
NCT02796755,Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation,0.00024448248950703156,0.0002588426101776538
NCT02772367,Generation of Heart Muscle Cells From Skin Cells of Breast Cancer Patients,0.0002984649058247342,0.0003355691094808434
NCT02772731,Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients,0.00035419555545103436,0.00027175691038547475
NCT02764541,Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),0.00032989603213865544,0.0003912802520811289
NCT02741726,Efficiency of Acupuncture-assisted Anesthesia With Single Acupoint or Dual Acupoints in Patients Undergoing Radical Operation of Breast Cancer,0.00029916226294166953,0.00029465790237998403
NCT02741232,Comparison of Perioperative Opioid Consumption Following Pectoral Nerve Block for Breast Cancer Surgery,0.00024765111994279397,0.000247207662873516
NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,0.0003530761958085265,0.0003863595347100994
NCT02759549,Fatigue in Breast Cancer Patients Undergoing Radiotherapy-eSMART-MH,0.00036547022700225733,0.0003164840901449198
NCT02700386,Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes,0.00031698287034980963,0.00037893019987465684
NCT02738970,A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Early Breast Cancer (EBC),0.00028344194609134865,0.00025784347010828575
NCT02745262,Overall Survival and Disease-free Survival in Breast Cancer Patients Under COS,0.0003526704847124609,0.0003612179149540843
NCT02766530,Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer,0.0003388215104131672,0.0003251837025042052
NCT03041545,Tracking Physical Activity Throughout Chemotherapy for Breast Cancer,0.0003062015343375378,0.00022191374501140553
NCT03091842,Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer,0.00023603844272747165,0.00028020012943621856
NCT03027063,Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.,0.0002612094222158795,0.00028328804961848773
NCT03014076,Immunotherapy Vaccine and Herceptin in Breast Cancer,0.0002819201650435884,0.0003409269719751846
NCT03079219,Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients,0.0003149313760032527,0.0002964253128158785
NCT03005860,Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery,0.0002502644982801129,0.0001941760292086154
NCT03089918,A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain,0.00027020862838173496,0.00023098139631726018
NCT03089502,Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity,0.0002678035864864593,0.0002833160729201444
NCT03077841,Optimizing Preventative Adjuvant Linac-Based Radiation: the OPAL Trial - Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer,0.00030967067271370056,0.00035671405360580626
NCT03077776,Tracking Triple-negative Breast Cancer Evolution Through Therapy,0.0003769141584488225,0.00041125173832674806
NCT03087409,High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up,0.0002585190170156431,0.00024692247588060614
NCT03087461,Bridging the Gap: Incorporating Exercise Evidence Into Clinical Practice in Breast Cancer Care in Ontario,0.00028288940245453935,0.00036494547747827327
NCT03048942,Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer,0.0002994947551430623,0.00036406694717428797
NCT03018080,Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer,0.00030463535225809724,0.0003476908760251298
NCT03006172,"To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",0.0002691189953922578,0.00034619939527989833
NCT03006614,PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer,0.0002814462113911154,0.00031422567012037326
NCT03006055,The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device,0.0002780755829427002,0.0002134257489345125
NCT03078751,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer,0.0002867256148208725,0.00035770375817054275
NCT03078036,"International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study",0.00032879630696132763,0.0002902802819053783
NCT03036943,Fluciclovine (18F) Imaging of Breast Cancer,0.00033842717099000425,0.00028155508675422117
NCT03007979,Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,0.00025737976613069655,0.00028948031924611896
NCT03007992,Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer,0.00035687885461945445,0.0003164958635868915
NCT03046238,Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Breast Cancer Patients,0.0003519424965627456,0.00026734010728498
NCT03088527,"A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer",0.00029572149848685903,0.0003461373030069677
NCT03050398,A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib,0.0002779142460326288,0.0003401622798609274
NCT03050463,Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer,0.0003234576507413598,0.0002546741421485773
NCT03051750,Comparison of Techniques for Breast Cancer-Related Lymphedema.,0.00028544607547758747,0.0004302092216231125
NCT03051659,A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer,0.0002833287800742166,0.00034642098686816597
NCT03051828,Physical Evaluation and Quality of Life in the Practice of Fencing in Breast Cancer Support,0.00025327444826754526,0.00024380485391763961
NCT03051776,Kinesio Taping Versus Compression Garments for Breast Cancer-Related Lymphedema,0.00028298264723961226,0.00032378747281074197
NCT03063619,Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast,0.00033351653542552457,0.0003600188810541066
NCT03000764,RNA and Heat Shock Protein Biomarkers in Radiation-induced Fibrosis in Breast Cancer,0.00025213403793672917,0.0002445511800656775
NCT03000036,Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients,0.0003560429913485078,0.00020669590745771245
NCT03000920,Evaluation of the Short Message Service Effectiveness in the Screening Invitation Strategy for Breast Cancer (USIMaPI),0.00023994894701598706,0.00029972412294039416
NCT03022162,Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer,0.0003255208876476639,0.0002595439542481789
NCT03081234,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer,0.0002822991468311116,0.0003534749861132962
NCT03029182,Simulated-altitude to Optimize Aerobic Exercise Among Breast Cancer Survivors With Limited Mobility,0.00025060599165321575,0.00028848751115108416
NCT03058939,Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer,0.00029213274646395707,0.00031918530722567495
NCT03072992,"""Curcumin"" in Combination With Chemotherapy in Advanced Breast Cancer",0.0002993512121415086,0.0003926022638885756
NCT03072966,Development of Distress Management Algorithms Using Mobile Device Based Health Logs in Breast Cancer Survivors,0.00023657269430420617,0.0002572698166195474
NCT03039140,Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors,0.0002635612636718367,0.0002684290092379967
NCT03039127,Immunostimulating Interstitial Laser Thermotherapy in Breast Cancer,0.0002503403445177352,0.0002595777243652143
NCT03054025,Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors,0.0002575890752481632,0.00029603821655384483
NCT03054363,"Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",0.0002556406373101369,0.00030299878960295557
NCT03017404,A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer,0.0003319669848943009,0.00036541030975434613
NCT03074071,Enhancing Hope Among Patients With Poor-Prognosis Breast Cancer and Oncologists,0.0003141285152420907,0.0002584899929043921
NCT03011060,Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer,0.00027512686945799453,0.000356980659019339
NCT03080155,A Study of the 3D MIRA System in Classifying Women at for Likelihood of Breast Cancer,0.0005580027294853632,0.0002982329963258468
NCT03080428,"Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer",0.00025472983610401266,0.00036956327986727047
NCT03085368,A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin,0.00030209907131559726,0.0002459640609462013
NCT03095352,"A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",0.00032875309668058426,0.0003729174940837372
NCT03003611,Observational Trial on the Impact of Hypnose Used as a Sedation in Oncology Surgery in Breast Cancer,0.00025555012332641495,0.0003292877316115656
NCT03093350,TUMOR-ASSOCIATED ANTIGEN (TAA)-SPECIFIC CYTOTOXIC T LYMPHOCYTES ADMINISTERED IN PATIENTS WITH BREAST CANCER,0.00025413829244151875,0.00034643891687991993
NCT03061773,Physical Training on Patients With Breast Cancer,0.0003583497035032233,0.0004065107990255613
NCT03061175,Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy,0.00030596552808911996,0.0003431756563234734
NCT03010371,Presential Vs Online Group-based Psychosocial Treatment for Breast Cancer Survivors.,0.0003068358468465763,0.0002781299201238258
NCT03086785,"Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer",0.0003499677869654298,0.0003948337532350939
NCT03043794,Study of Stereotactic Radiotherapy for Breast Cancer,0.0003938754897149967,0.0004070071092264024
NCT03052634,RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer,0.00036856130423470313,0.00047050245894671627
NCT03012399,Biobehavioral Effects of Hypnosis During Breast Cancer Surgery,0.00035342746040534386,0.00029925585165536814
NCT03012477,CISPLATIN + AZD-1775 In Breast Cancer,0.0004703820438233301,0.00038690902348709807
NCT03025139,Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness),0.0002505546355708725,0.0003065988923970194
NCT03025035,Pembrolizumab in Advanced BRCA-mutated Breast Cancer,0.00036931413000719054,0.0003167612707632302
NCT03004534,A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201,0.0002837399913290256,0.0003419644326445576
NCT03083288,Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer,0.0002816259211705341,0.0002747325293948071
NCT03075462,A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients,0.00032923422601296537,0.0003456287683274738
NCT03099174,This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,0.0003487254089492863,0.00040938096560071255
NCT03045575,Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer,0.00027535448331330616,0.0003199070920229918
NCT03045653,Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer,0.0002839057049738141,0.0002605600179901322
NCT03002532,Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer,0.00026299124917430046,0.00028104950524953634
NCT03002103,A Trial Evaluating the Efficacy and Safety of EndoTAGÂ®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer,0.00032498878611374947,0.0002812591352242932
NCT03094052,"Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",0.0003080276017750138,0.0003388944195851761
NCT03067389,Combined Breast Cancer Risk Study,0.0005580027294853632,0.000293361090941081
NCT03024580,A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer,0.00030625291087749335,0.0004156445710582362
NCT03024463,The Clinical Significance of Internal Mammary Lymph Node Irradiation in Axillary Lymph Node Positive Breast Cancer Patients,0.0003055390344471457,0.0003819336181357169
NCT03082456,Molecular Breast Imaging in Screening Breast Cancer,0.00033561333458651053,0.0002872192947298328
NCT03065478,Observational STudy to Evaluate the EFfectiveness of OnLifeÂ® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy,0.0003260270672671193,0.00036271699905101695
NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,0.00036894226902428964,0.0003172207077056375
NCT00271661,Presbyopia in Breast Cancer Survivors,0.00046854042245142495,0.0002737701834885689
NCT00296036,Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer,0.0002892172584266525,0.00023830321586478233
NCT00220792,Group Therapy for Primary Breast Cancer,0.00046854042245142495,0.00027495893552660774
NCT00256243,Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer,0.00038964844032935396,0.0005123156587993404
NCT00256360,"Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer",0.00031291504496270905,0.0003228911002930877
NCT00291759,ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.,0.00032053081071297334,0.0003443736431967122
NCT00291135,Protocol for Women at Increased Risk of Developing Breast Cancer,0.00033751513819963493,0.0003029319886367618
NCT00291122,An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer,0.0002530954900002387,0.00022943624901483354
NCT00291083,Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer,0.0002918272308827695,0.00018382998640300988
NCT00291694,Protocol for Women at Increased Risk of Developing Breast Cancer,0.00033751513819963493,0.00021855768233130442
NCT00291096,Protocol for Women at Increased Risk of Developing Breast Cancer,0.00033751513819963493,0.00021057449308423514
NCT00228943,The Role of Serotonin in Hot Flashes After Breast Cancer,0.0002785778657133707,0.00017049130113310485
NCT00255060,Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer,0.0002829982866443111,0.00020601569658292495
NCT00243607,Hydrotherapy Against Menopausal Symptoms in Breast Cancer Survivors,0.0003336113961740093,0.0002815388584662637
NCT00204477,Soy Protein and Breast Cancer Risk Reduction,0.00033522861657013574,0.0001936699877824692
NCT00204490,Soy Isoflavones and Breast Cancer Risk Reduction,0.00027796446977225426,0.00018618067857026664
NCT00293540,Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer,0.00026391210159883074,0.00028944819621372093
NCT00293865,Study of Sentinel Lymph Node Assessment Following Previous Surgical Biopsy for Early Breast Cancer,0.00029280206199366123,0.0003019237557196408
NCT00235235,A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer,0.0003535726110737417,0.000369495294887641
NCT00244959,Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer,0.000273013348095574,0.00025131709904634256
NCT00278837,Avon Foundation Program to Improve Quality of Life in Breast Cancer Survivors,0.0002841429654327505,0.00020074008842965746
NCT00212121,Radiation Dose Intensity Study in Breast Cancer in Young Women,0.00040749124355499123,0.000587714874173103
NCT00212082,Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer,0.00027438284283797193,0.0003631068712711586
NCT00212095,Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer,0.000312118685211823,0.00036501623819040795
NCT00212069,Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer,0.0002782392476833744,0.000272215504125583
NCT00252811,A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer,0.0002910876951773439,0.00028854245150354763
NCT00242203,Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer,0.00029421767033215685,0.0003699175688096891
NCT00208273,Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer,0.00046896449730825576,0.00023576965294807382
NCT00208871,An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall,0.0002585055038711051,0.00030538958847564396
NCT00221221,Physical Activity Promotion in Breast Cancer Survivors,0.00034388036385219194,0.0003272782943968848
NCT00280930,Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer,0.0002975718730076541,0.0003141618848530798
NCT00241046,Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment,0.0002713503426567113,0.00036035095747294105
NCT00241449,A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer,0.00028385583170955817,0.000375707435651517
NCT00214292,Evaluation of Breast Cancer Surgical Margins Using Optical Spectroscopy,0.0002853453348956178,0.0002667861656307643
NCT00263198,PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer,0.0003130147765341547,0.0003553082069410895
NCT00263588,Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer,0.0003406533213857207,0.0003361664756174759
NCT00263211,A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients,0.0003349203413203731,0.0003783800093497179
NCT00263185,High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status,0.00023857879548830428,0.00028788496636245606
NCT00288795,A Randomized Study of Polarity or Massage Therapy to Reduce Fatigue in Breast Cancer Patients During Radiation Therapy,0.0003357684253610156,0.0003576023095783808
NCT00260975,Study of the Effects of Chemotherapy on Memory and Other Mental Functions in Women With Breast Cancer,0.0002850940173447794,0.00026422582414831067
NCT00274469,A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer,0.0003199374449393988,0.00035336496506885523
NCT00209001,Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer,0.0002845814722210105,0.0004404090201795379
NCT00209092,Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer,0.00030655092439138613,0.00033656062666753066
NCT00299286,Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer,0.0003270403088976813,0.00035552047030396305
NCT00299117,Brief Smoking Intervention for Women Undergoing Breast Cancer Surgery,0.00029721319529778484,0.00027911913600843003
NCT00247663,Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer,0.0003570706005949938,0.00041447884817093596
NCT00247975,Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy,0.00030620906502679834,0.00034454971717756683
NCT00245024,Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer,0.00033911219669597513,0.0002665149756431599
NCT00245869,Ultrasound and Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response,0.0002566932239977481,0.00031755285082463565
NCT00246597,"A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer",0.0002480657898539073,0.00032067616835463616
NCT00246571,Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer,0.0003753184391613535,0.00039580523244241205
NCT00246090,"A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine",0.00033744918557756994,0.0003932057308278657
NCT00261313,ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer,0.00026690371214914253,0.00032364991646308046
NCT00277004,Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.,0.0002612033344303241,0.0003627885231756528
NCT00239343,Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer,0.0003442648885805523,0.00038864631175429396
NCT00201942,PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial),0.0002500217796969014,0.000307231183389499
NCT00201773,"Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer",0.00026424563786188313,0.00022787746213778946
NCT00201890,"Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer ""DELTA STUDY""",0.00029940692987645714,0.0003059514682468077
NCT00201929,A Decision Aid for Women With Early Stage Breast Cancer,0.00034930763461607994,0.00029991105605226584
NCT00201851,Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer,0.0002571835735874269,0.00029535231168553543
NCT00201487,Choline Quantification in Breast Cancer by MRS,0.00033389572051010434,0.00032699313495479666
NCT00201864,Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer,0.0002728244343517756,0.0002649180005661621
NCT00201708,Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer,0.00026765880939282353,0.00034347621863197613
NCT00236275,PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer,0.0003169218349027177,0.0003067467713001
NCT00237211,Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer,0.00035987923043512385,0.0004378765515940072
NCT00237198,Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment,0.00037305302338958626,0.00035350889066734895
NCT00237224,Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole,0.0002984835752852803,0.0003877842777748786
NCT00237133,Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women,0.0003132606316795358,0.00033407631980147143
NCT00210145,Socio-aesthetic Intervention on Body Image and Quality of Life in Women With Breast Cancer.,0.00025819430101808183,0.0003073489385151985
NCT00210236,Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women With Breast Cancer,0.00026855343359802266,0.00030732602761807077
NCT00210197,Hypercoagulability After Breast Cancer Surgery,0.00035314426160169403,0.00025956807260459357
NCT00253539,Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer,0.00026163543023925993,0.0002249396221458742
NCT00259090,Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer,0.000256715994970576,0.0002492268915759483
NCT00273208,An Intervention to Decrease Fatigue Among Breast Cancer Survivors,0.000285306310590017,0.00031769950087217155
NCT00227656,Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer,0.000320113449302159,0.0002897187632587542
NCT00290758,Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer,0.00033911219669597513,0.00026617221702356824
NCT00217815,Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer,0.0003182121293580824,0.00042796360672341067
NCT00202046,Predictors of Lymphedema Following Breast Cancer Surgery,0.00035707169756964336,0.0003277557032884718
NCT00202059,Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer,0.00026186980160352913,0.00028130461817186
NCT00232479,"Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer",0.00025678998239253147,0.0003244885759659538
NCT00200174,Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease,0.00024817296841839773,0.0003630630141050872
NCT00289432,Hospital Based Group Intervention for Breast Cancer Patients.,0.0003582868946068732,0.000317638367090918
NCT00226928,Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer,0.0003710549921615096,0.0004805135841900453
NCT00226967,"Stress, Diurnal Cortisol, and Breast Cancer Survival",0.0003346643070410857,0.00041509817798883637
NCT00249015,Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors,0.00033905680483074693,0.00026426724956817797
NCT00276120,Young Women's Breast Cancer Research Program,0.0004752138787630337,0.0003649672119333728
NCT00276822,Improving Communication With Patients With Breast Cancer,0.0006150176815075327,0.00025318123623952247
NCT00238316,Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density,0.0002578549401074844,0.0002278858646545569
NCT00238290,Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer,0.00029931041800006805,0.0002740464503406969
NCT00206492,Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients,0.0003182958204104321,0.00035796497871611743
NCT00206453,Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer,0.000343300917167036,0.0004023665307795353
NCT00206427,Neoadjuvant GW572016 to Treat Breast Cancer,0.0004967929024157716,0.0005516663491411447
NCT00206414,"Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer",0.0002912905247529577,0.0004004560257198599
NCT00206518,Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients,0.0003147188208843073,0.0003657153842069793
NCT00267553,Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer,0.00031329300414813916,0.0003156109442038175
NCT00270894,Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients,0.00032025449439514994,0.00034044872875429067
NCT00234195,"Wellbutrin XL, Major Depressive Disorder and Breast Cancer",0.000333517175924447,0.00036374592157718073
NCT00234715,Psychosocial Study on Breast Cancer Risk Assessment,0.00032359418643249674,0.00023556371536310092
NCT00254592,Neoadjuvant Treatment of Breast Cancer,0.0004967929024157716,0.00034382722170113895
NCT00286117,ITA - Clinical Study Comparing ARIMIDEXâ„¢ With NOLVADEXâ„¢ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years,0.0002921824994729153,0.00028110124446767084
NCT00286819,Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer,0.00047263954708147573,0.0003663006386896168
NCT00286247,Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer,0.00030257679994703985,0.00037368604801988844
NCT00282529,Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study,0.00029203085756119115,0.00035061988054502533
NCT00272740,SAKK - a Trial to Evaluate Antitumor Efficacy of FaslodexÂ® After Aromatase Inhibitor Failure in Advanced Breast Cancer,0.0002687154157664508,0.00035799356669287446
NCT00248911,The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers,0.00028075053522322096,0.00020711597042681983
NCT00248170,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,0.00027993096531934286,0.0002732937471775969
NCT00213980,Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer,0.0002897174890941505,0.0003498183968020624
NCT02366806,Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer,0.00030486146011813345,0.00034696752273693626
NCT02366793,Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.,0.0002637305199399091,0.0002483493874689453
NCT02334345,Skin Protection During Radiotherapy in Patients With Breast Cancer,0.0003235168634305634,0.00033728482542295707
NCT02352779,Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors,0.00025908033068199017,0.0003792827109824538
NCT02352883,MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ,0.00035837654748992757,0.00032707223472853747
NCT02321527,Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients,0.0002906883021283943,0.00025550159940702965
NCT02380209,An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer,0.00033344766210143006,0.00026026313831225775
NCT02305641,An Observational Study of Kadcyla Safety in Breast Cancer,0.00032508574436430405,0.00030737666914514234
NCT02305628,An Observational Study of Herceptin SC Safety in Breast Cancer,0.00032887701089631026,0.0003309296088898665
NCT02312700,An Interactive Empowerment Tool for Breast Cancer Patients,0.0006150176815075327,0.00043189987162878723
NCT02310464,"Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects",0.0002587115010627832,0.0002829200280703692
NCT02306096,Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer,0.0003388743277430866,0.00025829011550176044
NCT02324101,Clinical Trial of Quantitative Detection Kit for Hsp90Î± in Breast Cancer,0.00028078639093776354,0.0002526753465472049
NCT02347449,The Impact of the Oncotype DXÂ® Breast Cancer Assay on Treatment Decisions in a Canadian Population,0.0002758378942201136,0.00032529827268421843
NCT02322814,A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,0.00035747014995997546,0.0003710683640502861
NCT02349581,Ultrasound Guided Pectoral Nerves Blockade for Persistent Pain After Breast Cancer Surgery,0.00024835458599417604,0.00026915497262379245
NCT02336737,SentiMagÂ® Intraoperative Comparison in Breast Cancer,0.0003370283367044456,0.00030730544346931196
NCT02336529,Nerveblocks for Persistent Pain After Breast Cancer Surgery,0.00035522882515770076,0.0003165672480555359
NCT02350582,e-CUIDACHEMO: Telerehabilitation During Chemotherapy in Breast Cancer,0.00036209668868278117,0.000372918461758327
NCT02362230,Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy,0.0002924521172607912,0.0003588209899552638
NCT02300675,Therapeutic Education Intervention in Breast Cancer: PEPs Hormonotherapy,0.00031214098819878563,0.0003709682728085152
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",0.0002702779638022603,0.0002991704134197817
NCT02308085,Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer,0.0003707748735950641,0.00030736473428675414
NCT02375048,Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI,0.00031309741479399443,0.0003496595255585195
NCT02345772,"Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",0.00031596106498287777,0.00027271034802578946
NCT02386371,Intraoperative Radiotherapy After Local Recurrence in Breast Cancer,0.0003369035149219233,0.0002452822988841732
NCT02344940,Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer,0.00032524378435053495,0.0002560701414877915
NCT02365805,Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer,0.00027273912022149967,0.0003152630366999021
NCT02389686,Intra-operative Radiotherapy For Breast Cancer Women After NSM,0.0004890441595013054,0.00033614267055219807
NCT02389673,Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer,0.00034722471718522335,0.00022206108603434183
NCT02379585,Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,0.00035410944222302835,0.00037915380103388253
NCT02379247,BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,0.00029627527098069706,0.0003075762165249298
NCT02391818,The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients,0.00033305661204701504,0.00031975163449376803
NCT02384733,Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost,0.00046854042245142495,0.0002988668116004232
NCT02338167,Praegnant Breast Cancer,0.0008984903380354321,0.0003047508989428639
NCT02338115,Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients,0.00032149997266730954,0.0003861010839901243
NCT02338349,"A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer",0.00029774872834094135,0.0003737333742142841
NCT02315196,Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer,0.00031032119670935303,0.00039668122575589544
NCT02358837,Improving Breast Cancer Diagnostic by Novel sonographicTechniques Study,0.00040190260154003983,0.0002538099934846177
NCT02327442,68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and Applications in Glioma Patients or Breast Cancer Patients,0.0002964053179704008,0.00037310867746803873
NCT02327572,Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer,0.00025568560364470526,0.00026188914139195225
NCT02340494,An Online Enhanced Education Tool for Young Women Newly Diagnosed With Breast Cancer,0.0003436591201631601,0.0002515449987233147
NCT02340858,Percutaneous Irreversible Electroportion for Unresectable Breast Cancer,0.0003340848516120757,0.00030665251281806273
NCT02304640,"Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients",0.00030332396716669274,0.00032869679851431973
NCT02364726,Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients,0.00032307102005568516,0.0003186483462489223
NCT02364492,A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse,0.0003476408971198676,0.0004360641350813186
NCT02303145,Breast Cancer Survivorship & Work-Related Cognitive Limitation,0.0004755386780981432,0.000267263315556008
NCT02376413,Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients,0.0003370215705866706,0.000329665619778142
NCT02331212,Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast Cancer,0.0002891607427300309,0.0003012171313369257
NCT02370277,Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer,0.0003180018734031873,0.000359732329585125
NCT02370264,Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer,0.0003133614550427978,0.00035302893622599313
NCT02333370,"A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",0.0003346659854524385,0.0003719777624390208
NCT02333890,"A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer",0.00028023942041824617,0.0002818351174076809
NCT02348320,Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy,0.00031443465524582835,0.0003297574819737449
NCT02387671,Weight Management Among Breast Cancer Survivors,0.0003363612924533681,0.00021518331358572423
NCT02387320,Evaluation of a Self-Care Toolkit in Surgical Breast Cancer Patients,0.0003752454334128232,0.0003042561622341393
NCT02313116,"Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)",0.00029740086236323715,0.00028007907200180656
NCT02313051,Everolimus trIal for Advanced prememopausaL Breast Cancer Patients,0.0003793924909044356,0.0003027681723787703
NCT02301767,MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study,0.0002753530535531221,0.0002448836959364879
NCT02316795,Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma,0.00027835483160765196,0.00025958881524202937
NCT02316509,Study of SRN-927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,0.00031066024406577273,0.00032253398195002955
NCT02390427,Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,0.0003051897837918267,0.0003450510344415462
NCT02326857,Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment,0.0002795369212650969,0.00036509042659947145
NCT02311543,Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer,0.0002642093503192459,0.00017556785115332163
NCT02311647,Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients,0.0002968091784990548,0.0003402701917560389
NCT02311933,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",0.00031758233987515066,0.0003272018706601714
NCT02360059,Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer,0.00029962697759705625,0.00035819346265685736
NCT02360904,A Yoga Program for Breast Cancer Patients Undergoing Chemotherapy,0.000336142612037177,0.00032676763511779315
NCT02393105,Sense of Hope Alleviates Fatigue in Breast Cancer Survivors,0.0003377137583518621,0.0003541391805116714
NCT02339532,"Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status",0.00032620762537405,0.00029970667822372486
NCT02357927,A Single Session Intervention For Fear Of Recurrence In Breast Cancer Patients,0.00030344096027307827,0.00020879013816823544
NCT01396174,A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors,0.0002797959096747526,0.0002155753756973416
NCT01396655,PET in Breast Cancer Receiving Neoadjuvant Chemotherapy,0.0003169218349027177,0.0003170148626448063
NCT01308775,Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer,0.000319907432130095,0.00038473889347543364
NCT01304797,Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer,0.0003763124721046992,0.0003404462387249292
NCT01301911,Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer,0.0003525762766280846,0.00033366769508555926
NCT01301729,A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment,0.00030397114605062195,0.0003302554760097274
NCT01327781,Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer,0.00031096339772457564,0.00032809671880194716
NCT01351584,Tumour Registry Breast Cancer,0.00034002744042031547,0.00034443177917189
NCT01351376,LLLT Combined With CDT in Breast Cancer-Related Lymphedema,0.0002559997795004016,0.0003147550356729883
NCT01351974,Sentinel Node Biopsy in Breast Cancer Patients,0.0004330900679404511,0.0002909982802355978
NCT01351844,The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer,0.0002720035782275839,0.00030315695112941493
NCT01340300,Exercise and Metformin in Colorectal and Breast Cancer Survivors,0.00028176737004317995,0.0003126873195569389
NCT01340430,"Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer",0.00026985437062075114,0.0003160942954542094
NCT01336257,Effectiveness of a Decision Support System in Improving the Diagnosis and Screening Rate of Breast Cancer,0.00024835314124534364,0.00025564178388402754
NCT01387373,Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer,0.0003130091968093085,0.0002870865520863318
NCT01387295,Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease,0.0003055743639337164,0.0002751890775975347
NCT01331629,Impact of Art Therapy on Fatigue and Quality of Life of Patients Treated With Adjuvant Radiotherapy for Breast Cancer,0.0003014753746651383,0.0004167005635949634
NCT01331772,Impact of Nutritional Intervention in Women With Breast Cancer Under Adjuvant Chemotherapy,0.00033636862235213893,0.0002376143266186862
NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,0.00028961156196615504,0.0004503712246637365
NCT01339650,"Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",0.00027164130154642583,0.0002877435953688697
NCT01339780,Imaging of Prostate and Breast Cancer Bone Metastases Using Magnetic Resonance Imaging and Nuclear Medicine Techniques,0.0002446001241518836,0.00036397938404949046
NCT01339351,Teleconference Group: Breast Cancer in African Americans (STORY),0.0004713817215549723,0.00025810594405876444
NCT01303419,Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer,0.00024729016248349964,0.00028773208438766733
NCT01358877,A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer,0.0002953302902394927,0.0003026281617935207
NCT01320488,Breast Cancer in Young Women: Is it Different?,0.0008984903380354321,0.0002690438130184675
NCT01320592,PD0332991/Paclitaxel in Advanced Breast Cancer,0.0005211184264943355,0.0003221331993824357
NCT01320111,Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment,0.00032228594176375683,0.0003184286657058203
NCT01399359,Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer,0.0002791493060811154,0.0002834855582036492
NCT01321775,"Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer",0.00028517594172788765,0.0003394129307370277
NCT01325207,Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer,0.00034999293169823986,0.000402314072281668
NCT01311037,The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer,0.00028009236264227386,0.000341146032627762
NCT01356862,Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer,0.00024231015415960102,0.0002736111892075668
NCT01390064,Vaccination of High Risk Breast Cancer Patients,0.0003561819543994293,0.0002775749073665894
NCT01302002,The Use of Metformin in Early Breast Cancer Patients Pre-Surgery,0.000367804436813482,0.0005087941172327677
NCT01302379,Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors,0.0002782063849010694,0.00032362964488208765
NCT01386411,Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer,0.00024492738591571907,0.00027633201238979677
NCT01367028,A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer,0.0004126569226256081,0.0003413055433790372
NCT01380912,Can Methylprednisoloneacetate Prevent Seroma After Mastectomy for Primary Breast Cancer,0.0002518014534316263,0.0003141320631228502
NCT01380925,The Jewels in Our Genes Study - an African American Family Study of Breast Cancer,0.0003936874263495753,0.00046267503121987056
NCT01355393,Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer,0.00029706947723078653,0.00036879528358424246
NCT01355523,"The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients",0.0002900821461477238,0.00027455579411510316
NCT01359501,Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients,0.0003316519816510305,0.00032172476248341404
NCT01310530,Partial Breast Proton Therapy for Early Stage Breast Cancer,0.0002926223529716597,0.00022513838628816565
NCT01366248,Integrative Oncology Outcomes Study in Breast Cancer,0.0003936874263495753,0.0003195008722356117
NCT01322412,Adapted Physical Activity Effect and Fatigue in Patients With Breast Cancer,0.00032295149323734797,0.00031172782318849706
NCT01391039,Diagnostic Study of Early Breast Cancer Using Ultrasound,0.0003305558241024379,0.00031013969556460745
NCT01391689,Diindolylmethane in Treating Patients With Breast Cancer,0.00043129179889895826,0.0004736742528525406
NCT01391806,The Impact of Preoperative Breast MRI in Patients With Breast Cancer Selected for Breast Conserving Surgery,0.0003562212735160766,0.00031871540417905526
NCT01344109,A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy,0.00035476049937648377,0.00038228763966361264
NCT01334099,"Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients",0.00036247015164005743,0.0004228502306145258
NCT01334021,Genomic Testing for Primary Breast Cancer,0.0008984903380354321,0.0003347225030202633
NCT01361945,AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer,0.0003132923226273408,0.00035958759491429233
NCT01384838,Exercise Training in Postmenopausal Patients With Breast Cancer,0.00032863116612205195,0.00029104163097305155
NCT01342302,An Online Psychoeducational Intervention for Young Women With Breast Cancer and Their Partners,0.00047844215270982453,0.0002674725508580269
NCT01338753,Study to Evaluate Markers of Response in Locally Advanced Breast Cancer,0.00030988683737669977,0.0003238175198650427
NCT01370239,HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy,0.00033729247205044734,0.000317311437524834
NCT01370551,Clinical Study of Vaginal Lactobacilli and Estriol (GynoflorÂ®) for Atrophic Vaginitis in Breast Cancer Patients,0.0003203024598339807,0.00028571780751928175
NCT01316328,Determination of Predictive Genetic Markers of Toxicity After Hypofractionated Radiotherapy in Breast Cancer Patients Post-Conservative Surgery,0.00030366982265086714,0.00034167571086860047
NCT01305915,Getting Back on Track: An Educational Group for Women With Breast Cancer,0.00027959634656501254,0.0002893869454014777
NCT01305954,Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients,0.00039776986033762186,0.0002847902175535149
NCT01305239,A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (AromasinÂ®) In Postmenopausal Hr+ Patients,0.00031756700332161576,0.00032385205281286835
NCT01305941,"A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",0.0002878788984808316,0.0002885044642809978
NCT01368380,Hand in Hand. Psychological Support and Counseling to Breast Cancer Patients and Their Partners,0.0002980099958039051,0.0003786308617836622
NCT01368744,Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology,0.00027668022181947323,0.0002652818317293141
NCT01368263,Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer,0.0003027807251847843,0.00038222920788337326
NCT01377363,Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis,0.00028651290470360695,0.0003037940266464685
NCT01382082,Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy,0.0003175268643167858,0.00033056906599817097
NCT01354041,Fear of Recurrence Pilot Intervention for Women With Breast Cancer,0.0002844144784921292,0.0003290084005231831
NCT01354522,TAC Versus TCX as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer,0.00032057788392699947,0.00030732870707279305
NCT01392248,Prediction of Pain After Breast Cancer Surgery With EEG,0.00035522882515770076,0.0003012523525003593
NCT01343849,Blood Test for Breast Cancer Associated Auto Antibodies,0.0002772401806078225,0.0003321503215369996
NCT01300871,Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer,0.0002666721897217259,0.00027880123731388557
NCT01300351,Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women,0.00037260817821936154,0.00038134250494181173
NCT01362712,"Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects",0.00029445637097647097,0.0003524806417210826
NCT01309607,Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (TykerbÂ®) in Patients With ErbB2-Positive Stage I-III Breast Cancer,0.00033736372300553606,0.00041408972827688175
NCT01363986,A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer,0.00034289112835432316,0.0003263357535307544
NCT01329640,Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01),0.0002842921146274376,0.0003837902900975753
NCT01329627,Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer,0.0003044391649882899,0.0003747097757922546
NCT01314833,Efficacy Study of Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients,0.0004000973571585218,0.0003535348304821396
NCT01349959,Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer,0.00033629566510977923,0.00037818102229950534
NCT01313039,Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer,0.0002491095661464633,0.00032731789244013116
NCT01352494,Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer,0.00029303360356223133,0.0003785143582935257
NCT01375023,"Allogenic Haematopoietic Cell Transplantation for Patients With Refractory ""Triple Negative"" Breast Cancer",0.00035609243861548515,0.0003201861913583487
NCT01335152,Online Stress Management and Coping Skills Training for Women With Breast Cancer,0.0002805546388742083,0.000318886553706522
NCT01394575,Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients,0.0003138871573135503,0.00031374232182267945
NCT01394315,Diffuse Optical Tomography (DOT) for Monitoring Response to Neoadjuvant (Preoperative) Chemotherapy in Breast Cancer,0.0002714730211614028,0.0003768711555606264
NCT01394211,Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer,0.00027929478480967214,0.0003435436690479753
NCT01365845,Proton Therapy for Lymph Nodes in Breast Cancer,0.0003351283113823888,0.00030209571675620213
NCT00815555,CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients,0.0003566450735274719,0.0003268018573514524
NCT00887536,"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",0.00025870962631786295,0.00035894589431765146
NCT00827307,Zoladex Plus Tamoxifen in Breast Cancer,0.0003404911915029894,0.0002532381514096952
NCT00880009,Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer,0.00028224280654685983,0.0003013541826408279
NCT00880711,Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC),0.00030153107458194165,0.0003269703881954846
NCT00880022,Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer,0.0002641083645112923,0.0002698346707530802
NCT00880464,"Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer",0.00024030407775993905,0.00023755972319923716
NCT00878709,Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,0.0003108761756420804,0.00044046835837873957
NCT00878930,"Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer",0.0003118778528895012,0.0003682438244418818
NCT00813878,"Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease",0.0003127923631249309,0.0003399159739920954
NCT00871858,Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer,0.0003284816897494316,0.0002798097797738351
NCT00856492,"S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",0.00026608785540586596,0.0003119488173865135
NCT00825682,The Effect of Reflexology on Radiation-related Fatigue in Breast Cancer Patients,0.0003099415738138415,0.00036801627263576074
NCT00853996,Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer,0.00028725129692649736,0.0002692765534301971
NCT00873366,Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer,0.00028180005827892457,0.0003573379633590616
NCT00873808,"S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307",0.0002551690546333987,0.00022968768229635823
NCT00877188,Effect of Combined Aerobic and Resisted Exercise in Breast Cancer Survivors,0.0004754606381545852,0.00040937215685347815
NCT00811824,Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors,0.00028594256065634255,0.0002701761046600408
NCT00811135,A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer,0.0003393460169779607,0.0003260762028072833
NCT00898131,Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer,0.00035575088462881275,0.00042639178125439096
NCT00898976,Biomarkers in Native American Women With Breast Cancer,0.00034057727867024324,0.00024974177446311153
NCT00898898,Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831,0.0003402321799972625,0.00037266327183657264
NCT00898703,Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer,0.0003353239024322205,0.00032048545340541447
NCT00898573,Lapatinib Resistance in Patients With Breast Cancer,0.00035492454753693827,0.0003729804496899608
NCT00898690,Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer,0.00032653804128472555,0.00033904438098517986
NCT00898937,Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast,0.00025611506239515063,0.00027427344180364923
NCT00881010,Automated Pain Intervention for Underserved Minority Breast Cancer Patients,0.00035838635698969907,0.000322690069122697
NCT00875238,Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab,0.0002654916991013801,0.0002246320045988035
NCT00875355,Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer,0.00029020768804591235,0.00026353988505935195
NCT00872625,Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer,0.00029166529706867574,0.00029542605273338954
NCT00872677,Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors,0.0003353186654290563,0.00020421995791906666
NCT00828854,"A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing",0.00030957829426291717,0.0003530208863941695
NCT00884143,Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer,0.00031585360871731744,0.00031859222364230707
NCT00807950,Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer,0.00032380386888840535,0.00027219381591047726
NCT00816244,Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer,0.0003019496033311725,0.00034419791137169645
NCT00816985,Liposuction for Arm Lymphedema Following Breast Cancer Surgery,0.0002667217133755004,0.00031957542629056226
NCT00845078,Prospective Outcomes After Reconstruction and Radiotherapy for Breast Cancer,0.00034779352388786505,0.00031152656949017714
NCT00802932,Pilot Study to Validate Metallic Markers for Image Guided Radiation Therapy for Breast Cancer Tx,0.0003285147341081063,0.00035357786970523897
NCT00802945,Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer,0.000363918379775013,0.0003756798025976475
NCT00821288,Post-treatment Care of Breast Cancer Survivors,0.0005240256729824867,0.0003699892740383651
NCT00821886,Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer,0.0002820872123699447,0.0003677816363358952
NCT00821964,Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer,0.0003168851422917568,0.0003223533740545811
NCT00821054,A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients,0.0003345565791665457,0.000385173874422151
NCT00837265,Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel,0.00032250883705381737,0.00026471044184778165
NCT00810017,Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer,0.00031061469275117594,0.00039616828911581453
NCT00818051,Radiation Therapy in Treating Women Who Have Undergone Breast Conservation Surgery and Systemic Therapy for Early Breast Cancer,0.00027674068647042096,0.00023812160076396109
NCT00814034,Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy,0.0003093991058867117,0.000311728165153612
NCT00882674,A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer,0.00029943098305542233,0.000320581925936031
NCT00882089,"Use of the Conturaâ„¢ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients",0.00031364349570891104,0.00032868572333294064
NCT00882596,"Use of the Conturaâ„¢ Catheter to Deliver Accelerated Partial Breast Irradiation to ""Low-risk"" Breast Cancer Patients",0.00029737596182718507,0.0003303930796676375
NCT00830544,Study of Neoadjuvant Chemotherapy of Breast Cancer,0.0003593624000397482,0.00034439672332492764
NCT00830635,Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer,0.00030161558121179183,0.0002676416820761445
NCT00860886,Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer,0.00027975086637197215,0.00028078506419765173
NCT00866905,Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer,0.0002697160431910384,0.000313419929286001
NCT00842998,Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer,0.0002871091577015509,0.00028836571084041177
NCT00859703,Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer,0.0003005224477641006,0.0003045721096393273
NCT00859651,Vitamin D in Postmenopausal Women at High Risk for Breast Cancer,0.0002942260182796271,0.0002881039344153033
NCT00892567,Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer,0.00030210488546452747,0.0003580212016752974
NCT00892515,Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer,0.0002858858223782718,0.00019699416476643604
NCT00892268,Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain,0.00025140692670264845,0.0002336024678271594
NCT00852332,Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer,0.00044060458500521597,0.00029907230832465406
NCT00852683,The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study,0.0002877058828120728,0.00035649236602094275
NCT00870415,Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer,0.00046995553895328547,0.0002982513010960013
NCT00862901,Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma,0.00031847554110431156,0.00033825291478510844
NCT00891969,Treatment Decision Making Between Oncologists and Women With Newly Diagnosed Breast Cancer and Their Healthy Companions,0.0003119996428831039,0.0003654200698515784
NCT00891800,Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver,0.0003106737224010374,0.00037057200908032357
NCT00861705,Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery,0.00031310370949459986,0.0003544568579728431
NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,0.00031984212638360755,0.0003713426122247159
NCT00849329,A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer,0.0002806736803436803,0.00025518203696124283
NCT00855114,Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery,0.0002947122122641296,0.00030227358922811805
NCT00854789,Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer,0.0003950009388790121,0.0002714924471619264
NCT00895414,Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer,0.00033398851934593823,0.00024578859186758585
NCT00897065,Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17,0.00026261684486292124,0.0002969288801309998
NCT00897884,Clinical and Biologic Effects of Metformin in Early Stage Breast Cancer,0.0002632944212444323,0.0003496227122965092
NCT00897416,Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer,0.00028702076278235694,0.00022960080196514707
NCT00897338,Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer,0.0003359350430715074,0.0002870215976099243
NCT00897845,Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer,0.00036799892505630073,0.0003827323951079254
NCT00897455,Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers,0.00046881978348539336,0.0003624786754985843
NCT00897728,Study of Tumor and Blood Samples From Women With Breast Cancer,0.00032843112011604484,0.00035031052173201084
NCT00897299,Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy,0.00036506953237550846,0.00030135439829026876
NCT00897208,"Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer",0.0002497237567400034,0.00021222337826573058
NCT00897702,Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer,0.0002989521704901124,0.0003455130283625728
NCT00897091,"S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil",0.0002651987996519929,0.00028540260858479197
NCT00897468,Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer,0.00033659643765890563,0.0003730731190866636
NCT00826085,Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall,0.00029099175288607493,0.00038422342225891094
NCT00826267,6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab,0.00029284431288442177,0.0002784688274927754
NCT00888082,Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy,0.0003050069749292575,0.00037808851339760373
NCT00836186,Cytokine Expression During Radiation for Breast Cancer,0.00028842190378255744,0.00028585061789410387
NCT00820872,"Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer",0.000315111985302704,0.00029189334886404127
NCT00820690,Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer,0.0003396149676861938,0.00034854910705394733
NCT00820924,Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells,0.0003244530954804255,0.000380299401175195
NCT00806507,Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients,0.00033311925079501837,0.0003155456919692189
NCT00885183,Adjuvant Acupuncture Care for Breast Cancer Patients Experiencing Side Effects From Chemotherapy,0.00033411118559479165,0.0003598669072812451
NCT00885612,10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI),0.0003267713298901616,0.000407852621577917
NCT00841399,Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients,0.00034351329395223255,0.000326856263421804
NCT00833963,"An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception (MotHER)",0.0002733678884504492,0.0002371550681700451
NCT00896324,Intellectual Impairment in Women With Breast Cancer,0.00033351964201914163,0.00025941010242787343
NCT00896857,Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer,0.0002477305767336024,0.00021715553326886436
NCT00896818,Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and Friends,0.00027781830577598937,0.0002951447624241611
NCT00896155,Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients,0.00036742399785624275,0.00030776709892106884
NCT00896623,SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897,0.00037067954556672597,0.0002758257504532074
NCT00896636,Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration,0.00028450386053694327,0.0003014415323252993
NCT00896649,Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer,0.00025689923339479464,0.0002637320184084724
NCT00899301,Collecting and Storing Tissue Samples From Women With or Without Breast Cancer,0.00047238557149693465,0.00040171327179090423
NCT00899288,Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98,0.00025106710925628083,0.00022191238832379068
NCT00899418,Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100,0.0003001938538309546,0.0003033884974736359
NCT00899574,Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases,0.0002981003603746301,0.00025674036518697743
NCT00899145,Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers,0.00046881978348539336,0.0003867026593197166
NCT00899509,Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer,0.0003152299324445054,0.0003851117131398127
NCT00839696,"Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk",0.000247165892881347,0.00019906274233078328
NCT00851110,Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors,0.0003274834342059478,0.00043128135805468854
NCT00851812,Exercise for Breast Cancer Patients (EXCAP),0.00043617701113235924,0.00032927214481751223
NCT00893061,"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer",0.00025812286512423495,0.0002718720204978361
NCT00801476,Pre-operative Magnetic Resonance Imaging (MRI) in Young Breast Cancer Patients,0.00043246645440124905,0.00035285979662346697
NCT00801411,Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery,0.00026294451800687235,0.00027553879131747767
NCT00869466,Weight Control Programs in Women Who Have Undergone Surgery for Early Stage Breast Cancer,0.0002768919356685102,0.0002189879722924556
NCT00869973,Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients,0.0002917344436021228,0.00030166043266489716
NCT00805597,Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes,0.0003031257322072131,0.00043542043328147385
NCT00823654,Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations,0.0002688879494480151,0.0003036319741369781
NCT00879086,A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer,0.0003423170048340921,0.00033840833615403175
NCT00846027,A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer,0.00034326172182699144,0.0003415661096518312
NCT01644890,A Phase III Study of NK105 in Patients With Breast Cancer,0.0004915603397778765,0.00048040239978519887
NCT01628887,Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors,0.0003400278477302595,0.000351116807137598
NCT01642511,Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative,0.0002980084480659395,0.00023648367948664821
NCT01642771,Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer,0.0002576713763607509,0.0003253349219752549
NCT01634984,The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer,0.00048072891205396695,0.0003307295813425561
NCT01630226,Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland,0.0003490016394632492,0.0004601397100029216
NCT01697345,"Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy",0.000264108492918322,0.00032593797624226074
NCT01697293,"Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",0.0003073198531998576,0.0003888444788552377
NCT01690325,Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON),0.00027819477450747416,0.00045717580061328036
NCT01690702,Study of Nab-Paclitaxel in High Risk Early Breast Cancer,0.00033650919473846225,0.0005895642133146062
NCT01676753,Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,0.00030367739172845466,0.0002589436405252423
NCT01621529,Contribution of 18FDG PET-Scan in Tumour Volume Determination in Patients Operated of Breast Cancer,0.0002917658505284237,0.0003135289136599471
NCT01643148,"The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer",0.00024304119246446027,0.00022143680689859298
NCT01698918,"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",0.0003029816945351973,0.00031597136855172924
NCT01698658,Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer,0.000341636229590435,0.00035201041415157706
NCT01620359,Study of ExAblate Focused Ultrasound Ablation of Breast Cancer,0.00032306692258685354,0.0003216318303264646
NCT01684579,Exercising Our ABC's (African- American Breast Cancer Survivors),0.0008984903380354321,0.00026405343279231104
NCT01684215,"A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer",0.00035767394197937637,0.0003635519340007319
NCT01647672,Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer,0.00028207033781217194,0.00029197661398967496
NCT01647607,Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer,0.0002815991293935485,0.0002543718902356336
NCT01627366,Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors,0.0005580027294853632,0.00036485076062989105
NCT01627704,Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer,0.00025389531229893294,0.0002352553322071477
NCT01602380,A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.,0.00035607910788631135,0.0003840363149859185
NCT01626950,Living Conditions and Breast Cancer,0.00033351732810263385,0.00027486832264893735
NCT01626781,"A Randomized, Open-label Phase III Trial of MapisalÂ® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer",0.00029466326279251997,0.00033006072062178666
NCT01695226,Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer,0.0002791311902528981,0.0003252899811444086
NCT01693731,Oral Health in Breast Cancer Survivors on Aromatase Inhibitors,0.0003386206061341267,0.000298686191342214
NCT01699867,"Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)",0.00029740086236323715,0.00028037367759516975
NCT01606072,Perioperative Use of Desmopressin (DDAVP) in Breast Cancer,0.0003334228715094608,0.0004206276291576992
NCT01688609,"Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer",0.0003244910735212878,0.0003692676157560362
NCT01688479,"Trial Comparing Calendula Officinalis With Aqueous Cream ""Essex"" to Treat Skin Reactions From Radiotherapy of Breast Cancer",0.0002604990423679117,0.00041886727205865416
NCT01622361,"Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer",0.000301537652145422,0.0002946497335514923
NCT01622868,Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,0.0002998554940644821,0.00033788392778412
NCT01668914,Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive,0.0003028865621083722,0.00029709628704014453
NCT01664494,"An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer",0.0003443564321323079,0.0003367248708601224
NCT01641406,"""Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer""",0.00030239203201620546,0.00033845809480682713
NCT01641068,Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms,0.00024017940428087845,0.00026206024830843994
NCT01618357,Pre-Operative Radiation and Veliparib for Breast Cancer,0.00034760206410836903,0.0003769661572827952
NCT01645059,Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy,0.00032098552687402605,0.00035177333693036094
NCT01645839,Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyteÂ®) in Meningeal Metastasis of Breast Cancer,0.00023969736444512805,0.0003333313476394585
NCT01654367,Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer,0.00028414683302535495,0.000260582069991028
NCT01654432,A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery,0.00024748407992286343,0.00025998211846053144
NCT01613560,Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy,0.0002697473875148913,0.00026346119208860386
NCT01613352,Feasibility of Ambulatory Surgery for Early Breast Cancer,0.00046854042245142495,0.00022177813719439113
NCT01614704,Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility,0.0003733430674471856,0.0002724883826756644
NCT01614184,Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer,0.00033531296544772637,0.00030840729590192874
NCT01660529,Multi-peptide Vaccine With Basilixumab for Breast Cancer,0.0002783247446115699,0.0001995934018962523
NCT01660542,"An Open-label, Multi-center Phase â…£ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(MonotaxelÂ®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer",0.0002900756763256123,0.00027031438208091374
NCT01661816,Breast Cancer and Quality of Life,0.0004743497325739597,0.00033607385220585004
NCT01694225,Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors,0.00031826680711558546,0.0003906552593810241
NCT01669252,Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer,0.0002919716517361203,0.00031492932209078333
NCT01669265,Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer,0.00047253109566095647,0.0002762107100887249
NCT01669239,"Study of Neoadjuvant MyocetÂ®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer",0.0002949231998306696,0.0003361994922890259
NCT01646346,4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer,0.0002512616644100465,0.00028581725912460616
NCT01646034,High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer,0.00028485343122311706,0.0003290902989935967
NCT01672021,Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients,0.00030349347862503945,0.0002166013723509891
NCT01648608,Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer,0.0002943595103959808,0.00026973261081468004
NCT01648322,Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,0.0003628469374887767,0.00046959937961516316
NCT01649258,Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy,0.00031259307040500995,0.00034776292725379533
NCT01649661,MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk,0.00028228566793473265,0.00028553820782584166
NCT01671943,Cryotherapy for Breast Cancer Trial,0.00046868186895277164,0.0003596525379049921
NCT01671319,Dose Dense TC + Pegfilgrastim Support for Breast Cancer,0.00033702102712152314,0.0003553084853036531
NCT01677455,An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer,0.00032413671950579434,0.0003688961516638797
NCT01611051,A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy,0.00034985881154640916,0.0003129037361093097
NCT01662726,"A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth",0.00029906198283471817,0.00033932368401588613
NCT01662128,Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer,0.0003010846794867417,0.00022173830076896266
NCT01625429,Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer,0.00030482149731279683,0.000322064947958747
NCT01625286,"Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",0.0004433407460496217,0.0003812267341306388
NCT01663792,Dietary Seaweed and Early Breast Cancer: A Randomized Trial,0.00047577494632216564,0.00024249616735969384
NCT01608451,Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer,0.00027337223912022647,0.0004636279909827934
NCT01632956,Developing Culturally-Tailored Information-Based Support Groups for Chinese Immigrants With Breast Cancer,0.00027993810991413284,0.0003102044248723145
NCT01632332,Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer,0.00035469082555806495,0.00034042383300310184
NCT01609920,Nodal Staging in Breast Cancer With MRL,0.0008984903380354321,0.00026395848648524365
NCT01670877,Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,0.00028854980415877476,0.00043531236564185824
NCT01637103,Treatment of Depressive Symptoms in Breast Cancer Patients: Comparison of Cognitive Therapy and Bright Light Therapy,0.0003113501580409913,0.0003366592190758658
NCT01605396,"A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)",0.0002803656988910086,0.00037079101684648274
NCT01686737,Iyengar Yoga for Chemotherapy-induced Fatigue in Breast Cancer Patients,0.0003357507637277361,0.00034873559126954654
NCT01674140,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,0.0003581725414682251,0.00031205580405056505
NCT01674881,The Effectiveness of Mindfulness on Chronic Pain in Breast Cancer Survivors,0.0002792858260515733,0.0003363465776457269
NCT01639417,Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients,0.00032857675814972195,0.0004075836154187216
NCT01612910,"Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery",0.0003174127444794395,0.00033409355935338006
NCT01612338,Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives,0.0002559719191304315,0.00019792009543387448
NCT01612871,Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer,0.00034104969181748037,0.0003301942500289434
NCT01612728,Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer,0.00030934815591442637,0.00034548643890550774
NCT01612247,Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy,0.00032486383131308277,0.00027233585862520464
NCT01658462,Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer,0.0003299801890095539,0.00048061835872245564
NCT01658176,Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer,0.00034680554580033656,0.0003521219090724635
NCT01652560,Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy,0.0002714060149294744,0.000376610371195547
NCT01619514,Uncovering Potential Breast Cancer Biomarkers Amp; Possible Drug Targets Using Advanced Quantitative Mass Spectrometry,0.0002642330552676067,0.00038866419483929215
NCT01619306,Knowledge and Attitudes of Patients and Healthcare Professionals on a Spectrum of Genetic Tests Relevant to Breast Cancer Patients,0.00028564079808662634,0.00039786296654118
NCT01012440,Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer,0.0003184582345759175,0.0003387224545152434
NCT01082068,Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer,0.00033985298756504544,0.0003340845851088114
NCT01042938,Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients,0.00030701292876881474,0.0003254597362995235
NCT01042548,Proteomics Research of Breast Cancer Markers in Interstitial Fluid and Serum,0.00028236118814154164,0.00029256635536046525
NCT01042379,I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,0.0002916857303176041,0.0003481299934489367
NCT01099436,Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients,0.00035534827068208565,0.00028670502613671345
NCT01081106,Low Level Laser Therapy for Hair Preservation With Chemotherapy for Breast Cancer,0.00026919393333088256,0.00030325868789582005
NCT01081509,Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence,0.00032522343241426534,0.0004897067262515808
NCT01096901,Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors,0.00033569572030899925,0.0003631377883027892
NCT01035112,Magnetic Resonance Imaging of Breast Cancer,0.00047023479662429646,0.00032300702948889895
NCT01035268,Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella,0.00025232863565631335,0.0003044821805379788
NCT01035099,RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF,0.0003193430285477303,0.00034177141262836804
NCT01090128,"Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer",0.000356847188618754,0.00038981111981149617
NCT01090687,Role of 3D Tomography in Breast Cancer,0.00033465669919524593,0.00029768973000220134
NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,0.00028281142684889504,0.0003367891554468189
NCT01072838,"Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB",0.0003126653704655323,0.0003279405657920269
NCT01072318,Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene,0.0002667746780430814,0.0003814103154100135
NCT01018251,Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer,0.00027459884981612494,0.00029169400072824977
NCT01018108,Visualization of the Effect of Acupuncture on Brain Serotonin in Breast Cancer Survivors,0.0002527417061055798,0.00023064756356037258
NCT01023802,The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer,0.00026414810152088173,0.0003170547847244267
NCT01023204,Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer,0.0004069434004610724,0.0005184102645515383
NCT01046929,Limonene Study in Women With Breast Cancer,0.0003936874263495753,0.00033556920498235365
NCT01086514,Digital Mammography for the Detection and Preoperative Staging of Breast Cancer,0.00033504066373635916,0.00027868531436220834
NCT01014715,Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer,0.00034925822855912846,0.00029907281276192856
NCT01091428,"MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer",0.0003433309779401682,0.00035396072612030224
NCT01043003,"Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers",0.00024970133704608046,0.00027015548850091865
NCT01043055,Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40,0.0002505745930947901,0.0003308940672042132
NCT01095003,Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer,0.000308443363029113,0.00028032206194197743
NCT01045044,Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy,0.0003123737762566758,0.00034088851469874594
NCT01064349,Breast Cancer With Over-expression of erbB2-BRAINSTORM,0.00047081846813521534,0.00033040028158350164
NCT01064635,"Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)",0.0002809697480811113,0.0002275174403810005
NCT01064427,Factors Correlated With Fatigue in Breast Cancer,0.00047463635589376396,0.00040562678391989186
NCT01051401,Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer,0.00026897299002633964,0.0003663758165058423
NCT01051609,"Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients",0.00029423425884376596,0.0003897899188006353
NCT01051492,Development of Predictive Biomarkers and Novel Approached to Therapy in Breast Cancer,0.00031144000499038046,0.00026441997869825325
NCT01026116,A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed by Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old,0.0002989633245378019,0.000307905764099739
NCT01027416,Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients,0.0003473587022857762,0.0004010765028652844
NCT01000883,Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior,0.0002848559986533766,0.00035727530499706336
NCT01034891,Women At Risk: The High Risk Breast Cancer Program,0.00034369465580253697,0.00033541952783866573
NCT01034215,Multi-Media Imagery Program for Breast Cancer Patients (Phase II),0.00029953416780769727,0.0003095335477288929
NCT01028352,Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain,0.00034734688892713855,0.00032247929082791424
NCT01010854,Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer,0.0003458387077617994,0.00039967703906821066
NCT01050634,Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST),0.0002851451958914439,0.00028103562543094023
NCT01070485,"BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease",0.00031613572506232094,0.00035148640227772375
NCT01047774,The Effect of Soy Protein on Post- Breast Cancer Surgery Pain,0.0002934412643651149,0.0003196143335022454
NCT01047358,Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer,0.0003526980666717078,0.00035372255852241544
NCT01097460,"MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer",0.00031652339628937505,0.0003076076014389158
NCT01097278,S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,0.0002837012034848084,0.0003745478044528244
NCT01053468,Facilitating Physical Activity Behavior and Health Outcomes in Breast Cancer Patients Receiving Chemotherapy,0.00031014493231776156,0.0003239305750131546
NCT01031030,"Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)",0.00029935331187568595,0.0002892820770734004
NCT01088893,Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy,0.0003745679421930999,0.0003786203501570251
NCT01088477,Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer,0.0002599216350582993,0.0002630405441866229
NCT01049295,Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer,0.00026983543157007537,0.0002815076773186217
NCT01049425,Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer,0.00031630216720438496,0.0003002003496452524
NCT01022086,Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab,0.0003027275799410724,0.0003187632914821421
NCT01061359,Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer,0.0003337163797290577,0.00029947444159729626
NCT01077154,Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE),0.0003052603580469355,0.00033419962088790297
NCT01077648,Brain Metastasis in Breast Cancer Patients,0.0004344766367325104,0.00039680768595526633
NCT01077726,A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression,0.0003223584377995067,0.0003109999315394776
NCT01077453,Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer,0.000300191204041048,0.0003397151809568575
NCT01089933,Reducing Pain and Disability After Breast Cancer Surgery,0.0002934413064841447,0.0002787118259038998
NCT01089764,Couplelinks.ca - An Online Intervention for Couples Affected by Breast Cancer,0.00047844215270982453,0.00017884026196544534
NCT01089699,A Trial Testing Professional and Peer-led Support Online Support Groups for Young Canadian Breast Cancer Survivors,0.0002799377530411398,0.00033549409921691445
NCT01089998,"PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations",0.0002988673921610279,0.00021487567215799412
NCT01005108,Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors,0.000279250927378065,0.0002738964356219765
NCT01005641,ELBA: Exemestane and Lapatinib in Advanced Breast Cancer,0.0003100065759576962,0.00025704346685275186
NCT01007695,Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot,0.00024412054886769705,0.0002805492988512887
NCT01007890,Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer,0.00031892332298604067,0.0003515749891560282
NCT01011218,Management of Insomnia in Breast Cancer Patients,0.00035345152087986925,0.0002639770315896352
NCT01011946,Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer,0.0003523209083971946,0.00030980016798706636
NCT01060514,Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer,0.0002520056686212748,0.00036504905369446895
NCT01009918,Lisinopril or Coreg CRÂ® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab,0.0002615718554001857,0.00025451623174763474
NCT01009788,ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer,0.00033436371491140136,0.0003564962845097358
NCT01009437,Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer,0.0002743276283911495,0.0002897231712651198
NCT01079676,A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer,0.00032354941239706866,0.00045987877778511565
NCT01015521,Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer,0.0003936874263495753,0.0006417843932755496
NCT01015131,18F-FLT-PET in Breast Cancer (MK-0000-139),0.00047601038216696324,0.00030840417523615216
NCT01015625,Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer,0.0004979917235373959,0.0003285575708882511
NCT01075802,Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms,0.00040306837781777725,0.0003469541198759141
NCT01019616,Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy,0.0002763058126370516,0.00034135245414627024
NCT01019512,Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer,0.00035692638014115063,0.0003767963242656275
NCT01055678,To Evaluate the Characteristics of a Breast Cancer,0.00048541835215319175,0.0003215363949542628
NCT01073865,Study to Compare Zoladexâ„¢ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer,0.0003258769039143045,0.0003344440541246022
NCT01004172,Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases,0.00028601161217961036,0.00033100566891947276
NCT01004744,Feasibility of Pre-Surgical Intervention Studies for Evaluating Targeted Therapies for Breast Cancer,0.00032586640487570605,0.0003584209044384802
NCT01004796,Study of Biomarkers in Tissue Samples From Patients With Breast Cancer,0.0003596256071426825,0.00038957053242601636
NCT01071564,RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery,0.00031497740217038746,0.00039082376718346183
NCT01071109,The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy,0.0002520025727966044,0.00031325673743910727
NCT01093235,Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer,0.00035905219371017383,0.00027618397820495497
NCT01093612,Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer,0.0003736755404850545,0.0002886641932578223
NCT02445482,SOLTI Breast Cancer Molecular Screening Program (AGATA),0.0002825960973702321,0.0002922820893051108
NCT02445586,Safety Study of Pertuzumab (In Combination With Trastuzumab and Docetaxel) in Indian Patients With Breast Cancer,0.00034343301729233404,0.00048158038554646905
NCT02411344,"Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Patients With Breast Cancer Sensitive to Hormonal Therapy",0.00033699381518543473,0.0003710943753782404
NCT02416427,Targeting the Hippo Transducer TAZ in Breast Cancer With Statins,0.0003336103865378517,0.0003451865797651076
NCT02475174,Manual Lymphatic Drainage in the Superior Member in Women in Post-surgery for Breast Cancer,0.0003532385688242448,0.0002277686740434544
NCT02404844,"Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer",0.00043148040406533765,0.0003029968698259024
NCT02481128,Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer,0.00027188255054653835,0.0003093652037978602
NCT02401685,POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer,0.00037210897672516983,0.00034079057586886686
NCT02487524,Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer,0.0003409052086007302,0.0002818149866206105
NCT02400060,Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer,0.0003568032161937984,0.00033052577891689607
NCT02400476,A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,0.00033144279523359554,0.0003515252302373641
NCT02400658,Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer,0.00030621081250405087,0.00038811910498156465
NCT02400567,"Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women",0.0002580257632458929,0.0003363828837530794
NCT02457039,Acupuncture Prevents Chemobrain in Breast Cancer Patients,0.00043326574200189884,0.00032269610602460563
NCT02479997,Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients,0.00029218723853893834,0.0002693369599857293
NCT02479607,Effects of an ICT-platform for Assessment and Management of Patient-reported Symptoms During Treatment for Breast Cancer,0.0003161364368030771,0.00036800142450331484
NCT02479347,Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine,0.00024599976410314377,0.00022819566460904493
NCT02444026,Feasibility and Efficacy of Internet-delivered CBT for Insomnia in a National Cohort of Danish Breast Cancer Survivors,0.00033398494377017313,0.0002595094129831649
NCT02419807,Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer,0.00029125751710774194,0.0003671094405323078
NCT02488603,Decision Aids for Tamoxifen Treatment in Breast Cancer Patients,0.000342816662602075,0.00033910330392056254
NCT02488187,Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients,0.0003602731880373691,0.00035586803891297984
NCT02432950,Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer,0.0002971669930798837,0.0003219155766860107
NCT02437318,Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,0.0003175736401937026,0.00033388938112642537
NCT02441270,Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients,0.00030386826319988197,0.0003893412543821908
NCT02441946,"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",0.000296334239822612,0.00032454550109193826
NCT02423902,A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer,0.0003228373331034691,0.00028709876437442146
NCT02449824,MRI and Early Decision-making in Chemotherapy for Breast Cancer,0.00036266390103587216,0.0003050727653912488
NCT02407613,Efficacy of MR-HIFU Ablation of Breast Cancer,0.00046882095238647367,0.00037531734166032065
NCT02429427,European Celecoxib Trial in Primary Breast Cancer,0.00046968333577554174,0.00040330689051672425
NCT02422641,Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis,0.0003055809628644143,0.00034043243483000213
NCT02422615,Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.,0.0003618560286187486,0.0003805978538672461
NCT02422199,"A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab",0.0003317746510768491,0.00031484095724589343
NCT02414776,Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy,0.0002580626494461156,0.00026919522847977634
NCT02462681,Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery,0.0002453229150448307,0.0002699007862703696
NCT02462226,Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow),0.0002536481675821059,0.00027398357769770586
NCT02402712,Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,0.00034854314015292566,0.00032402978972420626
NCT02455453,Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography,0.00025957453931817973,0.00034234832572008347
NCT02455791,Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery,0.0003272680204680084,0.00037630207955571473
NCT02430103,Study of Preservation of Ovarian Reserve Function During Chemotherapy for Breast Cancer Patients at Reproductive Age,0.0003342035091888804,0.00030716887604962593
NCT02476539,Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer,0.000349605292917772,0.00037653357550483565
NCT02472353,Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer,0.0003362585866547331,0.0002829128031893218
NCT02491957,Impact of LOFT Therapyâ„¢ on Breast Cancer Survivors,0.0005240256729824867,0.0003312619493383991
NCT02491697,Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer,0.0003088229768651563,0.0003409541678565894
NCT02499146,"Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer",0.0003055421287112459,0.0003120347150249761
NCT02499367,Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients,0.00032185379685298034,0.0003371839935297534
NCT02474641,Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer,0.0002790181014923971,0.00032698799340818405
NCT02428114,A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study),0.00027539439724446924,0.0003351686186035464
NCT02433067,Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer,0.0003076168374762572,0.0003317587342522918
NCT02480842,Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction,0.00024972969293325664,0.00038133459487264744
NCT02480933,Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens,0.0002686522810538214,0.0002604355611128809
NCT02467686,"Breast Cancer, Sexuality and Black Cohosh",0.000468680559275468,0.0004153266665111807
NCT02454777,High-Intensity Interval Training in Improving Fitness in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy With Trastuzumab,0.00033101455332843177,0.0003361242047195844
NCT02486796,Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer,0.00024735528561840414,0.0002984068922736282
NCT02458391,Complete Decongestive Therapy in Breast Cancer-Related Lymphedema,0.0002662057375155082,0.0003191776563357761
NCT02494869,Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer,0.00024994528986987534,0.00025131241773318627
NCT02494206,Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL),0.00026671036723843923,0.00031035775288005494
NCT02495155,Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer,0.0002702507952427546,0.00019657453624635914
NCT02413008,A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting,0.00028301110735031365,0.0003317247578236172
NCT02463474,Mobile Health (mHealth) Black Women With Breast Cancer,0.00046854042245142495,0.000338267558657885
NCT02463032,Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer,0.00043129179889895826,0.0005266439976104527
NCT02439554,Risk Factors for Medium-term Adverse Outcomes and Predictive Modeling for Breast Cancer Patients,0.0003520110444311342,0.00036793785836984914
NCT02415387,Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer Who Received Chemotherapy,0.0003135067575500789,0.0003358759623651694
NCT02493569,A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China,0.0003253244787109139,0.0004617229408162231
NCT02450357,The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment,0.0003195523919314089,0.0002534623699674692
NCT02450058,Adjuvant FEC Versus EP in Breast Cancer (MIG5),0.0008984903380354321,0.000311307335325663
NCT02448771,A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,0.00028549505113952797,0.0003181005415002002
NCT02483871,Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy,0.0003077036568753648,0.00036423062035137796
NCT02483377,Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer,0.0003381103240867591,0.0003103824823702439
NCT02483767,Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer,0.0002538964977513179,0.0003044958275231974
NCT02403973,Trial Comparing Perioperative Care for Breast Cancer Patients at a Patient Hotel vs a General Surgical Ward,0.00032683891753049324,0.00034990129538968765
NCT02438358,Feasibility Study of Intraoperative Imaging in Breast Cancer,0.00033464689825528723,0.0002909509010436946
NCT02440620,Cardiac Toxicity in Medical Treatment of Breast Cancer,0.0003063714520094861,0.0002930750002831545
NCT02440191,3DCRT vs. IMRT in Early Breast Cancer,0.0008984903380354321,0.00072317634944802
NCT02440230,Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients,0.00036015989033149606,0.00035550021182154123
NCT02460744,2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer,0.00043185449438527,0.0003414060438638653
NCT02453620,"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",0.00032235690106875644,0.00036353319570051534
NCT02482376,Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer,0.0002707597960644927,0.000284588618711702
NCT02482753,Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer,0.00032571391629792457,0.0003885876766168543
NCT02482506,Moving Forward: A Weight Loss Intervention for African-American Breast Cancer Survivors,0.0002830262842441217,0.00019753382477378142
NCT02426489,Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System,0.00034220422115258337,0.00029037669468331837
NCT02408393,MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery,0.00029195002929812384,0.00023921115558310323
NCT02408107,A Home-based Physical Activity Intervention in Breast Cancer Survivors,0.00026228130814205024,0.00027009451195543943
NCT02408770,Breast Cancer - Anti-Progestin Prevention Study 1,0.0003258386254168665,0.00027244501684980645
NCT02406794,Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women Given Breast Cancer Survivors,0.0003707759998357284,0.00031269320508186735
NCT02451735,Genetic Counseling for Breast Cancer Survivors (GC for BC),0.0004691032146431516,0.00030521593296722654
NCT02443428,Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry,0.0002837948332602925,0.000352029064146518
NCT02443493,Laser Therapy for the Prevention of Radiodermatitis in Breast Cancer Patients,0.00031643714456863146,0.0003022643327174301
NCT02443467,A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer,0.0002952376491549335,0.0003584824322464902
NCT02420249,Qigong for Breast Cancer Survivors,0.0004689658894943532,0.0003139930703522055
NCT02485626,Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors,0.0003388721670361755,0.0002858241528657259
NCT02485678,A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer,0.0003116622075550856,0.00025054068240477635
NCT02473159,Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer,0.000251358211174276,0.0002571304430939498
NCT02409316,[18F]FES PET/CT in Endocrine Refractory Breast Cancer,0.00047601038216696324,0.00032479751492490966
NCT02464982,Psycho-esthetic Impact of Tattoo Technology as Part of Mammary Reconstruction After Surgery Against Breast Cancer,0.00025444612977874127,0.00025598324323117467
NCT02424292,Evaluation of a Physical Activity Program in Overweight Breast Cancer Patients,0.0003033396489765393,0.00032619153260900766
NCT02468739,Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer,0.0002808103452674338,0.00025447655004837556
NCT00101400,BAY43-9006 - Phase II in Advanced Breast Cancer,0.0005211184264943355,0.00037637512708835896
NCT00165243,Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer,0.000348751364977225,0.0004165801288788702
NCT00121134,Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer,0.0002980739765940748,0.0003367975151522943
NCT00121992,Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (5 FAC) as Adjuvant Treatment of Breast Cancer Patients,0.0003232462430218999,0.00029779377485663136
NCT00102219,A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer,0.00035471855479764566,0.00039512236081712024
NCT00195013,Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy,0.0002931291123997858,0.00026405491188016014
NCT00195091,Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer,0.00039776986033762186,0.0003361748404911263
NCT00190671,A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients,0.000355934292902013,0.00039258669161055637
NCT00184210,Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue,0.0002789050550270337,0.00023145304214458546
NCT00179634,Study of Fine Art Photographs and Visualization Tapes to Improve Surgical Recovery in Breast Cancer,0.0002804234224477507,0.0002603660116104092
NCT00179309,Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer,0.00026695908143143033,0.00039231521298162833
NCT00110695,"Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer",0.0003152675262038422,0.0004172246279997987
NCT00185744,Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer,0.00033508060530874646,0.0002894030758139937
NCT00119262,Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer,0.00031168658675913264,0.0002947185184548818
NCT00124111,A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer,0.00027899148577772916,0.00031596012958105623
NCT00109239,A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer,0.0003580657431989658,0.00034388611900605355
NCT00109785,PET Scans in Patients With Locally Advanced Breast Cancer,0.0003820993646478516,0.0002932789360444753
NCT00171340,Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.,0.0002513680059614554,0.00021848489076536353
NCT00171314,The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer,0.0002632665906104733,0.00021756801048776537
NCT00171704,A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer,0.0002924606897982598,0.00029726418279382456
NCT00160901,Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer,0.0002707136248334195,0.00025317811833191323
NCT00127205,S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.,0.000336479033224612,0.00021917742610135798
NCT00133796,Neoadjuvant Herceptin in Patients With Breast Cancer,0.0003698397360021657,0.0004988680817340596
NCT00189644,6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer,0.00046953344498591916,0.00025771059467519084
NCT00189670,Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer,0.0003475989255540084,0.00025297854413426803
NCT00176046,"Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study",0.0003040082797319512,0.0003079143793898484
NCT00128856,"Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients",0.00031760422671038053,0.0002512527716669377
NCT00128362,Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer,0.0002788825287683937,0.0003208140149016178
NCT00128297,Pamidronate Administration in Breast Cancer Patients With Bone Metastases,0.0003154254249143009,0.00036775270338720953
NCT00174343,Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients,0.0003324191323938181,0.0003327787145153802
NCT00174707,Study of Docetaxel in Breast Cancer Patients,0.0004049144008353621,0.0003642478740866476
NCT00174655,BIG 02/98 Docetaxel - Breast Cancer,0.00048237417477065215,0.00029466624905173904
NCT00199212,PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2,0.00028408573831422736,0.000301140968574986
NCT00193726,Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer,0.00033816704802317355,0.00033225013558814615
NCT00193011,Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer,0.0002841424611442115,0.0002748394397143565
NCT00193115,Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer,0.0002578422515143105,0.0002430021899185896
NCT00193089,"Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer",0.000333301109008099,0.00030514213596508435
NCT00166998,The Study of Infrared Imaging on Breast Cancer,0.00039869345648378365,0.00029890527025637096
NCT00166543,Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer,0.00046854042245142495,0.0006229033808030089
NCT00149214,Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens,0.00030648318631417744,0.0003532983306578117
NCT00106145,A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014),0.00037802278324214583,0.0003565273152934285
NCT00155038,Imaging Characteristics of Breast Cancer in Women Under 40 Years of Age,0.0003389945983594215,0.0002895637326558118
NCT00155259,"Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer",0.00028912422891184204,0.0002925463430489531
NCT00136539,Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer,0.00029546815905875793,0.0003626713934352355
NCT00196872,A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN),0.00033281082080415675,0.00038961593997957476
NCT00196833,Breast Cancer in Pregnancy Register Study,0.0003233454501416859,0.00033258175434674596
NCT00148681,Preoperative Herceptin and Navelbine for Breast Cancer,0.00033876477528522103,0.00043295645922543114
NCT00148694,Preoperative Cisplatin in Early Stage Breast Cancer,0.0003500136997384892,0.00037494732394914733
NCT00148668,Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer,0.0002449764804045162,0.0003176329968244337
NCT00148720,Capecitabine in Women With Operable Breast Cancer,0.00047883695450085635,0.0006030843389947427
NCT00191789,Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer,0.0002723193308039498,0.0002547167038685143
NCT00191243,Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer,0.0003442437373338811,0.0003475013507615806
NCT00130533,Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients,0.0003423692133580468,0.0003658177798401901
NCT00130507,Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab,0.0003427964056450763,0.00026894824174949485
NCT00118508,The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study),0.00029694307113375306,0.0003201173274722591
NCT00161265,Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer,0.00030844842798338144,0.000412344175339263
NCT00123812,Frequency of Portal Images Required to Enhance Quality Assurance for Breast Cancer Patients Treated With Radiotherapy,0.0002969107666006515,0.00025982989384099915
NCT00123929,Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer,0.0002744996359286137,0.0002526613603145188
NCT00123669,Primary Progesterone Therapy for Operable Breast Cancer,0.0003708699522542053,0.00034442361447724627
NCT00123799,Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection,0.00032141296499390285,0.00033139100508964355
NCT00156039,Randomized Trial of Follow-up Strategies in Breast Cancer,0.00033885746591943023,0.00030525905041381337
NCT00156260,Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage,0.00035253202092072936,0.00025699249423652583
NCT00156806,Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.,0.00028512096802436453,0.0003089338025394138
NCT00156312,Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine,0.0002714493175470896,0.00045131207150904954
NCT00156416,Menopause and Meditation for Breast Cancer Survivors,0.0003377965019666558,0.00032803276794364587
NCT00156052,Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer,0.00025801804987759164,0.00020960003830748907
NCT00147550,"MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.",0.0002733489893002283,0.0003385779220410275
NCT00112749,Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer,0.000270780672682272,0.00030399235662817973
NCT00144898,GF-GS 01: Comparing Conventional Axillary Dissection Versus Sentinel Node Resection in Clinically Node-negative Operable Breast Cancer,0.0002414304667002028,0.0002619164714873873
NCT00153894,Effects of Exercise Intervention on Insulin Levels in Breast Cancer Survivors,0.00027755764598263885,0.0002722846342400143
NCT00146562,Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer,0.0002547201901088997,0.0002841545373129212
NCT00146601,Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer,0.00026928233486250483,0.0003942995062166135
NCT00146588,"Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer",0.0002835975636661171,0.0003899698511560276
NCT00150917,RCT of a Group Intervention for Women With a Family History of Breast Cancer,0.0002834985166111589,0.00025042764995682724
NCT00188721,Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.,0.0002711887025009699,0.0002715391119275315
NCT00188604,The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer,0.00033351632680197227,0.00035196794521488527
NCT00131963,A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide Â©) and/or Weekly Paclitaxel,0.0003365024554698644,0.00037571359312501456
NCT00172068,Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow,0.0002635053592073932,0.0003106020354841954
NCT00172029,Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid,0.00033410616255851464,0.00030628009506382544
NCT00115505,"Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer",0.00036601298406028707,0.00035646951104111355
NCT00115713,Effects of Aerobic Exercise Versus Weight Training in Breast Cancer Survivors During Chemotherapy,0.0002706292074330004,0.0003099402904103394
NCT00115414,Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC),0.00037407457364833707,0.000346709525013447
NCT00198250,Venlafaxine for Hot Flashes After Breast Cancer,0.0003350448171810319,0.000315164873699208
NCT00198237,Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer,0.0002632460820827819,0.00036065621862732566
NCT00100893,IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer,0.0003496978092645078,0.000245284126848746
NCT00152178,The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC),0.0003365806015173978,0.0003595230263480845
NCT00152191,A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC),0.00027154637005046407,0.0003200114566856405
NCT00107497,Radiation Therapy in Treating Women With Localized Breast Cancer,0.0004890441595013054,0.0002883523290814687
NCT00107094,Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer,0.00032827913559510747,0.0004051174660009643
NCT00107484,Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer,0.00029114078264722134,0.000294924828120254
NCT00107016,Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women,0.000272023970197582,0.0003576383902802901
NCT00140140,"A Phase I/II Study of ABI-007 (AbraxaneÂ®, NabÂ®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer",0.0003293466678836947,0.00030705428891240725
NCT00140075,Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer,0.00026738525306026277,0.0003399497487876367
NCT00186602,Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?,0.0002870175478753694,0.0003374167458295937
NCT00186524,Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?,0.00025587381835577295,0.000296661943227666
NCT00186641,High Dose Chemotherapy and Autologous Transplant for Breast Cancer,0.0003336113919936841,0.0003827690651731943
NCT00177840,Acupuncture to Treat Cancer-Related Fatigue in Breast Cancer Patients,0.0003045982276971675,0.0004508468702798688
NCT00167414,Study for Using Radiosurgery on Limited Metastases of Breast Cancer,0.0002912647323440813,0.00037442330857141845
NCT00175344,Does Scar Massage Improve Postoperative Pain and Function in Women With Breast Cancer?,0.00024056991571753687,0.00035356353379634045
NCT00145743,Diagnostics and Therapy of Disease-Related Quality of Life of Patients With Breast Cancer,0.00032084269601327165,0.00041126185609160576
NCT00129376,Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients,0.00031903557987676077,0.00034258098463909616
NCT00129389,FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients,0.00032493211910011096,0.0003611402709478038
NCT00129922,"Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) Versus FEC Plus Paclitaxel as Adjuvant Treatment for Node Positive Breast Cancer Patients",0.0003250688086386104,0.00035237387160894936
NCT00129935,"EC (Epirubicin, Cyclophosphamide) Followed by T (Docetaxel) Versus ET (Epirubicin, Docetaxel) Followed by X (Capecitabine) as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Patients",0.00030786279321550413,0.0002838825588404684
NCT00114816,"Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer",0.0002687421490613642,0.0003182491830639564
NCT00114296,Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer,0.0003397759837499333,0.00022515793317918963
NCT00194779,Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery,0.00031266828669336886,0.0003909899135978345
NCT00194363,Strength Training Intervention for Breast Cancer Survivors and the Effects on Lymphedema Status,0.0002586631995715286,0.0003051671676430747
NCT00194792,Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer,0.0003246833706146164,0.00033118108730957184
NCT00194571,Enhancing Connections: Helping the Mother With Breast Cancer Support Her Child,0.00033588507516676296,0.0002078826836594379
NCT00194337,"Digital Mammography, Ultrasound, MRI, and PET Scans in Women With Newly Diagnosed Breast Cancer",0.0002598408977058151,0.0002274650249243616
NCT00194753,Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12,0.00024432698406996213,0.00033190400217729453
NCT02139358,Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,0.00026999875594474254,0.00032575881085187923
NCT02150525,Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors,0.0004688261527814181,0.00021247402053867673
NCT02131506,A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer,0.00034591848708157203,0.0003563129497182159
NCT02131064,A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,0.0003576077712540015,0.00035197172493677686
NCT02163694,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",0.0002668537872317781,0.00031782363996807843
NCT02102490,A Study Of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread,0.00039453067907617,0.0006183453784621282
NCT02102282,Breast Cancer During Pregnancy,0.0004691000605511326,0.00026479539740846894
NCT02102568,Study the Impact of Chemo-induced Menopause on the Quality of Life in Young Women of Childbearing Age and Diagnosed With Non-metastatic Breast Cancer,0.00028015873580197406,0.0002892098778012748
NCT02178475,Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy,0.0003382060234902495,0.00035805810069034703
NCT02162719,"A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors",0.0002972827464770298,0.0003416687463106937
NCT02162667,Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer,0.000410437541607277,0.00039767814238792957
NCT02104830,Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients,0.0003341470077186974,0.00035414694201845685
NCT02168452,Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer,0.00024265111151650445,0.00027497101291119
NCT02168179,KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer,0.0003206999661290554,0.0003409165184411663
NCT02177175,Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification,0.00025964403541584973,0.0003080929168978248
NCT02188745,ER Reactivation Therapy for Breast Cancer,0.0005240256729824867,0.00025343170374396515
NCT02195076,Non Invasive Detection of Lung and Breast Cancer by Odor Signature,0.0002526121737272613,0.00024215449182798428
NCT02195960,Supplementation With Dietary Anthocyanins and Side Effects of Radiotherapy for Breast Cancer,0.0002887842763650006,0.00029539633374585286
NCT02134977,"Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: ""QOL Survey in Premenopausal Breast Cancer Patients""",0.0002890754828598115,0.00024407070358626037
NCT02157051,Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer,0.00035230380498784634,0.00033434300160166473
NCT02125006,"The Effect of an Inter-Disciplinary Program, Including MBSR, in Breast Cancer Survivors With Chronic Neuropathic Pain",0.0002805206833871412,0.0002758943116470805
NCT02125344,"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)",0.000329365527092886,0.0003192321074422512
NCT02125630,Bone Metastasis and Surgery in Breast Cancer,0.00035493543231871665,0.00026768739553674617
NCT02125019,Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer,0.0002689453915195935,0.00034933516902070785
NCT02112682,Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy,0.00032081842433520353,0.00034122013416808565
NCT02166983,Cognitive Enhancement Program in Improving Cognitive Function in Breast Cancer Survivors,0.00028122615341870415,0.0003530231138435334
NCT02166281,Impact of Adjuvant Treatment With Aromatase Inhibitor on Sleep Disturbances in Postmenopausal Women With Endocrine Responsive Early Breast Cancer,0.00028827649042446326,0.0002915215869674636
NCT02183805,Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer,0.0002802755192993753,0.0003101942664427163
NCT02159157,"A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer",0.00031680148810238275,0.00030980968843053526
NCT02127073,"Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer",0.00027651004004969386,0.00029430291835758564
NCT02144012,A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer,0.0003438957107686062,0.0003770200826720255
NCT02135159,Patients With Brain Metastases From HER2-positive Breast Cancer,0.0004344766367325104,0.0003267057584437712
NCT02129556,"Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer",0.0002839139024272926,0.0003588626812585467
NCT02129686,A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients,0.00034976545618633034,0.00032465863096668414
NCT02107703,A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,0.0002826891117524126,0.00027898412614459366
NCT02154776,"Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.",0.0002998615276412234,0.00034703583506465955
NCT02154139,"Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey ""Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)""",0.00029213208325970627,0.0002634429565640353
NCT02152462,Exergaming Intervention and Breast Cancer Biomarkers in Black Women,0.0003474025314562835,0.0002654407360727226
NCT02190539,Homeopathic Protocol for Advanced Breast Cancer,0.0003045371525852954,0.00034445374079303427
NCT02120417,A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,0.0003021653005766772,0.00034004506897619696
NCT02171078,Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance,0.00030581758721575514,0.00020933050782851232
NCT02133677,A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases,0.000328703629372482,0.00030204042998103103
NCT02158299,Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer,0.00024085651888380958,0.00022542743410833012
NCT02187718,Ambulatory SNP Under Local Anaesthesia in a Subgroup of Breast Cancer Patients - Trial,0.0003518430838580476,0.0003869362902141752
NCT02187289,A Study to See Whether Adding Night-time Compression to the Standard Care Will Result in Improved Control of Arm Swelling (Lymphedema) in Breast Cancer Subjects,0.00026827061861562257,0.0002921679817808028
NCT02117011,Effects of a Structured Exercise Program on Cancer-Related Fatigue in Women Receiving Radiation Therapy for Breast Cancer,0.0002556681889934451,0.0003061709942361035
NCT02167932,The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer,0.00026280131964550164,0.0003436637966721585
NCT02167854,"Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",0.0003372310644497211,0.00037291779974197046
NCT02103140,An Exercise RCT Targeting African-American Women With Metabolic Syndrome and High Risk for Breast Cancer,0.0002849211385702175,0.0002549266431765253
NCT02103634,NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer,0.0002904057761933469,0.0002644322263384645
NCT02103387,Five Sessions Intervention to Facilitate Adaptation to Breast Cancer,0.0003403407718732502,0.000200540996423398
NCT02199418,Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer,0.000318704335387395,0.0003384115191691613
NCT02119481,Effects of Mindfulness Meditation and Stress Management After Breast Cancer,0.00025406118469774644,0.00023908552332937413
NCT02119715,A Phase II Study Comparing Pegylated rhG-CSFï¼ˆHHPG-19Kï¼‰ and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy,0.0003714839433404653,0.0003165469010428716
NCT02189278,Improving Adherence to Recommended Surveillance in Breast Cancer Survivors,0.0004699558903544415,0.00030077901997021514
NCT02194166,An Open-Label Randomized Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Patients With HER2-Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration,0.00032857131879123375,0.00025833507297829696
NCT02115984,"Study of the Safety and Leukostimulatory Activity of the Preparation ""Panagen"" in Patients With Breast Cancer",0.00033345628236849527,0.0004175837677180539
NCT02115594,Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer,0.00030632537137213837,0.00028163990208901246
NCT02115282,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,0.0003219280728221431,0.0003724499507600381
NCT02115152,Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer,0.0002780627706510259,0.0002393791693248963
NCT02115048,Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,0.0003449879496450367,0.0004071401652815024
NCT02148575,Integrating Palliative Care Into Self-Management of Breast Cancer,0.0003338975055886465,0.000271859310601592
NCT02185352,"Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases",0.000248660404403247,0.00036210645920893824
NCT02165605,HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer,0.0003198739393820197,0.0003534853194292208
NCT02142868,"Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",0.0003237752932726684,0.0003988723872244516
NCT02142010,Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer,0.0002759018264060996,0.00034987445221825337
NCT02161900,Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer,0.0002794909498083578,0.0004822486551474794
NCT02161315,Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer,0.0002509816739090629,0.00022627966817892408
NCT02126800,Rapid Medical Donation Programme for Breast Cancer,0.0002802874300952399,0.00034108873012734744
NCT02126449,DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer,0.0003557022679088393,0.0002935709531510636
NCT02132000,Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients,0.00031372023795822075,0.0002692131993089919
NCT02132390,"Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea",0.0002693106779394907,0.00025448304180429094
NCT02132949,"A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",0.00037181542050552304,0.0004083612705544616
NCT02108561,Breast Cancer Tumor Heterogeneity,0.0004773286719148827,0.00031507609117260757
NCT02137252,Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer,0.00032936950840943525,0.00035770837549875013
NCT02198118,Domiciliary Physiotherapy During Breast Cancer Radiation,0.0003477055131934477,0.00033974558390583045
NCT02141139,Perioperative Inflammation and Breast Cancer Outcome,0.0004692624285686759,0.00025501137159805764
NCT02141373,Effectivenes of Cyanoacrylate (Glubran 2Â®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection,0.0002977787673519788,0.00032036244072340106
NCT01169792,"Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients",0.0004915603397778765,0.0004292058839110933
NCT01187381,An Observational Study of the Mean Duration of Herceptin (Trastuzumab) Treatment in Patients With Early or Metastatic HER2-positive Breast Cancer (HERODOT),0.00035432407307302565,0.00032399458085646625
NCT01190566,PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer,0.0002748867689152881,0.00027899896567253675
NCT01190345,Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer,0.00025735665737658587,0.00034685227295931897
NCT01175694,Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer,0.00027894658430186625,0.0002679204451793696
NCT01149083,Veliparib With or Without Carboplatin in Treating Patients With Stage III-IV Breast Cancer,0.00031634442398803335,0.0003672797126386332
NCT01181518,Tamoxifen Pharmacogenetics in Asian Breast Cancer Women,0.00047858834564166596,0.0004097958814819336
NCT01126190,Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003),0.00032250883705381737,0.000263107014612806
NCT01120158,Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer,0.00036454960581750785,0.0003964320724842384
NCT01120171,Myocet Plus Endoxan for Older Patients With Breast Cancer,0.0003513971475771963,0.00035183040196753865
NCT01106820,Progressive Resistance Training Versus Relaxation for Breast Cancer Patients During Chemotherapy: Biological Mechanisms and Effects on Fatigue and Quality of Life,0.0003099938942838428,0.0002553791906749802
NCT01140282,Exercise Program for Early Breast Cancer Survivors,0.00034288800046162213,0.0003679071968108716
NCT01140776,Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy,0.0003660498935989911,0.0003135531863650123
NCT01140763,Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer,0.00024832557623432044,0.00027105982788425755
NCT01171508,Circadian Disturbances After Breast Cancer Surgery,0.0004979917235373959,0.0002785659104918444
NCT01171417,A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer,0.00034587257578281953,0.000270967364422928
NCT01155063,Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients,0.0003342369125435433,0.00028480530270461973
NCT01127373,Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer,0.0002506734266731802,0.00028775793041124135
NCT01127763,RAD001 Plus Carboplatin in Breast Cancer Patients,0.0004351692350109705,0.00043729035591720745
NCT01127295,Pharmacology of Adjuvant Hormonotherapy in Breast Cancer,0.0008984903380354321,0.00046743598850962955
NCT01159405,The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer,0.0003980524029730522,0.00043793533788658376
NCT01159236,Molecular Triaging of Newly Diagnosed Breast Cancer,0.0003429463624033047,0.00039713098100882765
NCT01154972,Preoperative Localisation of the Sentinel Lymph Node in Breast Cancer,0.00047253109566095647,0.00031537427776521826
NCT01189851,Intraoperative Radiotherapy for Early Stage Breast Cancer,0.0003492518412452544,0.0002151314823157843
NCT01116713,Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer,0.0002792640624740766,0.0003078154173417361
NCT01153035,Excision Followed by Radiofrequency Ablation for Breast Cancer,0.0003345570551665555,0.0002857843378119192
NCT01153282,Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer,0.0002622405882670163,0.00021472071565215917
NCT01194427,A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer,0.0003001971278372242,0.0003645368672050575
NCT01194869,Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer,0.00026283262023067406,0.00036975901478095846
NCT01142778,A Study of Avastin (Bevacizumab) Added to Herceptin (Trastuzumab) Plus Docetaxel in the Neoadjuvant Setting in Patients With Early Stage HER2-Positive Breast Cancer,0.0003535356453064622,0.0003497542640984164
NCT01142661,Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies,0.00028235537574142845,0.0003421030772609566
NCT01142141,Manual Therapy in Postoperative Breast Cancer,0.00046854042245142495,0.00019962590060640145
NCT01142479,Compound Herbal Formula (TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy,0.00029852784134762426,0.0003236458630670704
NCT01148875,Mammography Reminders for Encouraging Women to Undergo Regular Mammography Screenings for Breast Cancer,0.00033619239186441876,0.00022161730781114313
NCT01172886,Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer,0.00033437001643783114,0.00023934143114784942
NCT01172223,Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer,0.0004599687777748781,0.00029795231257697275
NCT01196052,"A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer",0.0003548969927480984,0.00033935690247895205
NCT01196936,Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors,0.0002783163185067087,0.0003252512425739409
NCT01164930,Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer,0.0003487428578336415,0.0002833541433405377
NCT01132664,Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer,0.00041027319335060387,0.00044030029643604116
NCT01141868,Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors,0.0003408100255971902,0.00029727212512362404
NCT01141530,Deep Sequencing of the Breast Cancer Transcriptome,0.00033408443011726847,0.00025250205752650964
NCT01138553,Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer,0.00028857093012942106,0.00032419621886558685
NCT01138345,Biomarkers in Blood Samples From Older Breast Cancer Survivors,0.00034190342300851614,0.0003290295314780619
NCT01130259,"An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer",0.0002788319040282416,0.00033071162138172404
NCT01160718,Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy,0.00034346052456131005,0.0003404086740714242
NCT01177124,Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors,0.0002535460155208725,0.00027051012756365464
NCT01197456,Predictors of Ovarian Insufficiency in Young Breast Cancer Patients,0.00043157559510382436,0.0003853861776081363
NCT01108224,Psychotherapy to Patients With Primary Breast Cancer - Psycho-social and Survival Outcome From a Randomised Trial,0.00043129179889895826,0.00038203755354627875
NCT01191164,Pilot Study of Partial Breast Irradiation Utilizing Permanent Breast Seed Implant to Treat Breast Cancer,0.00027802287433836587,0.0003867396638653251
NCT01191580,Interpersonal Therapy for Depression in Breast Cancer,0.0003711499344316883,0.00024271362872242404
NCT01122342,Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.,0.00024220690765771962,0.0003024818006519271
NCT01192308,PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM),0.0003139062730157361,0.0003515814111938799
NCT01121549,A Non-Interventional Study With AromasinÂ® As Adjuvant Treatment Of Invasive Early Breast Cancer,0.0003020930668709458,0.00031588695701227393
NCT01151215,Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer,0.000306940060261831,0.00032097653310902415
NCT01151488,"Nutrition, Exercise, and Breast Cancer Survivorship",0.00033877972470066866,0.0002465722525103031
NCT01151046,Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer,0.00027068747727589717,0.0002542469211299326
NCT01134172,"Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life",0.00027938650994284605,0.0002994796201067163
NCT01111201,"International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients",0.00031365375397948025,0.0002761642406663589
NCT01137136,Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea,0.0003345642226955512,0.00028390198863305577
NCT01152398,A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy,0.00029162993950913174,0.00029347717380593904
NCT01152606,A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin,0.00033596011283055995,0.00028744219306774593
NCT01144572,Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment,0.00033248503024510583,0.00039496717834381435
NCT01144481,Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases,0.0002926424395164309,0.0002773812297576808
NCT01157767,Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation,0.0003276349393298223,0.0003423961308503102
NCT01157026,A Pilot Clinical Trial With Tocotrienol on Breast Cancer,0.00033772080112164256,0.0002485386506362881
NCT01157130,Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory,0.0003178366257876234,0.0003501594913385334
NCT01180335,Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer,0.00032529578864307676,0.0003917983202936426
NCT01166763,Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D,0.00028710473022583894,0.00020224844392683798
NCT01156168,Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab,0.00032356246056833326,0.0004367916528387467
NCT01156753,A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer,0.0003754348752612908,0.00037452449212869846
NCT01156961,A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX),0.0003371529287956321,0.0003314768809748668
NCT01104571,Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer,0.00035008520175948583,0.00032504737395353504
NCT01186367,Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer,0.0004712349684557014,0.0003217971024791945
NCT01112826,Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer,0.00028673496332226416,0.0003384029102053461
NCT01112839,Reducing Breast Cancer Recurrence With Weight Loss,0.0003378157044482189,0.0001846494255495751
NCT01112254,Evaluation of the Diagnostic Performance of MRIÂ±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer,0.0002640754206331434,0.00044299817563143534
NCT01170143,"Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer",0.00031028072539379057,0.00036973923593597915
NCT01110954,Fluorescence-guided Resection in Breast Cancer,0.00046983058888797877,0.00044501838602547774
NCT01162200,CyberknifeÂ® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer,0.0002887852896157379,0.00023377132044635995
NCT01199432,"Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer",0.0003143537937549091,0.0003552699444183028
NCT01118975,GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers,0.0002699641622871554,0.0003033932624448201
NCT01118624,Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer,0.000353115958960523,0.00038962750889602734
NCT01147016,Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery,0.0002819263581862071,0.0002655417596614993
NCT01182519,Lung Inflammation and Lung Metastases From Breast Cancer,0.0003334228715094608,0.00023884935567371852
NCT01182506,Rehabilitation of Cognitive Changes in Breast Cancer Survivors,0.0003341679620979398,0.00026608628042034044
NCT01185509,Trastuzumab and Vinorelbine in Advanced Breast Cancer,0.0003170733164646951,0.0003865398440630088
NCT01185132,Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy,0.00025768872366431375,0.00024030475861518466
NCT01105468,Breath Gas Analysis for the Diagnosis of Breast Cancer,0.00028302185989085486,0.0002790935944357523
NCT01176838,A 5 Year Follow-up on Newly Diagnosed Breast Cancer Patients,0.0004395077745741627,0.000339197703229944
NCT01113554,Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors,0.0002831338649036071,0.0003404518320769109
NCT01136369,Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer,0.0003162115724953807,0.0003225475906366668
NCT01114464,Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer,0.00036360358811736535,0.0003312474174134867
NCT01101438,A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer,0.00026617532029340644,0.0003324703763554502
NCT01143974,Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer,0.00029832864932706775,0.0002594004862157408
NCT01150513,Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer,0.0002696909642566079,0.00025724230210068125
NCT02089100,Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer,0.00043129179889895826,0.0003249410256148776
NCT02057029,Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer,0.00030870357427213876,0.00023196757444114948
NCT02057133,A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread,0.00032265842078949366,0.00033446338237554677
NCT02057536,The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.,0.0003054848628230433,0.0003506480823128942
NCT02000193,Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer,0.0002980584576994353,0.00038851857769823676
NCT02086578,Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions,0.00033544287726568943,0.00035524535452476416
NCT02017496,Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment,0.00031302545019089973,0.00042789912800051094
NCT02022202,Breast Cancer Genome Guided Therapy Study (BEAUTY),0.00035237021434726814,0.0003698571332268182
NCT02022579,DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer,0.00028401168688121556,0.0002473543990170436
NCT02068092,Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer,0.00033911219669597513,0.00028000781250423526
NCT02054338,A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer,0.00034880035876689203,0.0003420520263614517
NCT02009150,Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer.,0.000255254325770697,0.0003026216593653602
NCT02001506,Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer,0.00031584151738602527,0.00029212257711389743
NCT02066025,Blood Test for Breast Cancer Associated Auto Antibodies - Improvement of Octava Blood Test,0.0002772401806078225,0.00021520930851205526
NCT02046421,"Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",0.00030523234228291757,0.000409503882973513
NCT02046057,Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer,0.0002473439093489596,0.00028784377046784553
NCT02062983,Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients,0.0003566009685117403,0.00021912341137386335
NCT02062489,"Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients",0.00031884580389009766,0.00038290316661748796
NCT02028221,Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk,0.0002923772400025674,0.0003145412235609667
NCT02024074,Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients,0.00032166607230447157,0.00031930291007576143
NCT02094495,Pilot Study About Tamoxifen Therapy for Breast Cancer Patients,0.00038185284479535283,0.000390474319977996
NCT02015676,A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer,0.00035609724148590337,0.0003405990486064554
NCT02031042,Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer,0.00031423935848715637,0.0002971648772146148
NCT02041338,Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer,0.000338925774819799,0.00041594168978600264
NCT02041364,Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer,0.0002630958338287392,0.000341557181039132
NCT02091765,RCT of an Internet-based CBT Program for Sexuality and Intimacy Problems in Women Treated for Breast Cancer,0.00033829082541419553,0.00040828058457605283
NCT02091960,"A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer",0.0003038994858391271,0.00036634503561043736
NCT02053597,TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen,0.0002988622883893498,0.00024762645975585885
NCT02011880,Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer,0.00029754086693895595,0.0003460532472018119
NCT02078531,A Prospective Pilot Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive and Brain Function of Breast Cancer Patients,0.0003314410878552225,0.0003236274368651465
NCT02078570,Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol,0.00024483587878533774,0.00029895503063043325
NCT02078388,Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients,0.000318429302082082,0.0003148080210495084
NCT02060253,"Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer",0.0002613131893155631,0.0002976876104654549
NCT02065908,Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer,0.00034199522895329403,0.0002538359678547041
NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,0.0003447808580924676,0.0003194158370542192
NCT02056886,Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer,0.00032548463902147675,0.0003066739727489237
NCT02056483,REBECCA - Research in Rehabilitation After Breast Cancer,0.0004695259990623425,0.00028627793259467416
NCT02079662,The Role of Lifestyle Factors in Breast Cancer-Related Outcomes,0.00033936488700325246,0.0002953702494612601
NCT02048059,ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases,0.0004344766367325104,0.0005050838567944931
NCT02081612,Comparison of Nutrition Education Alone or With Acupuncture for Weight Loss in Breast Cancer Patients Post-Chemotherapy,0.0003062318715966162,0.00030621283312261494
NCT02080390,Strain Imaging in Breast Cancer Patients Receiving Trastuzumab,0.0003274798159499609,0.00035000255117331296
NCT02004496,Randomized Controlled Single-blind Trial to Evaluate the Mobile Tracking of Symptoms in Ambulatory Breast Cancer Patients,0.0002945764219046651,0.0003171094978233193
NCT02008734,Randomized Phase II Study to Assess PD 0332991 in Breast Cancer,0.000398554680326669,0.0003784717106296453
NCT02005926,The Accuracy of Sentinel Node Biopsy of Breast Cancer With Sonographic Abnormal Axillary Lymph Nodes,0.0002787813714422065,0.00027599065256622376
NCT02005549,A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer,0.00034780844119043056,0.0003804703056700001
NCT02005770,Anesthesia and Circulating Tumor Cells in Breast Cancer,0.00033445904563355054,0.00020731445707778125
NCT02027818,Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy,0.00039378378870296436,0.0003406971235220318
NCT02027376,Study With LDE225 in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients,0.0003559933837046673,0.0005071076928720942
NCT02037542,A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer,0.0002889619313698003,0.00029677930438954417
NCT02037269,LightPathTM Imaging System for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical Specimens,0.00025390588503317973,0.00028645367742769173
NCT02051010,ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer?,0.0003785402944323655,0.00037103221056696933
NCT02051751,A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,0.0002998389783293123,0.000382032056538631
NCT02058758,Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer,0.0002520536421825234,0.00016038458128605617
NCT02058667,Reirradiation With Concurrent Paclitaxel for Breast Cancer,0.00034546908920824306,0.00033663814892006795
NCT02010021,Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.,0.0003537634003980583,0.0003821352837260202
NCT02073045,Intensive Education in Increasing Understanding of Lymphedema in Patients With Breast Cancer Undergoing Surgery,0.00031191037748883467,0.0002964494514243808
NCT02050620,Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer,0.00030061361626287556,0.0003152170421557931
NCT02088710,Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer,0.0003420053386751608,0.000345335928138181
NCT02088684,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,0.00035271000803282723,0.00029414298129847315
NCT02007512,Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,0.0003504443309373556,0.00040649365243181854
NCT02095210,HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025,0.0003593148662763795,0.0003339865904816609
NCT02095743,Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer,0.00024085295814051238,0.00032642623989524993
NCT02077569,AKT Inhibitor in Oestrogen Positive Breast Cancer,0.0002891452717258686,0.00027379876914470925
NCT02077933,"Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",0.00034044250869750945,0.00034579767216360587
NCT02097459,Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer,0.00026251967580114715,0.0002720856481141661
NCT02067416,PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer,0.0004967929024157716,0.0003530905084531698
NCT02067884,Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery,0.0003163144882520077,0.0003550926868155519
NCT02067481,Effect of a Diet and Physical Activity Intervention in Breast Cancer Survivors,0.00026246152599183946,0.000284529325644721
NCT02067351,Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy,0.00033787985409408145,0.00026101399619137396
NCT02067741,CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer,0.0008984903380354321,0.0004153882774028296
NCT02032823,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,0.0003154194228246607,0.0003144936695740898
NCT02084784,Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research,0.0002945540319312128,0.00031136820430553957
NCT02030353,The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors,0.00027958215791206527,0.00027947733511448454
NCT02072512,The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer,0.00029909336867696705,0.0003731379812022433
NCT02069093,"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer",0.0002991731638922176,0.0002959288594257681
NCT02040935,A Study of Subcutaneous Herceptin (Trastuzumab) Administered at Home By Single-Use Injection Device in Patients With Early HER2-Positive Breast Cancer (HOMERUS),0.0003280035066897869,0.0002970626524407025
NCT02040493,Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer,0.000299799903899871,0.00032253870091822616
NCT02063893,Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer,0.00027769228533721204,0.0002431485674701396
NCT02063906,Prognostic Relevance of Biological Subtype in Breast Cancer,0.00033475143908572323,0.0003513526128709064
NCT02059876,Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer,0.0002685345164847887,0.0004024472353492397
NCT02076074,Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer,0.00029877417731629074,0.0003649225380250809
NCT02023008,Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy,0.00031705593655317166,0.00037489577932924456
NCT02002533,Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy,0.0003217805498118403,0.00036063187257500475
NCT02003209,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",0.00032847834035515866,0.00041271980262047966
NCT02003599,Laser InGaAlP (660Nm) to Prevent Radiodermatitis in Breast Cancer Patients Submitted to Radiation Therapy,0.00030538474207942413,0.0003599823736520554
NCT00938171,Comparing Local Anesthesia With General Anesthesia for Breast Cancer Surgery,0.00029185709706735217,0.0005299187232133988
NCT00999557,Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants,0.0003044276259786814,0.0002374340675991323
NCT00999921,Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer,0.00026105999149301845,0.00030890763293368715
NCT00959244,Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105,0.0002825927583118739,0.0003583242591515566
NCT00959556,Study of Blood Samples in Patients With Breast Cancer,0.0003988124310653164,0.000394564811162064
NCT00959985,Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer,0.0002958461055585974,0.00032675775080963224
NCT00902668,Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer,0.00028828793820991007,0.0002557302770413345
NCT00902954,Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer,0.00030319708987262085,0.00031152726829949663
NCT00902330,Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer,0.00027028185275755346,0.00024289952956198246
NCT00964522,Trial of the Effectiveness of a Nurse Education and Care Program for Breast Cancer Patients Treated With Chemotherapy,0.0003178789844142544,0.00034167773018745664
NCT00965939,An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients,0.0003416870455255433,0.00032585935574109344
NCT00965276,Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer,0.00032630240489795104,0.0003718657946835558
NCT00945607,Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer,0.00024264617383827286,0.0003182427172609869
NCT00983684,Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Early Breast Cancer,0.0003504492432338842,0.0002877859009578795
NCT00955890,Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer,0.0002778067574661828,0.00022044917417427602
NCT00989638,A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer,0.00024655106928065057,0.0003363823996277303
NCT00998738,Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer,0.0002966020863471827,0.00038130647500019064
NCT00917735,Green Tea and Reduction of Breast Cancer Risk,0.0003352249372647864,0.00019845170332059682
NCT00948285,Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer,0.00033459509858033983,0.00042108593512769747
NCT00918892,Assessment of Candidate Protein Expression in Breast Cancer Specimens,0.00025653490153976607,0.0003478215771187693
NCT00944047,Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression,0.0003282339944696094,0.00038502443455471413
NCT00992602,Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer,0.00029927609577182364,0.00035394721848710684
NCT00950742,Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinÂ® in Patients With HER2-positive Advanced Breast Cancer.,0.00031733082532797594,0.0003572110774699498
NCT00950300,A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer,0.00028388058679199723,0.00033110270485272686
NCT00910884,"Natural Supplements and a Special Diet in Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Prostate Cancer, Breast Cancer, or Uterine Cancer",0.00029465403094159904,0.00024354483852126083
NCT00927511,"A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)",0.0003487153234792293,0.00037868584016717473
NCT00958971,Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer,0.00028731645072805755,0.0002699074111021084
NCT00949247,"Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases",0.0002512009437227244,0.00024274517697119857
NCT00949923,Green Tea in Breast Cancer Patients,0.00043138521804808437,0.00025632609015375477
NCT00949871,Study of Support Groups for African-American Breast Cancer Survivors,0.00032631060474917994,0.00038394689368274757
NCT00935558,Dendritic Cell Based Therapy for Breast Cancer Patients,0.0003812544660842709,0.0003560577634054159
NCT00967824,Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer,0.00027918974319868434,0.00031550495906681325
NCT00904410,Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET,0.00032436110072039644,0.0003800149737761807
NCT00957125,A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early,0.00026999050753123677,0.00033992974416398043
NCT00934856,"A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer",0.0002997749397705169,0.0003234104581628556
NCT00934401,Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer,0.00028136591338216217,0.0002876349501597693
NCT00972400,Fatigue in Breast Cancer Survivors,0.00047463635589376396,0.00024753982483344586
NCT00926315,Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation,0.0002524399255080345,0.0003062608667450234
NCT00929591,SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer,0.00028161999543394566,0.0002783310916512142
NCT00929214,Aggressive Local Therapy for Limited Bone-only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients,0.00028719930893401734,0.00037181045943944507
NCT00993642,ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer,0.0003103448825039363,0.00033103418384707517
NCT00933309,The Impact of Obesity and Obesity Treatments on Breast Cancer,0.00037144153570598865,0.0003793020583011195
NCT00933088,Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer,0.0002555098173413608,0.00028087260364679796
NCT00933517,"Assessment of the Efficacy of the Neoadjuvant Combination: ""Chemotherapy-Targeted Therapy"" in Breast Cancer.",0.0002775712537288984,0.0003197380078170087
NCT00963417,Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02,0.00027594003305673467,0.0002878337902719789
NCT00963729,Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery,0.0002830152963472889,0.00028442148767698477
NCT00963209,Tamoxifen Citrate in Patients With Breast Cancer,0.00043195470835315095,0.00030163022678744115
NCT00923377,Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer,0.0002572550805826416,0.00019307695924035068
NCT00971945,Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer,0.0003831083360256593,0.00042352076699971085
NCT00915018,Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer,0.0003107156590821864,0.0003549286685813699
NCT00915369,"A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer",0.0002965313154283181,0.0003375373771198458
NCT00906321,Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk,0.00029873542902215933,0.00034986971573431166
NCT00978913,Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma,0.00033934915996999593,0.00038367343122863533
NCT00978770,MRI in Predicting Early Response to Chemotherapy in Patients With Locally Advanced Breast Cancer,0.0003593673000085782,0.00032735569939316777
NCT00940277,Couple-Focused Intervention for Breast Cancer Patients,0.0003567528275555997,0.0003580719453597917
NCT00900367,Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women,0.00028596601297052035,0.0002347561412592182
NCT00900133,"Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer",0.0003465942876022322,0.00031110753439601206
NCT00900627,Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II),0.0003362966150453069,0.00045715224232830933
NCT00977379,A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis,0.00028771450326212707,0.0003264690016264851
NCT00921115,Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,0.0002686744126017594,0.000315485862410494
NCT00932997,Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors,0.00027661469375300535,0.00017109039608012328
NCT00932035,Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer,0.0003114094583799216,0.0003310303711189172
NCT00976339,Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer,0.0002975806827218026,0.00028389243211367264
NCT00976131,Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer,0.00031720197399254696,0.0003742595656686716
NCT00976989,A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer,0.00030206767671438623,0.00030660090707353393
NCT00931450,Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer,0.00029254744518965287,0.0002383870481225816
NCT00968214,Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27,0.00028280159425397015,0.00036051431045906485
NCT00954135,Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients,0.00032769540769042436,0.00040531527809733987
NCT00912080,Utilization of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer,0.000305877305306467,0.000357640706432196
NCT00912444,"Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer",0.00026555173831513645,0.00031447177688227263
NCT00908791,Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue,0.00025240313638497764,0.00028939482038755807
NCT00981305,Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors,0.0002769220343793421,0.00043781604102944416
NCT00981812,Positron Emission Mammography (PEM) Biopsy Accessory for the Diagnosis of Breast Cancer,0.00028403462231671445,0.00028485653629456903
NCT00990977,Mindfulness and Cancer Mamma - Clinical Trial MBSR Among Women Operated for Breast Cancer,0.00026016679291719766,0.00039084544486259155
NCT00984399,Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen,0.00024461822144613605,0.0002503237131073442
NCT00909506,Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients,0.00043271214506448703,0.00037246792578924314
NCT00909662,Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers,0.0003170014430529114,0.00029700430647796965
NCT00909818,Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients,0.00030298659847515685,0.00032624099472460276
NCT00909441,Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer,0.00026786781310394016,0.0003288295867281936
NCT00909909,Radiation Therapy in Treating Women With Early Stage Breast Cancer,0.00036254549751307537,0.00027279326376743944
NCT00986609,MUC1 Vaccine for Triple-negative Breast Cancer,0.0003409684128803352,0.0002298872776340581
NCT00960401,A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer,0.0003623549191790594,0.00032239931931709643
NCT00914017,Statins and Breast Cancer Biomarkers,0.0003407649873972753,0.000268333045336716
NCT00925652,"Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer",0.0002459270210258535,0.0004117962326688293
NCT00916825,Effectiveness of a Rehabilitation Programme for Mothers With Breast Cancer and Their Children,0.00025528907024580685,0.00025273674147677287
NCT00916162,Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy,0.0003088488366944204,0.00034114895596189075
NCT00991978,VEGF Early Imaging for Breast Cancer,0.0004759151026646897,0.00032740829200703927
NCT00991263,Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741,0.0003020133105013002,0.0003624646780190093
NCT00996632,The Use of a High-frequency Ultrasonic Knife in Breast Cancer Surgery,0.00026692235137307625,0.00022878995875831948
NCT00911911,Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy,0.00027778866405158797,0.0003280880862378813
NCT00937989,Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer,0.0003773825176631161,0.0004287346996115338
NCT00903162,Extended Endocrine Therapy for Premenopausal Women With Breast Cancer,0.00028557970594491363,0.0003357593048050831
NCT00903006,"Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer",0.00025876968212468774,0.0003559026895151175
NCT00913016,"Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy",0.0003260734266724289,0.0003134556130502314
NCT00952679,Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients,0.0002979388821682457,0.0002635671902460205
NCT00975676,Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02,0.00028355653231450966,0.0002822202574329096
NCT00919880,Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer,0.00029091027290871165,0.00029326271153872385
NCT00956813,Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy,0.00024298301213937908,0.00021688348928954867
NCT00038402,Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer,0.00027077765601043395,0.00039061810246486436
NCT00038467,Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer,0.0002713272495516395,0.0002263887221757975
NCT00071383,"Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2",0.0003550991342635171,0.0004082647016443671
NCT00022204,Vitamin E and Pentoxifylline in Treating Women With Lymphedema After Radiation Therapy for Breast Cancer,0.0002622910257541632,0.0002441168965014476
NCT00022074,Gabapentin For the Control of Hot Flashes in Women With Breast Cancer,0.000278084703986406,0.00036916702081254336
NCT00022516,Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer,0.00025016062233496495,0.0002498019733440786
NCT00022087,"Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer",0.0002422113087274884,0.00021464393860319133
NCT00093795,Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer,0.0002796181427256041,0.00027784658697924857
NCT00093002,Fulvestrant (FASLODEXâ„¢) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer,0.00027416136198829956,0.00032672053868399483
NCT00093145,Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer,0.00034628821749585037,0.0003801644590029972
NCT00064857,Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors,0.0002777649818450166,0.0003631295507110439
NCT00028964,Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer,0.0002683652522916783,0.0003073498435628767
NCT00028704,Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy,0.0003022497201519007,0.00031820765117205756
NCT00006459,Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer,0.0003134413074614595,0.0003930698630230477
NCT00006421,Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study,0.00027751892180288715,0.00031436153700027794
NCT00006425,Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study,0.00027751892180288715,0.00026942783473071785
NCT00006225,Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer,0.00035229051889558904,0.0003411052543499098
NCT00006825,Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer,0.00031580392821329163,0.0003296032291470193
NCT00006433,Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer,0.0003057678395948778,0.00038816079607549206
NCT00084669,Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer,0.00024356398732837772,0.0002262241734652163
NCT00066586,Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer,0.00029278917732255286,0.0002786113906574244
NCT00066573,Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer,0.0002791646146619893,0.00024395502007832658
NCT00066690,Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer,0.00024299411332524522,0.0002747623720151788
NCT00066703,Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer,0.0002485323847745741,0.0002168689729239627
NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,0.0003459457697909049,0.0003910670548676445
NCT00041353,Comparison of Biomarkers Based on Fine-Needle Aspiration in Women at Increased or Normal Risk of Breast Cancer,0.00024672720716632074,0.00024256406465547682
NCT00041223,IH636 Grape Seed Extract in Treating Hardening of Breast Tissue in Women Who Have Undergone Radiation Therapy for Early Breast Cancer,0.0002520707713271491,0.00030467729992544396
NCT00041652,Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer,0.0002902276949638807,0.0004738736308577968
NCT00087347,Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer,0.00029767961376967497,0.0002831300419524945
NCT00087958,"Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment",0.00033067333505312643,0.0002973964254583103
NCT00087178,Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer,0.0002839679521841402,0.00026963501696001754
NCT00087399,Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy,0.0002562993971405238,0.0002752189323176972
NCT00083304,"Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer",0.0002502083012257661,0.0003517629590314462
NCT00083148,Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer,0.000308444109374735,0.0003073720588696182
NCT00083993,Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer,0.000297976431318047,0.00032353941729690316
NCT00083174,Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer,0.00026777689263072905,0.0002628388686377439
NCT00083044,Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy,0.00028343864917466466,0.0002839096052382203
NCT00083018,"Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer",0.00025198677131363953,0.0002578825078649905
NCT00033683,Combination Chemotherapy in Treating Women With Resected Breast Cancer,0.0003382543464600875,0.00028857178641336515
NCT00033345,Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer,0.00033911219669597513,0.0003692110920310035
NCT00033397,Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery,0.00029788927069696584,0.00039397711861389323
NCT00060138,Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases,0.00025262493639168605,0.00020771741128276414
NCT00060320,Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer,0.00033498665599606444,0.0002933556889446649
NCT00016406,"S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer",0.00026600259008245224,0.0002711635290196771
NCT00016549,Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer,0.0003072820166976688,0.000550055737274199
NCT00010153,ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer,0.0003521470562017667,0.0003335216700569272
NCT00010140,Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer,0.0002723002484031631,0.0002706660385879501
NCT00015886,Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery,0.0003036639750963234,0.00040874338997815213
NCT00063934,Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer,0.00032034684258723517,0.00031080480270407717
NCT00078832,Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer,0.00029317673214618583,0.0002712187551268064
NCT00012129,Chemotherapy in Treating Patients With Breast Cancer,0.0004599687777748781,0.0004106409641027651
NCT00074139,"Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer",0.0002863647008257699,0.0002842129116301058
NCT00074152,Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer,0.00025811517103785245,0.00028937697336696606
NCT00014222,Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer,0.00033825505877031883,0.0003036226759712156
NCT00014430,Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer,0.00038570121228571365,0.0003580982548904325
NCT00030758,Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer,0.00026874586742462863,0.0002307475289610936
NCT00030823,Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence,0.0003202443165925235,0.0003142503662385428
NCT00049114,"Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer",0.0002804528028539314,0.00036507044491184494
NCT00049452,Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer,0.0002733536826888553,0.00027420397960674836
NCT00029224,"Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions",0.00031125163431756827,0.00027749751580622713
NCT00047099,Combination Chemotherapy in Treating Women With Breast Cancer,0.0004750217306378242,0.000314422899991736
NCT00047255,Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer,0.00029891846222556085,0.0003312348472690366
NCT00047970,The Sister Study: Genetic and Environmental Risk Factors for Breast Cancer,0.0003247730201195149,0.00045719441744132143
NCT00081510,Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480),0.0002845892095051747,0.00027333899100736984
NCT00081796,Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer,0.00038323808320533,0.00036135782469594215
NCT00081003,"Nipple Aspiration, Ductal Lavage, and Duct Endoscopy in Screening Women at Moderate-to-High Risk of Developing Breast Cancer",0.0002363474451953367,0.0002191999376379769
NCT00081965,Acupuncture in Treating Hot Flashes in Women With Breast Cancer,0.00033682209122492407,0.0002799241873778333
NCT00019643,Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer,0.00033665077588717777,0.0002443032151887282
NCT00019500,Raloxifene in Preventing Breast Cancer in Premenopausal Women,0.00033796702134193196,0.00035348937255837886
NCT00003013,Chemotherapy Plus Surgery in Treating Women With Breast Cancer,0.00038181936941591375,0.00043864543655110184
NCT00003000,Morphine for the Treatment of Pain in Patients With Breast Cancer,0.0003392361672569466,0.0002575280670652939
NCT00003771,Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer,0.0002906469032812062,0.0002465435143178925
NCT00003165,Doxorubicin in Treating Women With Advanced Breast Cancer,0.00037357108338405547,0.00041641615478712454
NCT00003455,Antineoplaston Therapy in Treating Women With Advanced Breast Cancer,0.0003318147722346638,0.00029572784715559125
NCT00003678,Tamoxifen in Treating Women With Breast Cancer,0.00047858834564166596,0.00026494944174697434
NCT00003736,MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer,0.00034318033509400333,0.00035265101888221566
NCT00003440,"Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic",0.00033825985446013165,0.0003392421586288011
NCT00003519,Combination Chemotherapy in Treating Women With Breast Cancer,0.0004750217306378242,0.000314422899991736
NCT00003099,Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer,0.0003204398393850603,0.00035969044440206687
NCT00003140,Letrozole After Tamoxifen in Treating Women With Breast Cancer,0.0003495481793624953,0.00024375336896634512
NCT00003016,Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer,0.0003566228992819004,0.00027867580615231947
NCT00003830,Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer,0.00025529432131937225,0.00023346079913009156
NCT00003428,Hormone Therapy in Treating Women With Breast Cancer,0.0004790047762716148,0.00028421125030512253
NCT00003679,Combination Chemotherapy in Treating Women With Breast Cancer,0.0004750217306378242,0.0002859988119372354
NCT00003357,Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease,0.00033624049631440165,0.00031551608247128567
NCT00003418,Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer,0.00029770260661898725,0.00024466235458179707
NCT00003536,Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer,0.00029060833146460417,0.0003157720943327974
NCT00003035,Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer,0.00031604155004435287,0.0003273699627118049
NCT00003088,Combination Chemotherapy in Treating Patients With Breast Cancer,0.00043574839165112713,0.00031195536026768585
NCT00003086,Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer,0.0003031613189677439,0.0003151628567863431
NCT00003012,Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer,0.00030726137370620197,0.00034571873008626674
NCT00003782,"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes",0.00026239885669335244,0.0002851912680024516
NCT00065533,Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer,0.00029200426941252387,0.00036676359823915584
NCT00065325,The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer,0.00027825276643001,0.00037766050825995706
NCT00096343,"Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer",0.000285625574730835,0.0003448082787323374
NCT00096369,Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer,0.0003425924608402737,0.00027693833323773446
NCT00096291,Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer,0.0002917456255783185,0.0003148832372065374
NCT00096356,Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer,0.0002805434456710466,0.00031581615253301087
NCT00088972,"S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women",0.00033848440943914004,0.00030025409864983024
NCT00088829,Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer,0.0002918520742109877,0.00030157946796244343
NCT00062400,Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer,0.00025531552096476925,0.00026614973437740934
NCT00091442,A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer,0.00035722418110368316,0.00038842867209034086
NCT00008034,Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer,0.00035759898329216274,0.00041626234156084095
NCT00008346,Screening and Diagnostic Trial to Compare the Effectiveness of Two Types of Mammography in Detecting Breast Cancer in Women,0.0002591181497381672,0.00031860998105168284
NCT00057993,Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer,0.0002858737872155727,0.0003412733219891044
NCT00094133,Hypnosis in Treating Hot Flashes in Breast Cancer Survivors,0.0003351332179873336,0.0003279288582428609
NCT00055991,Bexarotene in Preventing Breast Cancer in Women at Genetic Risk,0.0003349819454334784,0.00034100207578505854
NCT00040430,Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer,0.0002946614196433953,0.0003673106541957575
NCT00058526,A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer,0.0003562831956809903,0.000333626357012498
NCT00053911,Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer,0.0002676504369530753,0.00029302925459897026
NCT00099281,DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer,0.00028848356784830296,0.00031904033615091844
NCT00099437,Comparison of Fulvestrant (FASLODEXâ„¢) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.,0.0002742758785723959,0.0003480460185253239
NCT00079625,Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer,0.00030477304624016864,0.00045071366035850946
NCT00039546,Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery,0.00035759898329216274,0.0002930534829930485
NCT00039052,"Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer",0.00029107045057011257,0.00033121778635331165
NCT00052676,Technetium Tc 99m Sulfur Colloid and Blue Dye In Detecting Sentinel Lymph Nodes in Patients With Breast Cancer,0.00028983342702088895,0.0002450852057614221
NCT00052169,Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer,0.00034377127317528473,0.0004760577428766925
NCT00048633,"Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer",0.00030561624784972646,0.0003612153122317589
NCT00046865,Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer,0.00028014101121683863,0.00027560085581624803
NCT00046891,EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer,0.0002606357202073269,0.0002793682496340183
NCT00027118,Morbidity After Diagnosis and Treatment of Breast Cancer Patients,0.0003436424442933369,0.00037199539889298095
NCT00027105,Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer,0.0003436424442933369,0.00032672754450888673
NCT00027131,Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70,0.0002459764979193774,0.00029952877042484265
NCT00027885,Phase II Bevacizumab + Tax In Advanced Breast Cancer,0.0003740278230662824,0.0002985721522829093
NCT00045032,Trastuzumab in Treating Women With Primary Breast Cancer,0.000492637956478363,0.0002326861969500626
NCT00072501,Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer,0.00024814934434837905,0.0002651360230705313
NCT00072293,Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases,0.00025147716034722427,0.0002380455153713542
NCT00021255,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,0.00035416551729640177,0.00022383477039388786
NCT00020098,Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast Cancer,0.00027970106357561524,0.00023493225945723552
NCT00092950,Exercise in Women at Risk for Breast Cancer,0.0004754606381545852,0.0002541197612675373
NCT00051051,A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer,0.00033755950840179356,0.00031061614194178444
NCT00051779,An Investigational Drug (CAL) Versus Zoledronic Acid (ZometaÂ®) in Patients With Breast Cancer,0.0003151264692294663,0.00031158605037188
NCT00068601,S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer,0.0002987825196065656,0.00022478230819703295
NCT00068614,HER-2 Protein Vaccine in Treating Women With Breast Cancer,0.0003353104611687022,0.0003452037964903951
NCT00068341,Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer,0.00028799087196266566,0.0002761239431121445
NCT00036621,"A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy",0.00025289909100802794,0.00022137436979495633
NCT00036985,Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer,0.0002894466960428224,0.00027287866214715194
NCT00036686,Isoflavones in Treating Women Who Have Breast Cancer and Are Planning to Undergo Mastectomy or Lumpectomy,0.0002522185544425367,0.0002707105947658007
NCT00082433,Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,0.0003219323933775832,0.00033517619730642886
NCT00082979,Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer,0.00023291225944584897,0.00022400796823562587
NCT00082277,Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer,0.00029456841873801344,0.00030000766978977033
NCT00002707,Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed,0.0003152876700796863,0.00029281903144855
NCT00002784,High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer,0.000259406433594173,0.00027423642790104556
NCT00002942,Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer,0.000315956407172822,0.00027852932911300303
NCT00002455,"Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma",0.0003089180884566285,0.0003175298541252278
NCT00002509,High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer,0.0002954766242197497,0.0003614488788507997
NCT00002934,Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ,0.00027308616796669266,0.0003689920501355806
NCT00002837,High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer,0.00032089486188582086,0.00038661653983888865
NCT00002529,Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer,0.0002725577081331153,0.00031993528612087236
NCT00002836,Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer,0.0002717819356124782,0.00029970807869543486
NCT00002646,Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer,0.0003067275595694941,0.00031500609113284584
NCT00002755,Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer,0.000263598487412932,0.0002971593099419661
NCT00002920,"S9630, Medroxyprogesterone in Treating Women With Breast Cancer",0.00046854042245142495,0.0002764096908703742
NCT00002460,Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer,0.0004790047762716148,0.0002216556160566038
NCT00002662,Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer,0.0003194049346500768,0.000380412917099435
NCT00002772,"S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer",0.00033919607432631707,0.0002851746115467449
NCT00002967,"Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer",0.00030356292517625267,0.0003586338762810661
NCT00002627,Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer,0.0003276874814792641,0.00034133745312959725
NCT00002616,Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer,0.00033698728794807545,0.0003538185163045721
NCT00002564,Nutrition Intervention in Treating Women With Breast Cancer,0.0004686837499406256,0.00030851494852872135
NCT00002679,"Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer",0.00033546429746201823,0.00037488036307287354
NCT00002542,Tamoxifen in Treating Women With High-Risk Breast Cancer,0.0003453702986254241,0.00033407273441188274
NCT00005879,LY353381 in Preventing Breast Cancer in Women With Hyperplasia,0.00046854042245142495,0.000369961500279114
NCT00005587,Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer,0.0003144583675293656,0.0002548479996711573
NCT00005058,Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer,0.00033674007358952676,0.00039310178312325014
NCT00005970,"Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer",0.0002595496687541436,0.00032533363323687924
NCT00005588,Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer,0.0003144583675293656,0.0002548479996711573
NCT00005886,Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer,0.00034842301571403,0.00029895622302223367
NCT00005054,Temozolomide in Treating Women With Advanced Breast Cancer,0.0003690323163467406,0.00043597676852212384
NCT00005798,Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer,0.00033919607432631707,0.00039502543120628955
NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,0.00027102897415344767,0.0005397037013205913
NCT00005993,"Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer",0.0003084596263688859,0.0003477881168553206
NCT00005975,S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer,0.000306139905066246,0.0003514257906558138
NCT00086749,Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer,0.0002619736818243063,0.00022452696602759734
NCT00050141,Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer,0.00031433875592616335,0.00034473720827499113
NCT00050011,Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy,0.0002527996298149855,0.00021264821939642986
NCT00050427,A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer,0.0003517436428258091,0.0004035554577432772
NCT00050167,Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer,0.0003100034589563503,0.0002999841758946432
NCT00004565,Susceptibility to Breast Cancer,0.0004691099120299059,0.0002804318689711761
NCT00004156,Vaccine Therapy in Treating Patients With Breast Cancer,0.0004323173750780106,0.00033297278971821845
NCT00004038,Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer,0.0003732686119358902,0.000407537540747087
NCT00004205,Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer,0.00030098835328863183,0.0002866372971844907
NCT00004157,"Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors",0.0002884851973149166,0.00030704582303889364
NCT00004092,Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer,0.0003588811953941276,0.0003121603001605439
NCT00004174,Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer,0.00034012938608821256,0.00038524915701430466
NCT00004067,Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2,0.000265145406605984,0.00026054851052884195
NCT00080756,Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease,0.00023896021133685256,0.0002526151195350556
NCT00080613,Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer,0.0002856175487929817,0.00033545040812853097
NCT00080626,Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer,0.0003045986034308884,0.0003631905653492015
NCT00080301,Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,0.0003219323933775832,0.0003621512809629137
NCT00054587,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,0.00035416551729640177,0.00024841656213136023
NCT00054418,Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer,0.0002721665486092112,0.0002470378395965371
NCT00054028,Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer,0.00029736667586718765,0.0003756749092651395
NCT00001806,Methods in Education for Breast Cancer Genetics,0.00033601576077769215,0.000293284561797255
NCT00001385,Positron Emission Tomography in Patients With Breast Cancer,0.00043640747286960245,0.00039069413527604587
NCT00001504,A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients,0.00035655161972715445,0.0003828630913727345
NCT00001496,Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer,0.0003037601258798958,0.00019863997278418843
NCT00001498,"A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer",0.00031249228601032837,0.00028741411572997107
NCT00001378,A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer,0.0002587508115845905,0.0002907633922413281
NCT00001193,A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer,0.00030802166102219283,0.0003863885018988084
NCT00001338,"A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer",0.0002678085200109378,0.0003187428043731308
NCT00001493,"Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer",0.0002640337047445477,0.0003990153891381713
NCT00001440,Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy,0.0003333832076747188,0.000367768568613058
NCT00035594,Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy,0.00033490112292820036,0.00033870072005446104
NCT00035126,EPO906 Therapy in Patients With Advanced Breast Cancer,0.00040667792599457874,0.00040839384712682025
NCT00044291,Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer,0.00030019278067539744,0.0002997572452918252
NCT00007904,Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes,0.00029266400065027274,0.0002583365870729651
NCT00026949,Study of Etoposide in Breast Cancer Patients,0.00039798366744105926,0.0003232338583157869
NCT00026286,Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer,0.0002492720385960251,0.0002508252040546089
NCT00026117,Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer,0.00033619952854134933,0.00028881585492804155
NCT00009997,Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer,0.0003001332663349438,0.00038004910178792946
NCT00056082,Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women,0.00033848440943914004,0.00036816255800618174
NCT00089479,A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer,0.0002978833276770055,0.00024088742488574195
NCT00089661,AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer,0.0002851273461885417,0.00042594693651177114
NCT00089973,Study Of Ispinesib In Subjects With Breast Cancer,0.0003936874263495753,0.0003508971726112263
NCT00073073,Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer,0.0002681306613828444,0.0003615941882332802
NCT00032136,Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer,0.00029770260661898725,0.00024302786261663287
NCT00090480,Vaccine Treatment for Advanced Breast Cancer,0.0003328204803423765,0.00041631379430933366
NCT00090974,"Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer",0.0002568433524357337,0.00028370175150760265
NCT00090857,Letrozole in Preventing Breast Cancer in Postmenopausal Women,0.000358940431876358,0.00027545307769443096
NCT00097344,The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer,0.00030019278067539744,0.00029124371552605654
NCT00031850,Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer,0.0002769891406049374,0.00032097750403197367
NCT00031681,7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007),0.00029525615157012844,0.00029156321644894265
NCT00031811,Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer,0.0002827621411675849,0.00028210118311996926
NCT00031772,S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer,0.00024003327106159609,0.0003219951520789199
NCT00070564,"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer",0.0003287165390092874,0.00030727716159018845
NCT00070278,"Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer",0.00026833552128003387,0.0002784373293949859
NCT01483196,Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery,0.00032487092397528924,0.0003610081751673895
NCT01463007,Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer,0.0002895153156544589,0.00031218440237351305
NCT01459003,Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer,0.0003733919964196675,0.0004979134891420686
NCT01471106,Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer,0.0002576549582326973,0.00030612436666124126
NCT01471847,A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab,0.00041027319335060387,0.00033583169304296045
NCT01427933,A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer,0.00030028838723197805,0.00041293977604913736
NCT01427166,Non-Invasive Imaging for Cording in Breast Cancer Patients,0.00035597048565986903,0.0003271853242745814
NCT01417286,Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer,0.0003666473221266286,0.0004238950223713017
NCT01491737,A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer,0.0003140779022098594,0.0003550545995255018
NCT01425476,Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors,0.0002836850687832066,0.0002907255045753673
NCT01450020,Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors,0.0004715104149819505,0.00033950310875950895
NCT01419197,A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy,0.00028793684420377533,0.00030320056283939423
NCT01419613,Promoting a Healthier Lifestyle Among Breast Cancer Survivors,0.0008984903380354321,0.00046913166147345323
NCT01437865,Gadofosveset for Axillary Staging in Breast Cancer Patients,0.00035234906024823426,0.00030243463069589045
NCT01466972,Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib,0.00030337618817896346,0.00031503210041053896
NCT01409811,Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid,0.00030868296594510966,0.0003901892210625314
NCT01431196,Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer,0.00029309462250141146,0.000372798871939056
NCT01431872,Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors,0.00029343641779283787,0.0003189185399289324
NCT01431053,Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer,0.00031735317258012937,0.0005541855809403197
NCT01400438,Experience of the Patient Treated With Trastuzumab (Herceptin Â®) as Adjuvant for Breast Cancer,0.0003273894082623919,0.00030164608352859553
NCT01400399,Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer,0.0002546955940492295,0.00033226356181504616
NCT01421017,"Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases",0.00025122580803156673,0.0003485789146922375
NCT01421472,A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer,0.00048647849283700275,0.00042250868648495264
NCT01407770,Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer,0.0002983637854884386,0.0003380539212724967
NCT01433562,Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients,0.0003684357194206736,0.0003477689689298213
NCT01433926,"Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years",0.00029483412052160794,0.00023058039235110948
NCT01482702,Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors,0.00027854656717583073,0.0002739095915159542
NCT01426880,Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer,0.0002986227541580888,0.0003659666599032049
NCT01480674,An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years,0.0003517530435549901,0.00035884113977774725
NCT01480583,GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases,0.0003157607040088882,0.0003680973118810103
NCT01480869,Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients,0.0003328822900133613,0.00034335916753835114
NCT01472445,Vitamin D and Breast Cancer: Does Weight Make a Difference?,0.0002780231050780001,0.00028805637210103344
NCT01472146,ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer,0.0002721354504178002,0.0003039966155519087
NCT01494662,HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,0.00047318207366759817,0.00028616987213559125
NCT01445054,111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer,0.0002539265560998473,0.0003929749110374404
NCT01441947,Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,0.00029727472782007134,0.00034214731929211944
NCT01441596,Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases,0.0003046518321343211,0.0003370513993868672
NCT01492101,The BEACON Study (Breast Cancer Outcomes With NKTR-102),0.0005580027294853632,0.0003209933749374048
NCT01411787,Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer,0.00038106536062260967,0.0002999022957947864
NCT01411943,Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer,0.0004721028447230588,0.0002563944464873356
NCT01493310,Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer,0.00031713526034091757,0.00036291315431141583
NCT01495650,Effect of a Tailored Program of Physical Activity and Nutritional Counseling on Fatigue Reduction in Breast Cancer Patients Receiving an Adjuvant Treatment,0.0003165888877747432,0.00029269940928957695
NCT01452672,Resource-sparing Post-mastectomy Radiotherapy in Breast Cancer,0.0003484634490939516,0.00032274616087055007
NCT01452399,A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients,0.00029828977857432977,0.0003214136115060598
NCT01432886,A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer,0.00030464901790504305,0.0003429980812511692
NCT01432002,FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer,0.00026367417687490804,0.0002818297673815842
NCT01423123,Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer,0.00026809751949001775,0.0003036542767172671
NCT01423890,A Prospective Cohort Study to Evaluate the Oncotype DXÂ® Test in Early Stage Breast Cancer,0.000290549803179463,0.00036420120123463836
NCT01440010,TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry,0.00027743863990345804,0.0003758344735839053
NCT01440413,Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer,0.0002990612766078449,0.00038623534357383785
NCT01422551,Facilitating Positive Adaptation to Breast Cancer,0.00035026422960941485,0.00028313908259732927
NCT01422408,Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy,0.00029203376026461637,0.0003532817489225236
NCT01478477,"Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole",0.0003045206298683874,0.00031467166698306446
NCT01439945,Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer,0.00026187181261177924,0.00027683911057959076
NCT01439282,Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer,0.00027953510844140573,0.00025006361106865295
NCT01416389,A Study of LY2523355 in Patients With Breast Cancer,0.0004915603397778765,0.00040416571391504406
NCT01404377,Wound Infiltration and Breast Cancer Surgery,0.00029193239841105204,0.00022397487661729643
NCT01424865,Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial,0.00030521511833241967,0.00035538620399825965
NCT01497015,Memory Training Intervention for Breast Cancer Survivors,0.0003402477431132352,0.00018173642272045008
NCT01415336,AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer,0.00031273847426109574,0.0002733836047950408
NCT01446185,"Treatment Decision Impact of OncotypeDXâ„¢ in HR+, N- Breast Cancer Patients",0.0003807851751638982,0.00040366298526151154
NCT01487954,Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy,0.00026138414844900995,0.0002639068173049745
NCT01420185,Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28,0.0003541569659812719,0.0003264249631047152
NCT01401166,Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer,0.0002507030305404443,0.00030761641506038876
NCT01428739,Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer,0.00026877149277555263,0.00045342144936617624
NCT01428414,Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer,0.0003091204708941233,0.00036015753728899005
NCT01458457,Life Quality and Mental State in Patients With Breast Cancer,0.0004314827218514101,0.0003493346112331874
NCT01473680,Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients,0.00029364829122200363,0.0003419262387126755
NCT01461070,Intestine Bacteria and Breast Cancer Risk,0.00033370574028256344,0.00029300406481156955
NCT01461044,An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer,0.00034618183218142374,0.00036996367012146527
NCT01447771,Decision Support for Women With Breast Cancer,0.0003370218593659648,0.0003103868790105377
NCT01484483,An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya,0.0002933166589862437,0.00034496936682170646
NCT01484704,The Significance of MRI in the Development of Diagnostics and Treatment of Breast Cancer,0.00031231564629389375,0.0005119840499053508
NCT01484080,Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates,0.0002757871327808499,0.0003203331463527387
NCT01499160,GCC 0901 - Study of How Well Letrozole Works in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer,0.0003039075222008624,0.00034913853093039966
NCT01499836,Quality Study of Anesthetic Technique on Breast Cancer Surgery,0.00033844685329467765,0.0002833113793056492
NCT01430585,Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer,0.00036060687813588743,0.00032464215878338036
NCT01435005,Breast Cancer and Exercise Trial in Alberta,0.0004754606381545852,0.0001955904487013595
NCT01413828,Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer,0.0002918132518372536,0.0002442432446708972
NCT01468766,Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy,0.00035204690377156996,0.000227798472818384
NCT01468649,Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer,0.00047253109566095647,0.0003465530137759578
NCT01468883,"The Treatment of Stage I and II Breast Cancer With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Radiotherapy",0.00027371088332906146,0.0003399871230127209
NCT01468246,The Young Women's Breast Cancer Study,0.0005580027294853632,0.0002581635863864265
NCT01498536,Effect of Diet and Exercise in Breast Cancer Survivors,0.0003391678206632515,0.0003207569448483895
NCT01498588,"Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer",0.00028120811809921587,0.00036753009058334066
NCT01479036,"Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer",0.0003136209395036806,0.0003925966093561059
NCT01479244,Efficacy and Safety Study of NeuVaxâ„¢ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence,0.0002708619598379944,0.00028578173589168096
NCT01479946,Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin,0.00030582874089547205,0.0003427172900981581
NCT01414933,High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents,0.00029931165675499617,0.00031469988207237477
NCT01485926,"A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.",0.00033652962246950033,0.0003551882375037809
NCT01249456,Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients,0.00037756485415990816,0.0003635047823052315
NCT01296555,A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,0.00030902108572600787,0.00031675630883197075
NCT01284751,The Use of Major Depression Inventory (MDI) in Measuring Preoperative Depressive Symptoms in Breast Cancer Patients,0.00029605407792309356,0.0003002316306259523
NCT01284153,Potential Benefits of Radiotherapy in Prone Position for Breast Cancer Patients: a Planning Study,0.0003404967926185136,0.00033229066800641776
NCT01243541,Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel,0.00029618598005905585,0.0003780999805360018
NCT01221688,Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer,0.00028378012330134,0.00034254721906319744
NCT01236417,Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia,0.00033862385812336916,0.000454230861387063
NCT01275807,Effectiveness and Safety of Acupuncture for Climacteric Syndrome in Patients With Breast Cancer,0.0002983638313568847,0.0003323005429899551
NCT01275859,Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer,0.00030745010133306154,0.00025466107632852737
NCT01267552,Study of Axillary Lymphadenectomy Without Drainage for Breast Cancer,0.0003242919397827444,0.0003428622008724597
NCT01222416,PET/CT Evaluation of Treatment Response in Breast Cancer,0.0002903089003982518,0.0003809292255610957
NCT01222052,6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients,0.0003045238504583179,0.00032633646435405834
NCT01222377,Endoscopic Breast Surgery in Treating Patients With Breast Cancer,0.00033044844704481583,0.00034415725836555637
NCT01266486,Effect of Metformin on Breast Cancer Metabolism,0.000335312382312209,0.00041085593527887546
NCT01254136,Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer,0.0003318150788973267,0.0004923758580031578
NCT01259076,Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer,0.0002536546983591967,0.00021949689425484722
NCT01225328,Participation Restrictions in Breast Cancer Survivors,0.00046854042245142484,0.0003264791478527787
NCT01225172,Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors,0.0003343989041299436,0.0003660473618420028
NCT01248897,Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib,0.0003386361044633999,0.000371275129624058
NCT01210768,A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients,0.0003446970467168491,0.0004042338816088643
NCT01223833,A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen,0.00029907976340355175,0.0003318274816928
NCT01220960,Art Therapy Intervention for Breast Cancer Patients,0.00035696516555857477,0.0003024723012140112
NCT01220570,The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050),0.0002934637502255079,0.00027746781848919785
NCT01220076,Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+,0.00031082624700523207,0.0003498908920965287
NCT01219075,Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer,0.00025487230114717253,0.00028316241531481384
NCT01227408,"Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer",0.0002636532814232627,0.000322958020226487
NCT01216033,Exploratory Study of Breast Cancer With ABY025,0.0005580027294853632,0.0006651800226796566
NCT01216176,A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,0.000317677018619875,0.00039801743910824675
NCT01203839,Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer,0.0003525768196103716,0.00038477242134138975
NCT01203267,Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer,0.0003170996268488006,0.0004086621124540492
NCT01256801,Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion,0.00025666058120345155,0.00022142278527066025
NCT01256008,Intervention Study of Depression in Breast Cancer Patients,0.0003549558039885034,0.00045490628164253073
NCT01256567,A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer,0.0005580027294853632,0.0003329965502485845
NCT01277926,"Patterns of Care in Hormone-receptor Positive, Advanced Breast Cancer",0.00031583812310918076,0.00035848958844140316
NCT01277757,Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer,0.0003781635710166184,0.0004263067823831064
NCT01268150,A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer,0.00027405383179811803,0.0003301483490807228
NCT01245205,Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer,0.00031827452786316253,0.00034460057335562895
NCT01215162,Phase II Study of Intra-Operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With T1N0M0 and T2N0M0 Breast Cancer,0.00033146259110686634,0.0003989440725636762
NCT01281696,Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis,0.0002929003499488278,0.00033643709445582747
NCT01281137,Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07,0.00028531522749594365,0.00033072540836504873
NCT01239745,"AromasinÂ® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer",0.000271877638739031,0.0003082840815704247
NCT01291082,Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo),0.0002817489596037877,0.00031280794300319107
NCT01262274,Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer,0.0002747069385408633,0.00033678631101460377
NCT01262716,A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer,0.00030582432127287766,0.00032382532939361164
NCT01204801,Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors,0.0002880978807337536,0.00036088733606329693
NCT01204242,IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence,0.00030425152683828135,0.0003102603078950903
NCT01204957,Brown Seaweed as a Breast Cancer Preventive,0.0008984903380354321,0.0002206507863935427
NCT01233947,Study of AFP464 +/- Faslodex in ER + Breast Cancer,0.00039500989838121137,0.0005170787640426767
NCT01205217,Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer,0.000336289193493878,0.0003936867442459081
NCT01240928,MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer,0.0003513417062707354,0.0003127285902562526
NCT01240941,Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer,0.0003513417062707354,0.00039289556988593357
NCT01240681,Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy,0.0003326071120641922,0.00035802753720674666
NCT01240421,"An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory",0.000276292684617655,0.0003263001067137764
NCT01263366,Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients,0.0003324353781357337,0.00034286304723782184
NCT01263613,Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer,0.0002796611012706004,0.00034983046435288696
NCT01247233,Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI)for Breast Cancer,0.0002794835760644107,0.0003501762621858419
NCT01247480,Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast Cancer,0.00024261786458257888,0.0003357150969512642
NCT01241721,Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer,0.0003329357584136224,0.00037544412022409566
NCT01202591,Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients,0.000325814164409468,0.0004512564792247298
NCT01202851,Relaxation for Women With Breast Cancer Undergoing Radiotherapy,0.0004890441595013054,0.00028503475727106723
NCT01224678,Vitamin D and Breast Cancer Biomarkers in Female Patients,0.00035808759533981644,0.00034987626940538027
NCT01224873,"Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET",0.0002445351146919382,0.00029257634509598067
NCT01252277,Breast Cancer Risk Biomarkers in Premenopausal Women,0.0003448343777940909,0.0002899765522355504
NCT01252290,Breast Cancer Risk Biomarkers in Postmenopausal Women,0.0003567562810167778,0.0002969171775467854
NCT01272401,Quality of Life in Breast Cancer Patients and Survivors,0.0004352097190974083,0.0003573111181050224
NCT01272037,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",0.000310831183808887,0.0003450142316068964
NCT01272570,Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors,0.000266026277326622,0.0003220359544408147
NCT01244087,Pilot Clinical Trial (Phase II) of Inquiry-based Stress Reduction (IBSR) Program for Survivors of Breast Cancer,0.0002583520887938072,0.00018663984940517854
NCT01231386,MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer,0.0003496614384571509,0.0002855958538283119
NCT01257932,Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging,0.0002684823391673867,0.000254802357744758
NCT01207635,Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer,0.0003026923588188463,0.0003427825280547147
NCT01276769,Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer,0.00030750707650626416,0.00034174100904919646
NCT01276704,Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer,0.0002475366007873602,0.0001929778336914162
NCT01276041,"Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",0.00028419157180410113,0.0003589515098741054
NCT01276938,Exclusive Intraoperative Radiation Therapy for Breast Cancer,0.00046923924633659976,0.0004111644902486581
NCT01229605,Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer,0.000295651200555631,0.00037830799310803134
NCT01273415,Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer,0.00029307038535937623,0.00025622022846322456
NCT01209091,Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden,0.00038197507612641187,0.0003346955452692359
NCT01250379,A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA),0.00034367762578234773,0.0003140668293411673
NCT01230671,The Physical and Psychological Benefits of Yoga and Breast Cancer,0.00028324779244509276,0.0002888374970033348
NCT01230970,Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer,0.0003060303129074093,0.0003165029944321858
NCT01292408,Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients,0.00043138766250340276,0.0003734244483779035
NCT01293032,Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer,0.00032948984710302843,0.00030107372787326476
NCT01293682,Effects of High Dose Calcitriol in Breast Cancer Patients,0.00035520583947359614,0.00037361918133554137
NCT01208779,Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer,0.0003014604087716045,0.0003109052173624908
NCT01271920,Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab,0.0003543751958352841,0.00036089344535982637
NCT01271738,Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer,0.0002983903159265427,0.00033305909305118207
NCT01206881,Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer,0.00026852770222722685,0.0002996765090138332
NCT01264562,Cognition in Breast Cancer Patients: The Impact of Cancer-related Stress,0.00030224888487719655,0.00035636322356702855
NCT01232881,Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer,0.00031956918185306116,0.000448678241402167
NCT01278212,Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer,0.0003056114787049415,0.0003507018247013776
NCT01278810,Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients,0.00035272272684367095,0.00048030407663401893
NCT01234402,Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients,0.0003652364178817176,0.0003595656739673426
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,0.00028772591488043987,0.0003902661415853674
NCT01234857,A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3),0.0003444575394803734,0.00036201353354806874
NCT01265927,A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer,0.00030064044075882106,0.0003895347119759479
NCT01265654,Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer,0.00033181575633594023,0.000372648839152877
NCT01217385,Diffuse Optical Spectroscopy Imaging in Monitoring and Predicting Response in Patients With Locally Advanced Breast Cancer Undergoing Chemotherapy Before Surgery,0.0003372119026937083,0.0003929710803841321
NCT01217411,RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer,0.0003075714341200285,0.0003169986072268727
NCT01290354,Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer,0.0003299953132068759,0.00033862627721918567
NCT01290718,A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.,0.00036165998805493086,0.00034524022145558973
NCT01298362,Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer,0.0002690648160295456,0.00033239686036905415
NCT01298193,Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients,0.00031382243839533534,0.00037571021656191593
NCT02941614,Implementing Systematic Distress Screening in Breast Cancer,0.0003354293882804071,0.00033938355445928985
NCT02941536,Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer,0.0002490509402782782,0.0002708873558975641
NCT02934815,Relational and Emotional Mechanisms of a Supportive-expressive Group Intervention in Breast Cancer,0.0002834962866450837,0.00026471073491402935
NCT02934828,Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer,0.0003277504403659302,0.0004178460762248041
NCT02934126,The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer,0.0002930618698082887,0.00032397262793587166
NCT02934880,Impact of Adapted Physical Activity on Cognitive Functions in Breast Cancer,0.00028526961835609137,0.0003570490061214641
NCT02969291,A Home-Based Study to Enhance Activity in Breast Cancer Survivors,0.0003257272397044143,0.0002651771340976975
NCT02921152,Bone Marrow Micrometastases in Patients With Early Stage Breast Cancer,0.0003064406892543406,0.00030130977472052036
NCT02921191,"Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated",0.00031397855018250423,0.0003019564517738214
NCT02917005,PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer,0.00028322039560959124,0.0003265531738682369
NCT02907918,Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer,0.00029741403138159906,0.00028075897114336254
NCT02997995,Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure,0.00024389783653948926,0.0002718977890543308
NCT02997384,Feasibility of Breast Cancer Risk Evaluation in Women From the General Population,0.000344810428161434,0.00028417155325066197
NCT02964234,Empowering Latinas to Obtain Breast Cancer Screenings,0.00033523492420579274,0.00017772461600018414
NCT02964507,Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer,0.0003016159521858894,0.00034417130072297793
NCT02980965,"Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer",0.0002917570262331287,0.00031708849560713165
NCT02938780,Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors,0.00027790369482196887,0.0002665229994706909
NCT02958852,A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer,0.00033068578264882514,0.0003566685520513865
NCT02958774,Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation,0.00036276264589823966,0.00039397485695577507
NCT02958332,Effects of a Videogame-based Program on Women With Lymphedema Secondary to Breast Cancer,0.00028466497001892424,0.0002739914895212652
NCT02924584,"Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan",0.0002959004876214915,0.00022044958604398336
NCT02948478,Economic and Social Disparities and Breast Cancer,0.0008984903380354321,0.0002903310839279996
NCT02948764,Diagnosis of Pathological Complete Response by Vacuum-assisted Biopsy After Neoadjuvant Chemotherapy in Breast Cancer,0.00027238169355206347,0.00031124621393691375
NCT02902991,The Study on the Clinical Utility of Liquid Biopsy in Breast Cancer,0.00032504091189419326,0.0003263321505949371
NCT02970344,I HEAL for Breast Cancer Survivors With Diabetes,0.0003334228715094609,0.00018586419423626932
NCT02952729,Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,0.00035311903126064955,0.00032324323310218477
NCT02956473,Supine MRI in Breast Cancer Patients Receiving Neoadjuvant Therapy,0.0004502620956597309,0.0003436559306016668
NCT02992730,Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer,0.0004790047762716148,0.0003767163838879758
NCT02992769,Predict the Risk of Axillary Metastases in Breast Cancer Patients With Axillary Ultrasound,0.00031534337956620566,0.0003074102231775741
NCT02992067,CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer,0.00025392158771446623,0.00021260063367276627
NCT02992574,Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer,0.000254443818399549,0.00026302441555767437
NCT02909361,Fulvestrant 500mg in Patients With Advanced Breast Cancer,0.00038112808018719353,0.0005488664044172755
NCT02909751,Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer,0.0002890884201105116,0.000365930371937199
NCT02900469,Presurgical Trial of Denosumab in Breast Cancer,0.0004693795206523656,0.00046190325660321085
NCT02900118,Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis (EMOS),0.00027577188141034446,0.0003568766667324752
NCT02900326,Mindfulness-based Stress Reduction (MBSR) Program Combined With Endurance Exercise Training: a Help in Treatment for Breast Cancer?,0.0002619389924855488,0.0002942426632073171
NCT02939274,"An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (VisudyneÂ®) for the Treatment of Cutaneous Metastases of Breast Cancer",0.0002553191089661864,0.00033492873901796506
NCT02936206,Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.,0.00024730864042464036,0.0003204962996639178
NCT02923037,Hatha Yoga in Breast Cancer Survivors,0.0004703711272459319,0.0002554699788252821
NCT02923401,High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer,0.00046868017286316136,0.00029952843496127974
NCT02903524,Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer,0.00031729348229394834,0.00031794893259369495
NCT02940470,Weight Loss Pilot Study in Postmenopausal Breast Cancer Survivors,0.00033629302748841165,0.00030853095409485716
NCT02931864,Effects of an e-Home Based Symptom Management and Mindfulness Training Programme on QoL in Breast Cancer Survivors,0.00024462950565959623,0.00035685314971993314
NCT02963740,Feasibility of High Levels of Energy Expenditure From Physical Activity for Breast Cancer Survivors,0.0002480331995479171,0.00030091973054841107
NCT02963363,Adapted Physical Activity for Breast Cancer HER2 Positive Patient,0.0003210232649702127,0.00042897960254341595
NCT02918084,CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer,0.0005240256729824867,0.0003826901648964393
NCT02926690,Safety and Efficacy Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer,0.0003518863775593854,0.0004141533344591081
NCT02926729,Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy,0.00025579190127164434,0.00029011143302548994
NCT02926547,New Approaches for the Identification and Characterization of Functional Markers of the Risk of Extension of Breast Cancer Without Lymph Node Involvement,0.00024465567726030506,0.00024240801722035177
NCT02965950,The p53 Breast Cancer Trial,0.0008984903380354321,0.0003376563151527814
NCT02982980,Upper Limb Muscular Strengthening in the Rehabilitation of Patients Submitted to the Breast Cancer Surgical Treatment,0.0003223571621215491,0.0003316142515521927
NCT02982564,Effect of Low vs Moderate-intensity Endurance Exercise on Physical Functioning Among Breast Cancer Survivors,0.00024745422674746383,0.00028636778591910935
NCT02982421,The Effect of Art Therapy on Physical and Psychological Symptoms of Breast Cancer Survivors,0.00025679524258565603,0.00028911463425994804
NCT02982148,Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients,0.00031463585898966365,0.0003760803664370841
NCT02946294,Modified Pectoral Nerves Block Versus Serratus Plane Block in Major Breast Cancer Surgery,0.00029240452293048793,0.00030939799068056665
NCT02946619,Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors,0.0003348919259169777,0.00036871417837082383
NCT02993159,Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer,0.0003152711503273429,0.00034472865860867073
NCT02993198,A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging,0.0003348696173050965,0.00038036485529094295
NCT02988986,"TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",0.00036915985820473284,0.00033975507016489653
NCT02927249,"Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy",0.00033492933199631356,0.0003480589309140728
NCT02927912,Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction,0.00030611969296374486,0.0003288476074416903
NCT02949310,Effectiveness of Nefopam in Breast Cancer Surgery,0.00029307239324431343,0.0002273107443808092
NCT02944604,The Efficacy and Safety of PEG-rhG-CSFï¼ˆPegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy,0.0003126426192564049,0.0003403063005153714
NCT02944721,"Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer",0.00025244039360959694,0.0002454868871468229
NCT02999074,Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,0.0003275935928015847,0.0004018254858927113
NCT02999477,A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer,0.0003030609842735269,0.0003259651928633722
NCT02915445,EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer,0.00037067954556672597,0.00033378697909168363
NCT02922244,Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients,0.000305638969916124,0.00032226818725737336
NCT02995772,Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients,0.00033727164746908864,0.0004667079888805234
NCT02942615,The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.,0.0003402714692371621,0.00022405176963405076
NCT02942355,Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,0.00028883131929251644,0.0003183930808734102
NCT02955394,Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,0.0003379336577418681,0.00040532446000108777
NCT02947061,S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer,0.0003475706552499109,0.0004392200753806528
NCT02983604,GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,0.00026641925931230156,0.0003204682258836896
NCT02983279,"Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer",0.00030838483903712486,0.00029862553603542824
NCT02967146,"Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(MedicloreÂ®) After Axillary Dissection for Breast Cancer",0.00025133848543505954,0.0002603300862738044
NCT02935920,A Study on Optimizing Follow-up for Postmenopausal Women With Breast Cancer Treated With Adjuvant Endocrine Therapy,0.00034063607918253803,0.0004099551527702533
NCT02979678,European Organisation of Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ) Breast Cancer Module Update,0.0002774477546221032,0.00032589086074251737
NCT02950259,Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC),0.0004914572079149077,0.00043969627728759046
NCT02953860,Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,0.0003065659284998782,0.000363225563928378
NCT02945579,Eliminating Breast Cancer Surgery in Exceptional Responders With Neoadjuvant Systemic Therapy,0.0002761758857625701,0.0003713003489294155
NCT02544945,Comparing 3-D Printed vs Standard Bolus for Breast Cancer Chest Wall Radiotherapy,0.00026173559777505393,0.00028561270453380594
NCT02569489,Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer,0.00031360636544106274,0.0003352390647974064
NCT02569294,Feasibility and Impact of Group Interventions on Breast Cancer Patients Well-being,0.0003533083881782401,0.0003175868548529432
NCT02526498,Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery,0.00032029517026635853,0.00038532604970086594
NCT02570100,Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM),0.00027843778003046424,0.0003131985712322097
NCT02530008,Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer,0.00024372927440322983,0.00030977145977999134
NCT02530411,Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer,0.0002645489138979133,0.0003371590310562998
NCT02561832,"A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer",0.0003455499733819859,0.0003008491072878842
NCT02598557,Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer,0.0003248497725732625,0.00034540330870369736
NCT02556632,Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer or Breast Cancer In Situ,0.00028926353544479587,0.00028106667903569807
NCT02556684,Breast-Specific Gamma Imaging and Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy,0.0003038259199072657,0.00035680416559763766
NCT02583204,Taxane Chemotherapy and Nail Toxicity in Women With Breast Cancer; Stage Two: Evaluation of Interventions,0.00026404223591591634,0.00029988943208017515
NCT02583568,Fluorescence Guided Surgery in Breast Cancer,0.00035428580079353183,0.00027866516689868236
NCT02505906,Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost Technique,0.00031245781133488906,0.00037611358415413584
NCT02586025,"A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Early-Stage or Locally Advanced HER2-positive Breast Cancer to Evaluate Treatment With Trastuzumab + Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel",0.00038679025227577045,0.0003908006509433072
NCT02586675,TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,0.0003009057967061562,0.00029821474150495747
NCT02582801,Clinical Research of 18F-Alfatide â…¡ PET/CT in Breast Cancer,0.000282601582643606,0.0004196530943940226
NCT02560662,PhysSurg-B : Physical Activity in Relation to Surgical Operations - Breast Cancer,0.00027317746507596124,0.00034566998162530784
NCT02520063,"Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",0.00026601534606006844,0.00031910837584616595
NCT02584712,Effect of Exercise Training in Autonomic Modulation in Breast Cancer Patients,0.0003568117337778287,0.00035272201057713333
NCT02541435,Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer,0.00026118065209504416,0.0002991624346226497
NCT02541188,Genotype and Phenotype in Early Onset Breast Cancer in Young Women on the Two Shores of the Mediterranean Sea,0.00033389617794539825,0.00020253989291211527
NCT02513394,PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer,0.0002835881090381358,0.00032540728851208276
NCT02513329,Stellate Ganglion Block (SGB) For Women for Breast Cancer,0.00033408650233802327,0.00025915738356099404
NCT02518477,Preventive Intervention Against Lymphedema After Breast Cancer Surgery,0.00029778730959658745,0.0002720382314627752
NCT02545023,"Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy",0.0002722811056156192,0.00031384679205170266
NCT02596867,Neoadjuvant Propanolol in Breast Cancer,0.00035248271476633265,0.0003806167760741466
NCT02553707,A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer,0.00027119874677271225,0.00021991826057387058
NCT02553850,An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat),0.00032499797802898543,0.00029912609355329487
NCT02547961,Chimeric Antigen Receptor-Modified T Cells for Breast Cancer,0.0003354642029065057,0.00044692485198798485
NCT02510781,A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs,0.0003128124381218614,0.00031219097897720703
NCT02510430,The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors,0.00032297848431955036,0.0002745683605941366
NCT02510456,Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging,0.0003194118484879098,0.00036197999587508326
NCT02548338,Argon Plasma Coagulation Scalpel on Surgical Treatment of Breast Cancer,0.00028793082334384383,0.000250296366733119
NCT02535221,Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer,0.0003307356020479517,0.00035818406676764946
NCT02549534,Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer,0.00027859071724101024,0.0003155529516487155
NCT02549677,"Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer",0.000255679074103182,0.0002979070282548987
NCT02522234,A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,0.00034584252589477593,0.0003239402088013622
NCT02522260,OptiTrain - Optimal Training Women With Breast Cancer,0.0004712349684557014,0.00031673571043948964
NCT02532400,Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients,0.0003172666004772634,0.00028280311220268576
NCT02515487,An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors,0.000307025791289556,0.00032284397544945397
NCT02515110,Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer,0.0003514283035985994,0.00033553863043085295
NCT02521961,Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors,0.0002593376757233736,0.00028309464254633614
NCT02521441,"A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.",0.00037180372218479133,0.00037792241765617466
NCT02521077,Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer,0.000263126650835117,0.00031147938157564714
NCT02574780,Lymphedema Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy,0.00024171386536192346,0.00028990366628250285
NCT02574546,Markers for Predicting Risk of Breast Cancer in Women of Different Races,0.00047907240132673805,0.00034386414958459475
NCT02574507,Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners,0.00027741465097082913,0.0003128161752462878
NCT02514837,Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer,0.00028400615973574,0.00027913415639446894
NCT02514499,"Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study",0.00040498355842266616,0.0003297944364282208
NCT02528747,A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate,0.0003026914549155045,0.00028640188261377957
NCT02528539,Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP),0.0003171596044159572,0.00036964756105819884
NCT02509871,Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2),0.00035813736512388747,0.00036116412583348033
NCT02592070,Activity & Cognition After Treatment for Breast Cancer,0.0003083802490312597,0.0003010861386757577
NCT02567929,Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer,0.0002953793903481245,0.000291632575488771
NCT02599363,A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,0.00038719596810751804,0.00037841425003438657
NCT02599467,EMG at Performing ULTN 1 in Breast Cancer Patients,0.0006150176815075327,0.0003007103000562086
NCT02599974,PET-CT in the Initial Staging of Breast Cancer and in the Early Assessment of Response to Neoadjuvant Chemotherapy,0.0002784056314835083,0.00038996869991142876
NCT02595138,Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer,0.0003115102704383824,0.00033763311288727824
NCT02595905,Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer,0.0003006274718130608,0.00035448429946870045
NCT02580799,Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples,0.0002813204870275042,0.00031424574994567863
NCT02580396,Evaluation Of CanADVICE+Â®M-Health System To Support Breast Cancer Patients Receiving Capecitabine,0.00030838081944367424,0.00022885978178677807
NCT02580279,Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy,0.00032517672621191004,0.0003169037293625843
NCT02506790,Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer,0.0002717844698563007,0.0004237575909541197
NCT02506361,Evaluation of the Relationship of TOP2Î± Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer,0.0002585425443596557,0.0002948603814429765
NCT02506530,"Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment",0.0003147069904005408,0.0004174879705991276
NCT02506556,Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer,0.0003031612896974256,0.0003603988492396248
NCT02506777,Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.,0.00028658186074134723,0.0003800239866530358
NCT02550795,Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer,0.00027668116593485654,0.000297109183953391
NCT02536794,MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,0.0003222281315765701,0.0003275942868417417
NCT02590458,Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer,0.0003222139203889959,0.0003262428190657027
NCT02581839,Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate,0.00030808622785840814,0.0003473882183517551
NCT02581670,Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer,0.0002903274011924731,0.0003670082471472049
NCT02581956,Walking Affecting Immunology and Quality of Life of Breast Cancer Patients,0.00031629851986238454,0.0004194314942045973
NCT02559362,Study on Breast Cancer Patient Perspectives of Exercise,0.00040177675794757,0.0003827309734837479
NCT02571894,The Cardio-Oncology Breast Cancer Study,0.00039959048705929927,0.00032725527095221215
NCT02571530,Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer,0.00026286819541049484,0.00034030651336298614
NCT02527746,Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,0.00042236360474075534,0.00032206033511293603
NCT02527889,The Effect of Resistive Exercise on Forearm Blood Flow and Tissue Oxygenation Among Breast Cancer Survivors With or at Risk for Breast Cancer-related Lymphoedema (BCRL),0.00024358333373489138,0.00032484896358246916
NCT02527317,Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer,0.0003002060134808354,0.0003144229931499859
NCT02517086,Vascular Changes Due to Different Treatments of Lymphedema Secondary to Postoperative Breast Cancer,0.0002659411544404424,0.000334190365347336
NCT02517593,Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake,0.00025241408477474204,0.0003167418312843294
NCT02562118,Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer,0.0002667997209880303,0.00037387862026821235
NCT02575612,Diagnosis of Pathological Complete Response by Minimal Invasive Biopsy After Neoadjuvant Chemotherapy in Breast Cancer,0.00026670707375788915,0.0003649555348071907
NCT02597179,Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer,0.0003339876346420212,0.00043146229224066935
NCT02591316,"Nutrition, Physical Activity, and Cognition in Breast Cancer Survivors",0.00025810542453415415,0.0002892812157793708
NCT02591966,Genetic Alteration After Systemic Treatment in Breast Cancer,0.00037077330673236875,0.000451749651484427
NCT02523417,HepaSphere Interventional Therapy Using Digital Subtraction Angiographyï¼ˆDSAï¼‰for Breast Cancer,0.00031061746189934485,0.0005243941210363774
NCT02587663,Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI,0.0003346566991952459,0.0002766429650034102
NCT02557776,Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer,0.00035160207622819196,0.0003379963048137886
NCT00616967,Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer,0.00026629024532285364,0.0002715372147049911
NCT00670644,Self-Care for Lymphedema in Patients With Breast Cancer,0.0004352211059286076,0.00045980781355870436
NCT00670878,"Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer",0.00027934948171161344,0.00036545740327417384
NCT00667121,"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline",0.00023886526346924788,0.000209433190255791
NCT00678626,"Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer",0.00037787265262066776,0.00036321618642171105
NCT00678509,Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer,0.00031810292773573704,0.0004012097106789618
NCT00695916,MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery,0.00034262254662683836,0.0002818195892960694
NCT00676663,Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer,0.0003251725439397492,0.0004604577740602685
NCT00623519,Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole,0.0002707327917100456,0.00030844636598002605
NCT00617539,Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases,0.00031259333244610077,0.0003215008392253018
NCT00617370,Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility,0.0002928092870184868,0.00034302629665339013
NCT00617942,"Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer",0.0002762719484491578,0.0002908416674045921
NCT00614172,Proton Therapy for Early Stage Breast Cancer,0.00034902710324698157,0.00043868667989263604
NCT00614978,Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer,0.00026423645793830267,0.000363885973734565
NCT00633750,Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery,0.0003281488343414134,0.000295456956852013
NCT00662025,Study Of Sunitinib With Capecitabine In Breast Cancer,0.00032842445299467726,0.0004399726571111594
NCT00631852,A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer,0.00023811033921244747,0.00028600287002469426
NCT00652678,Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients,0.0003232359725355784,0.00036360005799358937
NCT00636441,Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer,0.00024962997041351524,0.00030694573977714767
NCT00673335,Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation,0.000358940431876358,0.0003579812385675592
NCT00610181,Magnetic Resonance Imaging in Patients With Breast Cancer,0.00043246645440124905,0.00033912494613084473
NCT00650910,Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer,0.00027871367406295415,0.0002974794564744364
NCT00600275,A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer,0.0003779423958530683,0.0003516641143599613
NCT00600249,"Assessment of the Efficacy of a Neoadjuvant Combination: ""Chemotherapy-targeted Therapy"" in Breast Cancer.",0.00029976202577691616,0.00037303200484931174
NCT00659906,Optimizing Body Composition & Health After Breast Cancer,0.0003354616274859285,0.00023953255549324234
NCT00696527,National Survey on Infiltrative Breast Cancer,0.0003340802749070289,0.0004017336548150479
NCT00696072,"Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic",0.0002755099131529055,0.00031311883837543443
NCT00611715,"Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.",0.0002461912717114463,0.00021634275027648432
NCT00637481,A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer,0.00029405247951412984,0.00030632936473414354
NCT00637325,Trastuzumab Optimization Trial in Breast Cancer,0.000492637956478363,0.00040492126185415867
NCT00657137,APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202),0.000303106828017218,0.0003336093598756469
NCT00681369,Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France,0.00033383185712621347,0.00041067994174926196
NCT00682253,"Use of Bone Scintigraphy, CT and MRI in Breast Cancer",0.00033588879620691556,0.0002748805933263224
NCT00684216,Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer,0.0003288782121524476,0.00036191544880801287
NCT00684983,Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer,0.00032807295593985554,0.00035772585231623363
NCT00665899,A Couples Approach to Enhance Breast Cancer Survivorship,0.0008984903380354321,0.0003236155973829783
NCT00668616,Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes,0.00037210214654099074,0.00046184246971859444
NCT00669773,Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient,0.00032318644948717013,0.0003464280325070896
NCT00669565,Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer,0.00029996730127802986,0.0003384334822810508
NCT00669591,A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer,0.00035723347665582385,0.00044380107824480556
NCT00653718,"Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study",0.000354674810238446,0.00044186498210048084
NCT00634634,Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer,0.00028688411877944136,0.0002828780907982904
NCT00634088,Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,0.0002957143415977533,0.00033722136608988466
NCT00649090,A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer,0.00030588273574499016,0.00038412222626017523
NCT00660803,Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer,0.00031499422755463825,0.00042440235854587804
NCT00660244,Breast Cancer Tumor Care Observational Programme,0.0002865890905449501,0.00045860518363329683
NCT00635596,"Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer",0.0002646626038977518,0.00024363044409097604
NCT00635713,Second Line Breast Cancer Trial,0.0004696688394542123,0.00037312930338579173
NCT00635050,"Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin",0.00028495331502928847,0.00034550492605948957
NCT00658281,Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients,0.00037998005836937057,0.0003316792549011488
NCT00656019,Development of Vitamin D as a Therapy for Breast Cancer - Phase II,0.0003069171535401368,0.0003654497282585997
NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,0.0003021832960919161,0.00035161706034684897
NCT00656604,"Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics",0.00036025384117759865,0.0003316454561983752
NCT00646633,Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors,0.000336823203580095,0.00029201914420560413
NCT00620594,A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer,0.0003779423958530683,0.00038067098920486656
NCT00691509,"Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer",0.0003334228715094609,0.00024688654772463256
NCT00691119,Relaxation and Visualization Therapy for Breast Cancer Patients,0.0003800518709769518,0.00034236349156733327
NCT00691678,Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer,0.00025494984030606846,0.0002121791683938602
NCT00639210,BREAST CANCER AND EXERCISE,0.0003335185927600995,0.0003333967158812232
NCT00639366,Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer,0.0002900370177876314,0.0002556999595038957
NCT00604435,Neoadjuvant Endostatin and Chemotherapy for Breast Cancer,0.0003128467596144926,0.0003406584640278305
NCT00651976,"Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",0.00027552733030278677,0.0003235163085031893
NCT00689156,Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer,0.00031499083950451985,0.00025605762512545885
NCT00612443,Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy,0.0002534292609679863,0.00035563246817632056
NCT00647790,Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer,0.0003438359032613662,0.0003861709535502836
NCT00647075,Yunzhi as Dietary Supplement in Breast Cancer,0.0004689682061347927,0.0006695351804322277
NCT00675259,Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer,0.0002722644018509183,0.000282533936829692
NCT00605267,Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment,0.0003505258382013018,0.0003194442037125808
NCT00688909,Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer,0.00027643325556916075,0.0003188904545827651
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,0.00029906692641422844,0.00036378428404117326
NCT00688246,Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer And Who Are Receiving Exemestane on Clinical Trial CAN-NCIC-MAP3,0.0002552052315901609,0.0002896643339875931
NCT00688337,Correlation Between Fluorodeoxyglucose (FDG) and FLT Uptake and Gene-Expression Oncotype Assay in Patients With Breast Cancer,0.00029737795974548673,0.0003028642872004824
NCT00690196,Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms,0.00033446222022911543,0.00031073127419759976
NCT00601406,"Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer",0.00032720417245009944,0.0003531034264639349
NCT00630591,DAMES: Daughters And MothErS Against Breast Cancer,0.0008984903380354321,0.0002571856583963335
NCT00630032,Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer,0.0002466740670937158,0.0002628050716483194
NCT00630695,Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer,0.0002804918560093371,0.0003343892869092272
NCT00607295,Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients,0.0004315733469282109,0.00025981661979116854
NCT00645138,Comparison of Paravertebral Block With General Anesthesia in Patients Undergoing Breast Cancer Surgery,0.0003100611478490732,0.00023517161921986633
NCT00629278,"Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer",0.00026219524378054914,0.00026060038431280884
NCT00629616,"Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer",0.00030307217671387014,0.0003113720738688821
NCT00602316,Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer,0.0002556535626875963,0.00027365167828043765
NCT00615524,Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer,0.00029174954854557696,0.00033006262425728025
NCT00615316,GuaranÃ¡ for Radiation Related Fatigue in Breast Cancer Patients,0.000328698022531962,0.0002841020673938498
NCT00615602,Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer,0.00032462015610285874,0.00032805714726719625
NCT00615901,"Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer",0.0002469419284456905,0.00033990002596811185
NCT00679185,Expressive Writing in Improving Quality of Life in Patients With Breast Cancer and Lymphedema,0.0003188580750204407,0.0003146905759168579
NCT00679783,Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer,0.00033193614905213344,0.00030618931941081237
NCT00679341,A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (HerceptinÂ®) and Docetaxel (TaxotereÂ®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease,0.00033709937671284895,0.0003133342479294797
NCT00679874,Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR),0.0002605959850574486,0.00032453411749826315
NCT00677326,Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer,0.00031810292773573704,0.0004012097106789618
NCT00622401,Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12,0.0003003295188808925,0.0003247317558589951
NCT00638599,Comparison of Laryngeal Mask Airway (LMAÂ®) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer,0.00024027638164627124,0.00019711681486318363
NCT00638391,Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer,0.00033980025386161057,0.0005236903387259239
NCT00632723,IRESSAâ„¢ (Gefitinib) in Breast Cancer Patients,0.0003515375128039407,0.0002989010021666439
NCT00632489,LBH589 in Combination With Capecitabine Plus/Minus (Â±) Lapatinib in Breast Cancer Patients,0.00032834603598084794,0.0002963317724368445
NCT00698035,Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients,0.0002930630824480855,0.0003448814609635326
NCT00666913,Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial,0.00028433455241095424,0.0002726870179273815
NCT00666822,Compliance to a Hormone Therapy Regimen in Breast Cancer,0.0002835910151738688,0.00027022453548024473
NCT00666731,Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer,0.0002804929334934854,0.00039589617684613395
NCT00674557,Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer,0.0003191741585860925,0.00025435431972376557
NCT00674414,Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery,0.0002764942688927877,0.0002312119058774227
NCT00674830,Self-help Treatment for Insomnia in Breast Cancer Patients,0.0003382150544209248,0.0003322641441381643
NCT00674011,Hypertension in Breast Cancer Patients Receiving Bevacizumab,0.00035544766845945294,0.000320422072443892
NCT00627627,A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer,0.0003491622082653095,0.0005427111333667931
NCT00627614,Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer,0.0002502791965432361,0.00022712332241870662
NCT00686127,Symptom Management After Breast Cancer Surgery,0.0003536194303741173,0.00027757281660339197
NCT00671918,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,0.00024021157469555386,0.00019898619290296106
NCT00692458,A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029),0.0003954796676435584,0.0006561988398569069
NCT00692289,Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer,0.0003301740071215356,0.000350690174162262
NCT00694252,Lapatinib and Circulating Tumor Cells in Breast Cancer,0.0003380385302100376,0.00041838032097953477
NCT00694200,Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer,0.00028192635738284966,0.00031212299902378955
NCT00680667,Clinical Trial of Trametes Versicolor in Women With Breast Cancer,0.0004747812568069214,0.0003231787292681228
NCT00378313,"A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer",0.00035779943687465164,0.000415213435416919
NCT00378638,Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study,0.00029883977206993464,0.00033524275898569404
NCT00382070,Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer,0.0002626890229045974,0.00023057816690576652
NCT00398567,A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer,0.00030498531474918475,0.0003706226295484613
NCT00398489,"Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",0.00028086834773399203,0.000306612082376909
NCT00369850,Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98,0.00027359572493259156,0.0002840135107884248
NCT00349011,Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer,0.000265399995622477,0.0003251212934410793
NCT00338728,Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Breast Cancer Patients,0.0003010207302552388,0.00034837755415202557
NCT00383500,Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status,0.0002591873438132096,0.00022880833367315258
NCT00373256,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,0.00036171059925355726,0.0005367579834485105
NCT00308178,Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer,0.00033759110009577063,0.00026837547786175153
NCT00328783,Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer,0.00024819034951459047,0.00030790295408028367
NCT00328432,"A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy",0.00027011727922222504,0.0003108907497671985
NCT00347568,BC-DAISY: A Breast Cancer Decision Aid System,0.00033398721659428976,0.00026227642601111834
NCT00347438,Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer,0.00033695800726065973,0.00039119093856742585
NCT00301106,Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver,0.0003337981648418231,0.000284811904814385
NCT00301925,Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery,0.0003214408336336956,0.00030926904662733143
NCT00301457,Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer,0.0002814934141572259,0.000383174847995449
NCT00301730,Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung,0.000288729667122986,0.0002855652678687224
NCT00301548,Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer,0.0003972368453903299,0.00032036126797704433
NCT00343382,Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer,0.00035148676438122675,0.0003035187010912924
NCT00343616,Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98,0.00026900357044485566,0.00023450909267644837
NCT00343863,Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer,0.0002961411791137837,0.00032685956113476526
NCT00343109,Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer,0.00033464942565820797,0.0002833091702796833
NCT00326820,Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer,0.0003028940763245496,0.0002860803247018597
NCT00370552,A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer,0.00026210585147950024,0.0003562377489676486
NCT00370240,Chlorhydrate of Ropivacaine and Breast Cancer Surgery,0.0003532390654443353,0.0003835774343928159
NCT00337233,Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer,0.00025384418249059423,0.00023866949780803408
NCT00337272,Treating Chronic Insomnia in Breast Cancer Patients,0.00043138523696283136,0.00046905240474735767
NCT00314977,Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.,0.0003667402568481957,0.00038084830728220563
NCT00319254,Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer,0.0003938774752843062,0.0004425325551998957
NCT00399802,A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED),0.0002813531429170915,0.00034303572046842445
NCT00399321,A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer,0.0003248502868233505,0.000368149053735747
NCT00375427,Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions,0.0003043919574288821,0.00033055569028927735
NCT00375752,Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer,0.00031909669994264144,0.000373065580379298
NCT00362973,PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer,0.0003299900061687355,0.0002940657736063126
NCT00304941,Insulin Resistance and Breast Cancer,0.0004685404224514249,0.00025549978294956793
NCT00334139,Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer,0.00029230966550222867,0.00033820053676596217
NCT00334542,Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer,0.00033920574879739483,0.0002419424557320372
NCT00360152,Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes,0.0003354147042480634,0.0002878541134639781
NCT00397501,BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain,0.00026450101434180806,0.0002456950350274502
NCT00372476,Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer,0.00033718536390377175,0.00040276894776859285
NCT00372710,Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions,0.0003139739010900491,0.0003659111965570998
NCT00372424,Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive,0.00036419139036971825,0.0003997683351755006
NCT00372996,"Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer",0.00031064033156760323,0.00041138389307027927
NCT00310089,AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer,0.0003730164592665791,0.0002576611739384717
NCT00310180,Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial),0.00026395305893438925,0.000349650468047745
NCT00310882,Involvement of Endogenous Digitalis-like Compounds in Breast Cancer,0.000333519459724938,0.00019292884063280607
NCT00381368,Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients,0.00035419209455813343,0.0004015766119620915
NCT00381901,Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery,0.0003058454823567433,0.0002304702884548131
NCT00381927,Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development,0.000255158393724925,0.00020602910276553888
NCT00316407,Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients,0.0003169417464558193,0.0003495466184551653
NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,0.0003217669264465445,0.00031747816177174243
NCT00365417,"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer",0.00029900113341201404,0.00040785891830468656
NCT00365105,"Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer",0.00028715184934111337,0.00020145118539970078
NCT00365599,Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer,0.00043808075395186663,0.00040941150999211455
NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,0.00033885147878784844,0.00037593777736094283
NCT00392392,Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer,0.0002958976288850711,0.0002362734578248315
NCT00392184,Partial Breast Irradiation With Multi-Catheter Brachytherapy for pT1-2pN0 Breast Cancer After Breast Conserving Surgery,0.00023564472951560577,0.0002937071523533963
NCT00318513,Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema,0.0002734238769548401,0.0003168114362049036
NCT00329940,Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,0.00032193957997671307,0.0004098010603647144
NCT00329017,Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer,0.0002918272308827695,0.00030347568028183015
NCT00356681,"A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer",0.00032030108800876737,0.000360717078733311
NCT00356148,The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.,0.00030096513877594016,0.00023087406416704944
NCT00309556,Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer,0.00029072435706679076,0.00030778374938394027
NCT00313248,Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer,0.0002970319499956843,0.00035715819436705625
NCT00332852,Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer,0.000353909084770884,0.0003661576792705326
NCT00332709,Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer,0.0003266888689984118,0.00031725659763367895
NCT00359060,Physical Activity and Breast Cancer Risk in Postmenopausal Women:the SHAPE Study,0.00030652485600721354,0.000288038075176197
NCT00359190,Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer,0.00032229744305185766,0.00037711896458490296
NCT00336791,Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer,0.0002680136824980234,0.00029766018814117917
NCT00336089,Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors,0.0002460909671162681,0.0001938582541245716
NCT00336102,Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers,0.0002830417478598242,0.00023114912512207944
NCT00320541,"A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer",0.000284861535362318,0.0004167351137050514
NCT00320710,Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer,0.00034047277628583355,0.00034429466852326835
NCT00325598,Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer,0.00043205112791927514,0.00047219237867190484
NCT00325234,Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer,0.0002632732028418287,0.00033705173501464333
NCT00367666,Using Diagnostic Tools to Stage Breast Cancer,0.0003569568554981239,0.00022187361690754125
NCT00330317,Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer,0.0003012399558195268,0.0003212927837202917
NCT00321464,A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.,0.0002992993673649829,0.0004408190339368904
NCT00321633,Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer,0.0002665144521125435,0.0002780793001200858
NCT00312208,Docetaxel in Breast Cancer,0.00048237417477065215,0.0002992176040776163
NCT00312637,Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease,0.00033569017539056354,0.000276350617865625
NCT00393939,Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer,0.00035294588419119673,0.00041326791818351976
NCT00393406,The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method Approach,0.00023934709093652382,0.00023474929389804918
NCT00393783,Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity,0.0003311144022995188,0.0003245475993865345
NCT00393341,Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer,0.00028377543324726993,0.0003452149906736321
NCT00371488,GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer,0.0003869689831268967,0.0004505460550637571
NCT00371254,A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer,0.0003556849148726249,0.0004111700258228048
NCT00341458,Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics,0.00039368742634957537,0.0002695238973368952
NCT00341315,"Breast Cancer, Breast Disease, and Pesticides",0.0002819074122944154,0.00027503238069589113
NCT00331942,Breast Cancer Associated Antibodies,0.00046981437892111436,0.00022318528848767107
NCT00357487,Evaluation of Two New Medical Instruments Dedicated to the Sentinel Lymph Node Technique in Case of Breast Cancer,0.00024142198036384644,0.00023161488105149285
NCT00357110,Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer,0.00033153400552115534,0.0002764586748013391
NCT00386087,Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy,0.00030671939162778543,0.0004001754567382931
NCT00354302,Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27,0.00028825626377797806,0.00027912274160683446
NCT00354900,Phase I Study of Aprotinin in Advanced Breast Cancer,0.00034960529291777213,0.0002929412038821814
NCT00322348,Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women,0.00031481119593134745,0.0002888360947170161
NCT00322400,Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer,0.00027895965228478154,0.00038881627572139873
NCT00322504,Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study,0.0002789999937990707,0.00032461510371927714
NCT00395655,Hydralazine and Valproate Added to Chemotherapy for Breast Cancer,0.0002983602562511031,0.0002654131734181562
NCT00300508,3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer,0.0002738747892845445,0.0003536574470483158
NCT00300781,Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer,0.0003504550518143341,0.0004727218202453041
NCT00390169,Randomized Controlled Trial Comparing MBSR to SET in Breast Cancer Patients,0.00035168181762597204,0.00031518210907352745
NCT00390377,Use of Hair to Diagnose Breast Cancer,0.0003419203038690822,0.0002629573345402512
NCT00376909,"A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women",0.0002382813334149483,0.00020321383814881833
NCT00376740,Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole,0.00029771586288869126,0.0003065845001276475
NCT00317720,Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer,0.0003643242702215034,0.0003926174958506484
NCT00317603,Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients,0.00028544024400985673,0.0002595666695050826
NCT00327769,Faslodex Advanced Breast Cancer Local Chinese Study,0.00035061941504290595,0.0003910337812144261
NCT00339248,Markers for Breast Cancer,0.00047907240132673805,0.0003273809687841989
NCT00388713,Radiation Induced Atherosclerosis in Breast Cancer Patients,0.0003621953328809783,0.00029260312852876776
NCT00352378,Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer,0.00026183286764985705,0.0003027326935133494
NCT00352872,Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer,0.00026131402372825744,0.00030569874244584035
NCT00355316,A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients,0.0003212207173240519,0.0002829683891247792
NCT00323479,Arthralgia During Anastrozole Therapy for Breast Cancer,0.00030819979001163694,0.00042891364441625083
NCT00323908,Protocol to Examine Methylation of Tumor Suppression Genes in Women at High Risk of Developing Breast Cancer,0.00024695609160781324,0.0002710267776407102
NCT00766454,Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer,0.0002840604369154897,0.00031926824801269235
NCT00793546,Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer,0.00027984953439420346,0.0002971092280354713
NCT00793962,A Phase â…¢ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer,0.0002636923548561008,0.0002961050865376844
NCT00793377,Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer,0.0002581552887727711,0.0004348497003986778
NCT00760370,Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer,0.0002527728170092035,0.0001784122684097605
NCT00760123,Lymphedema Prevention in Breast Cancer,0.00034122731334082436,0.0003196369992757476
NCT00780000,Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer,0.00030806969672634964,0.00035781650628222286
NCT00785382,Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery,0.00029214539748322586,0.00018689358182993085
NCT00784888,Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy,0.000324996171250237,0.00046654617828321184
NCT00723125,"Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer",0.00026679993783230017,0.00028686879734618356
NCT00723294,Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer,0.0003387332166475021,0.0003897813558215176
NCT00794989,Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer,0.0003377767343852703,0.000321780535510115
NCT00741260,Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer,0.0002889982794873014,0.00035796780089302507
NCT00756717,Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer,0.0002998813566389546,0.0003233795377704395
NCT00774371,Weight Reduction Intervention for Breast Cancer Survivors,0.00034166869394082423,0.0003185653976861806
NCT00774878,Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (FaslodexÂ®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer,0.0003520841786881298,0.000378631502780405
NCT00767520,Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer,0.00027804788327037174,0.0003463790851198447
NCT00767585,An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice,0.0002737771966609173,0.0003598127389394906
NCT00744653,Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.,0.00023599486190965284,0.0002268279193871439
NCT00783822,Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients,0.0003581559292278752,0.00033600183301445494
NCT00783757,TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer,0.00026767732579637346,0.0002953171745132653
NCT00746694,A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020),0.0003235657499603359,0.0003562975215719149
NCT00749255,Collect Breast Cancer Patients' Digital Mammography Images With Corresponding Reports for the Development of Software,0.00028617540850704194,0.00019153793478565088
NCT00725374,A Study to Investigate the Effects of Tibolone (LivialÂ®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469),0.0002808693263641462,0.000314307103169553
NCT00738777,Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer,0.0003215808102248252,0.0004955637064971537
NCT00738998,Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer,0.00025975560038064323,0.0003130086435419772
NCT00792077,A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue,0.00033131542573884776,0.0003490504069106246
NCT00726180,"Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer",0.0002574167059458372,0.0002651533895556164
NCT00700778,Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations,0.0003376796674126308,0.0002645640596669641
NCT00709020,White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors,0.0002909519784994956,0.00027363883706252876
NCT00775645,"S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo",0.00026113950687741273,0.00024930949676656356
NCT00769080,The Performance of Patient Support Program in Early Stage Breast Cancer,0.0003284490172437816,0.0003192050276234434
NCT00769821,The Impact of Lymphedema on Breast Cancer Survivors,0.0004743668103717435,0.00023055335546283548
NCT00772824,Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients,0.0003393490844178564,0.0002652414712981722
NCT00724386,Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer,0.0003127338444948291,0.00031003437657487046
NCT00734838,Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy,0.00029214223580601605,0.00030273781032824214
NCT00777101,Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer,0.0003012760197528393,0.00032195777349183335
NCT00796107,A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer,0.00031589149409650205,0.0003502390505788492
NCT00798070,Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients,0.0004915603397778765,0.00039396627909944634
NCT00712140,Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer,0.000492637956478363,0.000234600774088113
NCT00712569,Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety,0.000291159073484462,0.0002735709499405925
NCT00712881,Combination Therapy With MYOCETÂ® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer,0.00031699520606390507,0.00034649678250352965
NCT00712621,"Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination",0.00033309742376806624,0.000379487372165013
NCT00768859,Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study,0.0003016177850713147,0.00037337332630099656
NCT00768222,Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery,0.00026384234340811214,0.000339690489812911
NCT00757211,Study of Genes and Environment in Patients With Breast Cancer in the East Anglia Region of the United Kingdom,0.0004915603397778765,0.00036733391820915613
NCT00757302,Intraoperative Gamma Camera for Breast Cancer Surgery,0.00029202438376865975,0.00031323395078913384
NCT00719173,Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer,0.0003189071964767196,0.0002701654501395759
NCT00719875,HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer,0.0002569721212838171,0.00026779967046374836
NCT00719966,Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer,0.00027402323876463575,0.00028784907300375095
NCT00788489,"A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy",0.0003792334695521769,0.000410127360447056
NCT00788333,Combination Study of BMS-754807 and HerceptinÂ® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer,0.0003556245200935505,0.00034412336196479776
NCT00739063,"Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer",0.00028436581181836125,0.0003245913941384837
NCT00739544,Chronic Pain After Operation for Breast Cancer,0.00035371282318615087,0.00037289614678440635
NCT00742222,Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer,0.000317204452549003,0.0003723450088935193
NCT00773695,A Study of Avastin (Bevacizumab) in Combination With Neoadjuvant Treatment Regimens in Patients With Primary HER2 Negative Breast Cancer,0.0003390514951748282,0.00037010640175485327
NCT00727662,A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue,0.00028076130773028454,0.0002112090358666718
NCT00727883,Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients,0.00031968433999267115,0.000408399220701835
NCT00754845,Letrozole in Treating Women With Primary Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy,0.00028446667813907455,0.00026377811722950783
NCT00754312,"A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer",0.00028611099144938755,0.0003646781118438444
NCT00754325,Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor,0.00027513360181690024,0.0002983911327613265
NCT00702858,Trial of Blue Citrus Compared to Placebo in Patients Receiving Aromatase Inhibitor Therapy for Estrogen Receptor Positive Post-Menopausal Breast Cancer,0.0003128763140594779,0.00034496407274255955
NCT00770354,Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer,0.0004030277651885054,0.000404996543321477
NCT00713141,Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer,0.00026487802437664065,0.00023837115225433468
NCT00771433,G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer,0.0003626608531045561,0.0003468881635007881
NCT00771381,A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer,0.0003381579249109979,0.0003362829279283494
NCT00759785,A Study of Dalotuzumab (MK0646) in Breast Cancer Patients (0646-013),0.000397910832765915,0.0004465430513602792
NCT00728949,A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer,0.0003242659749482489,0.0003176001449841723
NCT00728442,Impact of OncoDoc2 on Guideline Compliance in the Management of Breast Cancer,0.00027826433563024486,0.0002871470635579475
NCT00752986,ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial,0.0003902741007731152,0.0003413246534614048
NCT00717886,Upper Extremity Lymphatic Mapping for Breast Cancer Patients,0.00035225024072668237,0.00029876144778254497
NCT00717405,A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.,0.0003327700898343554,0.0003394336041690429
NCT00717951,"A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer",0.000344721462738027,0.00030378502816379025
NCT00717015,Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer,0.00026923473944586666,0.00028041189875943433
NCT00776724,Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm,0.00028698913056495867,0.00027414269164466033
NCT00776308,Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery,0.0002934370516200135,0.00027498823501483815
NCT00776659,An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin,0.00033488168772361117,0.00039359409096029093
NCT00703326,Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer,0.0003320110823726036,0.0003062274111831401
NCT00701584,The Role of Diet and Lifestyle in Breast Cancer Survival,0.00033551886184070566,0.0003053919046687915
NCT00748267,Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer,0.00025380996829369584,0.0002702489752097913
NCT00748553,A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer,0.0003339966654582038,0.00036664305005431686
NCT00764322,Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen,0.00028302098289555004,0.0002812000280280325
NCT00721903,Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies,0.0003122175596291017,0.00041558856360231265
NCT00721058,Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.,0.0002889207338442241,0.00036893749398709077
NCT00721409,Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer,0.0003012574503077022,0.0003593517286792411
NCT00721565,An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial; Pilot Study),0.0003350300790749271,0.0003042926242677308
NCT00721747,"TaxotereÂ®, Followed by MyocetÂ® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer",0.0002560233206221766,0.00036219039578929216
NCT00721370,Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer,0.000333614773899048,0.00026685024507112974
NCT00705315,Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer,0.0002496446222076713,0.00033783376957914217
NCT00445458,A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer,0.0002844277413650362,0.0003807661092985447
NCT00445445,Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women,0.0003360886036188542,0.0003613891652326348
NCT00425672,ONTAKÂ® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment,0.00036033335367650405,0.0003052165307582594
NCT00425776,Treatment of Hot Flushes in Breast Cancer Patients With Acupuncture,0.000381456821300504,0.00034437899276191293
NCT00425516,Breast Cancer Treated by Neoadjuvant Chemotherapy,0.00038106536062260967,0.00034163261752835443
NCT00451555,Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer,0.00028167098201625567,0.00037487552983424613
NCT00407888,"Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery",0.00031298182398362595,0.00029703291350811743
NCT00407706,Using Test of SCM for Detection Breast Cancer,0.00033578977000895793,0.00024949434894569266
NCT00466830,Psychological and Social Factors That May Increase the Risk of Developing Chronic Pain After Surgery in Women With Breast Cancer,0.0002924510089837615,0.0002816408513978787
NCT00466102,Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases,0.0004330848406776811,0.0003777240579601739
NCT00465673,Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer,0.00035408341601575195,0.0002944710729051126
NCT00403182,Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer,0.00028740130342532757,0.00028226117378882774
NCT00477139,A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer,0.0003533847382896769,0.00031809727197698324
NCT00450762,Gemcitabine + Carboplatin in Breast Cancer,0.00033880838733963564,0.0002718144196352363
NCT00450866,Epothilone B in Treating Patients With CNS Metastases From Breast Cancer,0.0003514660156460323,0.0003266792701174081
NCT00450892,Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer,0.00034050096946447466,0.00037947996314642736
NCT00428896,A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer,0.00024483304238947563,0.000229741383040426
NCT00464516,Preoperative Estetrol in Breast Cancer,0.0008984903380354321,0.00032276791189010266
NCT00435409,A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer,0.00034258792514133647,0.000416174859494364
NCT00421447,Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole,0.0002979608771990806,0.0002934403553230134
NCT00417885,A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer,0.0002939942414378544,0.000334592719497561
NCT00412022,"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.",0.00033091225040992033,0.0003317401894011297
NCT00481884,Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients,0.00031559478625073036,0.00024766583216765184
NCT00481845,Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer,0.0002629718107859553,0.0002730960702968388
NCT00437879,Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment,0.0002705203854829978,0.0003589478533231667
NCT00437294,Enzastaurin in Combination of Capecitabine to Treat Breast Cancer,0.0002916460522867704,0.0003131194841635512
NCT00437073,Brain Metastases In ErbB2-Positive Breast Cancer,0.00047318207366759817,0.0003329290571765668
NCT00437359,Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer,0.00028259176814507273,0.00022166076310646632
NCT00433095,Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer,0.0003189587450279459,0.0005562619669065523
NCT00433589,Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes,0.00026205490828820654,0.0002772857302006396
NCT00433511,"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",0.0003100746116060748,0.00038103616601177384
NCT00433420,Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer,0.0002538754760733523,0.0002705572367798212
NCT00431704,"VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer",0.00028039126819505623,0.00036464705118140363
NCT00431080,Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer,0.0002508231541701899,0.0003311713205340589
NCT00448305,EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients,0.00035616416023698163,0.0003630950287567634
NCT00409071,Placebo-controlled Evaluation of CocculineÂ® Efficacy in the Management of Nausea After Chemotherapy in Breast Cancer.,0.0002564106546595582,0.00029098226774418903
NCT00476203,Yoga Study in Breast Cancer Patients,0.0003988668673754482,0.00040827864091301573
NCT00484614,Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer,0.0002879832424560667,0.0002625614473336306
NCT00446030,Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer,0.00030843579079205084,0.0003363442248152023
NCT00478257,Effect of Increased Light Exposure on Fatigue in Breast Cancer,0.00025514054432629546,0.0002085424150838892
NCT00478283,Views and Attitudes of Oncologists and Geriatricians on the Use of Chemotherapy and Hormone Therapy in Treating Older and/or Frail Women With Breast Cancer,0.0002736175210225155,0.00024800755306471903
NCT00478270,A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.,0.00032471129014836897,0.00026817418760769786
NCT00429286,Preserving Function in Breast Cancer Patients,0.00043338339096250724,0.0003977309919735857
NCT00429299,"Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer",0.0003138097473293534,0.00043519718155948426
NCT00429507,Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases,0.0002914745386300025,0.00024311904718888195
NCT00429403,Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer,0.000333436228899226,0.00032891370921582107
NCT00429247,Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients,0.0003272300022873642,0.00028974599147382784
NCT00429988,Study of Ductal Lavage in Women at High Risk for Breast Cancer,0.0003276959570370392,0.0002863581395038737
NCT00440089,Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors,0.00033790251346644634,0.00021616077638585225
NCT00459628,Trial of Tomotherapy in Breast Cancer,0.0004686817696958774,0.00028503427320813893
NCT00415285,Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer,0.0002708747455157567,0.0003383361986893627
NCT00422903,Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer,0.00027908566340412546,0.0002742053077228441
NCT00427726,Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies,0.0003139395663460778,0.000351174344393098
NCT00427427,Delayed Adjuvant HerceptinÂ® Treatment in Patients With HER-2 Positive Breast Cancer,0.0003218159928324623,0.0003528378091998165
NCT00418210,Accelerated Partial Breast Irradiation for Early Breast Cancer,0.0004692488259177234,0.00026412512932884276
NCT00418457,Regional Anesthesia and Breast Cancer Recurrence,0.00033639486364461573,0.0001800029049107309
NCT00418028,Standard Versus Continuous Capecitabine in Advanced Breast Cancer,0.0003103638293833467,0.00025020582397668927
NCT00418444,Body Image and Psychosocial Functioning in Women With Breast Cancer: Can We Fix What We've Broken?,0.00033389355265249737,0.0003511947095475807
NCT00473096,Efficacy Study of an Educational Program for Decision Support for Breast Cancer,0.0002809503675464407,0.0003123447268359136
NCT00472589,A Biological Sample Collection Protocol of Women With and Without Breast Cancer,0.00027878819290652856,0.00022848818002358287
NCT00496379,ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases,0.0004344766367325104,0.0003506065872668371
NCT00496665,ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer,0.0002731985677757983,0.000307031888252141
NCT00496366,Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer,0.0002693207427705991,0.0003953421363371142
NCT00496613,Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors,0.00030096245712675826,0.00028723976252925627
NCT00496288,Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer,0.000273004703577926,0.00020485909339239898
NCT00496795,Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer,0.00026279405665126046,0.0003534020297237596
NCT00452673,Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer,0.0003170084769354169,0.0003693033498626551
NCT00497458,Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects,0.0003551277339249908,0.00034690930346909627
NCT00488722,"A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer",0.000289445670702551,0.00029577617132492184
NCT00402519,APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer,0.0003072477143967299,0.0002254050334594036
NCT00463489,Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer,0.0003748837444911076,0.00029036842378387875
NCT00424983,Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year,0.0003546032636654679,0.000373626450213864
NCT00424606,Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients,0.00030583192828418775,0.00027532456473619967
NCT00499525,Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer,0.00034356734968268485,0.00035991051439217774
NCT00499603,Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer,0.00048647849283700275,0.00038680937900006007
NCT00436566,"Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery",0.00032651806728171707,0.0003077828716504806
NCT00436917,"Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer",0.0002561418308953078,0.00024011531369793132
NCT00436254,Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer,0.0002974885238876741,0.0002919199343040487
NCT00419900,Use of Hair to Diagnose the Presence of Breast Cancer,0.00028335135195313395,0.00023384072139920006
NCT00419822,Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients,0.000317782545113687,0.00036074507185355483
NCT00419679,Use of Hair to Diagnose Breast Cancer,0.0003419203038690822,0.00028049773211782437
NCT00458588,Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children,0.00026871076922680136,0.00025704395959646185
NCT00458796,Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone,0.00030046301115793607,0.00021877317843634536
NCT00462865,Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse,0.0002824025881451958,0.0003313844992245543
NCT00462696,MRI in Evaluating Early Response to Chemotherapy in Women Receiving Chemotherapy for Infiltrating Breast Cancer,0.00030455951043099997,0.0003003508924080831
NCT00462410,Effect of Advertisements on Treatment Compliance in Women With Breast Cancer,0.00030518953968382506,0.0003243783837624109
NCT00479856,Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer,0.00027980493771710024,0.00035451658335975816
NCT00490503,Non-Invasive Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy Techniques (MRS) for Assessing Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer,0.0002812795349213036,0.00035249703642443666
NCT00432172,Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients,0.0003278367659803269,0.0003251709555594113
NCT00416130,Clinical Trial of SAHA in Patients With Breast Cancer,0.0004354973998214846,0.00036688176623195885
NCT00416715,"Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",0.00025390200861081754,0.00023270071497396837
NCT00416689,Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer,0.00031281845793002016,0.0003153232960360948
NCT00404066,Phase II Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer,0.00025965177671094427,0.0003324194877708856
NCT00454805,AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.,0.00038112808018719353,0.0003735846190864116
NCT00470119,Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women,0.00024779314295612974,0.00019353541988021902
NCT00470847,Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer,0.0003158383947182744,0.00031895490169900554
NCT00493870,TAC Versus TC for Adjuvant Breast Cancer,0.0008984903380354321,0.0007116317877522614
NCT00493649,Adj TC + Herceptin Early Stage Breast Cancer,0.00035398840731604153,0.0003212494880525238
NCT00434369,5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients,0.0003078230801818723,0.0002554175693719637
NCT00434031,CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer,0.00028347868965638797,0.0003460448516025683
NCT00434941,Administration of Capecitabine Simultaneous to Radiotherapy for Local Relapse Breast Cancer Patients With Negative Her2 Tumours,0.00030418767514940755,0.00033761900542942134
NCT00461253,Case-Control-Study on the Breast Cancer Risk of MirenaÂ® Compared With Copper IUDs,0.00027456796955620504,0.000347114515747493
NCT00461773,Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer,0.0002872358822884955,0.0003086129413593005
NCT00461344,Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer,0.00033177332053576253,0.00033514991907866883
NCT00438074,A Pilot Study To Evaluate the Effectiveness of Pulsed Time-Domain Optical Spectroscopy for Monitoring the Responses in Neoadjuvant Treatments of Locally-Advanced Breast Cancer,0.0003034906355805373,0.0003463001030443758
NCT00471159,A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.,0.00038140495093349016,0.0005925946176758314
NCT00471276,Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer,0.0003690288584627169,0.000384075923495479
NCT00471601,Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions,0.00029229760734307927,0.0002690071748354741
NCT00408863,"Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)",0.0002842715033872182,0.000277456438093585
NCT00498771,Aquatic Exercise Study for Breast Cancer Patients With Lymphedema,0.00035918418805429346,0.0004162003398137277
NCT00485953,Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy,0.0002732511835100609,0.00021627824179537992
NCT00485979,"Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients",0.0003236305962295945,0.0003461914572274406
NCT00455273,Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer,0.0003740138592556814,0.0002706393655575967
NCT00455039,INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients,0.0003979119177801671,0.0004006382187618781
NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,0.0002964180244858633,0.0003392726460909267
NCT00489125,Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer,0.000353240904910142,0.00029276790169018225
NCT00494234,Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer,0.00032572898431333956,0.00040947174384187786
NCT00494481,E3 Breast Cancer Taxotere Combination,0.0003473445838353982,0.0003002485237122303
NCT00474604,Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants,0.00047665385772231657,0.00028237979796207497
NCT00482391,"Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer",0.000311739409220903,0.00043315201634978347
NCT00495209,Pre-Surgical Qigong Therapy for Women With Breast Cancer,0.00032067024899387836,0.0003230381381580146
NCT00486525,"Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors",0.0002433977291758793,0.00019572007775730423
NCT00426335,Evaluation of Group CBT Programme With Breast Cancer Patients,0.0003252600915626083,0.00039558517424920437
NCT01840293,Breast Cancer Proteomics and Molecular Heterogeneity,0.00047037320740989097,0.0002415242283652078
NCT01862900,Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions,0.00029454533925766174,0.00029228426238184896
NCT01879189,PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk,0.00046910791402175387,0.00019247525412848952
NCT01888419,Investigation of the Pain Relieving Properties of Lipotransplantation After Treatment for Breast Cancer,0.0002817046505816038,0.0003805328888975625
NCT01893944,Applicability of Video Games and Vibrational Therapy in Reducing Pain Secondary to Breast Cancer,0.00026342281726301234,0.00025853567009679354
NCT01824745,Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors,0.00033781133108899003,0.0003436552303930605
NCT01824498,"Dietary Fat, Eicosanoids and Breast Cancer Risk",0.0004689674396005906,0.00019633685229383295
NCT01848197,Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer,0.0005240256729824867,0.0002562574085325435
NCT01804309,Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer,0.00024640563346651535,0.00025380370396293545
NCT01843608,Effect of Combined Exercise Post-treatment Intervention in Lean Mass Recovery in Breast Cancer Survival.,0.0002692197227839042,0.00044047291481687494
NCT01864798,A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer,0.0003604504215194562,0.0004107812122705825
NCT01864083,FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients,0.0003259272501215394,0.0004618797521434025
NCT01869764,Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer,0.0003636489196116763,0.0003720796356084939
NCT01856543,Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation,0.0002939293622383929,0.0003157670280917815
NCT01856452,Comparison Study of Sentinel Lymph Node Biopsy by Multimodal Method in Breast Cancer,0.0002776101733645633,0.00024290957021913694
NCT01842321,Abiraterone Acetate in Molecular Apocrine Breast Cancer,0.00027751723438661766,0.0004165445245942808
NCT01891227,Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer,0.0002838675725467541,0.0003784587148071402
NCT01891357,Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer,0.0003333784071394084,0.00042740034335715215
NCT01831778,Breast Cancer Surveillance Consortium,0.0004699558903544415,0.00016138379433777386
NCT01874184,Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer,0.0002484673952953136,0.0002719257059898155
NCT01830933,Breast Cancer Risk Reduction: A Patient Doctor Intervention,0.00035808351731109357,0.00021462997097834247
NCT01830244,IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer,0.00029839564066513056,0.00043898152884544895
NCT01815242,Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer,0.0002702691347044734,0.0002947601609522335
NCT01828021,Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer,0.00033807712391282227,0.0004094617650021788
NCT01811264,Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer,0.00030647970451933617,0.00022142004633547976
NCT01857193,Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer,0.0002865836234342193,0.00031778344648658694
NCT01890824,Fat Metabolism Following Chemotherapy in Breast Cancer,0.0002989451286199722,0.0002821942994272716
NCT01894711,Real World Efficiency of Trastuzumab in Early Breast Cancer,0.000492637956478363,0.00028154668549939296
NCT01836640,Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer,0.0003110831753942438,0.00046877786166642563
NCT01818713,Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases,0.0003154816362764686,0.00034492729723951314
NCT01818063,Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer,0.0003104941301945205,0.0003571174133595677
NCT01855503,Breast Cancer Molecular Analysis Protocol,0.00033644201914037,0.0003131916931808492
NCT01819324,A Lifestyle Intervention for Breast Cancer Survivors,0.00047844215270982453,0.00032125464628942664
NCT01819233,Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy,0.0003258854346988341,0.00035032045344324085
NCT01819948,Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMedâ„¢,0.0002603759313976025,0.00032092843749375016
NCT01814865,Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer,0.00024362945195523277,0.0003316018975620346
NCT01814397,Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients,0.00035199007835520963,0.0003739596353785529
NCT01809171,Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients,0.0002909781385920827,0.000239172955596648
NCT01880853,Ultrasound and Mammography for Screening Breast Cancer in Chinese Women,0.0002797037687200622,0.0001981913392032342
NCT01880541,Assessment of Cognitive Function After Surgery in Two Types of Anesthesia in Patients Operated for Breast Cancer,0.0003132795616181782,0.00020300895261449805
NCT01805076,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,0.0003374306668704214,0.0003614439283457725
NCT01805908,Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC),0.0002730301574799187,0.00032477026487348994
NCT01805089,Melatonin Versus Placebo in Breast Cancer,0.0003366340148019154,0.0002785135595366506
NCT01805271,"Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy",0.000277795212077166,0.0003602725828330892
NCT01897441,Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,0.0003266049897307281,0.00040382047906283703
NCT01867229,Breast Cancer and Chemo-amennorhea,0.0004695380931503949,0.00048027747664356396
NCT01895491,Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer,0.0003952503936524914,0.0006129059321159768
NCT01816594,NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer,0.00028866706429526783,0.00024579495467802454
NCT01816035,Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery,0.00032207606757297003,0.0003732835189970816
NCT01861054,Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients,0.000338316496670628,0.0003285416475683741
NCT01829984,Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers,0.0003135288103842074,0.0002794386855062513
NCT01823549,Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients,0.00029714858051843216,0.00031982549504551975
NCT01823835,A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,0.0002947200233778715,0.00035717540780664235
NCT01823991,COGNUTRIN in Breast Cancer Survivors,0.0008984903380354321,0.00033695850426890836
NCT01827163,Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer,0.0002809507875345691,0.00046364753494913493
NCT01803958,Breast Cancer With Low Risk Of Local Recurrence: Partial and Accelerated Radiation With Three-Dimensional Conformal Radiotherapy (3DCRT) Vs. Standard Radiotherapy After Conserving Surgery (Phase III Study,0.00028806081825644424,0.0004043886897896257
NCT01803516,QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser,0.0003085145675221084,0.0003220247884440121
NCT01845519,Step by Step: A Tailored Walking Intervention for Breast Cancer Survivors,0.00034043495766831084,0.0004428814959705687
NCT01878695,Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer,0.0003001553825211595,0.00024686912482748183
NCT01896050,"Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer",0.00034076655542536173,0.00037995395715320585
NCT01881022,An Internet-based Psychosexual Intervention for Couples Following Treatment for Breast Cancer,0.0003775056015748579,0.00029176275539195254
NCT01859936,Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment,0.0002796801888453488,0.0003811860875255774
NCT01822314,Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer,0.00028459532754678777,0.0002785089335995138
NCT01866202,Study of Circulating and Tumor Biomarkers in Breast Cancer Patients,0.0003616670179833755,0.00041379884969859105
NCT01866813,Internet-Delivered Cognitive Training For Breast Cancer Survivors With Cognitive Complaints,0.00033530722485988507,0.00023982901604353501
NCT01866631,Using National University Cancer Institute of Singapore (NCIS) Registry to Measure Time Trends in Quality of Care for Breast Cancer Patients in a National Cancer Centre,0.00029844188545479833,0.00023850305522672875
NCT01847001,Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,0.0003542023899833957,0.000407931274809207
NCT01875367,A Phase III Clinical Trial to Evaluate PatientÂ´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC).,0.00031985701709633314,0.0003321022363094137
NCT01875666,"Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",0.0002569926764973043,0.00040623754340420525
NCT01892540,PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer,0.0003013721359764526,0.0003247361784901948
NCT01871116,POWER-remote Weight Loss Program in Early Stage Breast Cancer,0.00034883630344983643,0.00028990130124832323
NCT01806259,Ketorolac in Breast Cancer Surgery,0.00035314426160169403,0.00027690554688776026
NCT01872260,"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",0.00035672573426750456,0.00033585970474887355
NCT01887925,The Effects of Circadian Gene on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy,0.0003336812522023567,0.0004348438102953738
NCT01837563,Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer,0.000318521594038813,0.00032957347560016217
NCT01837602,cMet CAR RNA T Cells Targeting Breast Cancer,0.00047153848866586127,0.00021402441513977534
NCT01839045,Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification,0.0002558570023497453,0.00030580162791850075
NCT01849250,Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors,0.0003363948636446158,0.0003769143374864923
NCT01849614,Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart,0.00025300418788193254,0.0002743958514757478
NCT01849328,Testing Spectrosense EVA System for Detection of Breast Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air,0.00027731925629872746,0.0001852893462101859
NCT01849978,Enhancing Exercise in Breast Cancer Survivors,0.0004754606381545852,0.0003550914893649617
NCT01849380,Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer,0.00031767116767520245,0.00027060162870922377
NCT01858116,PET Study of Breast Cancer Patients Using [68Ga]ABY-025,0.0003565131412088488,0.00045161708267410646
NCT01876238,Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer,0.0003055695150719902,0.00031034928090790096
NCT01876251,A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer,0.0003640692431958771,0.00044362988191805526
NCT01817231,Epidemiological Analysis of Vitamin D and Breast Cancer Risk in Saudi Arabian Women,0.0004706723300569183,0.0003234765948133785
NCT01817452,"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol",0.00031969326024390625,0.00027817162967963007
NCT01801527,Telehealth System to Improve Quality of Life in Breast Cancer Survivors,0.0002804656509712221,0.0003756540755320214
NCT01800422,Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer,0.0003513889086394811,0.00031771700885720535
NCT01821768,Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy,0.0002992614811422533,0.00036344211125881695
NCT01969253,A Prospective Observational Study of Lymphedema in Breast Cancer With Axillary Lymph Node Dissection,0.00029505194491614094,0.00029798923059262233
NCT01969643,A Safety Study of SGN-LIV1A in Breast Cancer Patients,0.0004915603397778765,0.0003905461321612431
NCT01980823,Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer,0.0002641579229546327,0.000337383506776497
NCT01980277,Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer,0.0003419051492506924,0.0002681473754082841
NCT01937052,Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database,0.0002859153691203528,0.00020549040460743443
NCT01937507,Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer,0.0003336105489707825,0.0002036064219470781
NCT01937689,Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer,0.00034948521813582377,0.0003307476931829275
NCT01937039,Johns Hopkins Breast Cancer Program Longitudinal Repository,0.0004752138787630337,0.000306177637332649
NCT01937117,Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer,0.00033779114887862855,0.00028541103819080524
NCT01908270,Effects of Yoga on Menopausal Symptoms in Women With Breast Cancer,0.00033491992285138085,0.0003176347143565763
NCT01950182,Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer,0.0002747772874221597,0.0004097501766668516
NCT01952054,Denosumab for Breast Cancer With Bone Mets,0.0003362995372280455,0.0003790687810666585
NCT01954706,Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients,0.00030334411115595953,0.000323364791752585
NCT01954654,Effectiveness of Accelerated Intervention With Compression Sleeve in Mild and Moderate Breast Cancer-related Lymphedema,0.000242558372388756,0.0003212757236586525
NCT01919229,A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1),0.0004131642514468129,0.000570117796325134
NCT01982591,Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy,0.00032212924332198506,0.000359388428225829
NCT01921296,Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients,0.00034203135944493754,0.00032716573768314404
NCT01924078,Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer,0.00025964189722288357,0.0003148903009785147
NCT01924351,HER2-positive Breast Cancer With Brain Metastasis (GCC 1345),0.0003367949760012968,0.0002484985029839874
NCT01989780,Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer,0.0003121296068021953,0.0002988259248570542
NCT01914614,A Pilot Study of Working Women and Breast Cancer,0.0005580027294853632,0.0003103905340702211
NCT01956513,Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer,0.00029309267403790335,0.00040564642842815185
NCT01994369,Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17),0.00027670400253765695,0.0002669140071914264
NCT01996046,FDG PET/CT in Breast Cancer Bone Mets,0.00033588668907766047,0.00032511165768155077
NCT01996410,The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients,0.00033411118559479165,0.0003056776996591202
NCT01992952,Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer,0.00026459198045036613,0.00036789800872728443
NCT01992471,Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing,0.00027911869554575036,0.00029738934198264447
NCT01992250,Cryoablation of Small Breast Tumors in Early Stage Breast Cancer,0.0002885497003319108,0.0003632636117363704
NCT01963572,A Continuing Cancer Service Model Emphasizing on Functional Restoration: Model for Breast Cancer,0.00023698032473869183,0.00040574033009337676
NCT01927939,18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.,0.0003132287288313777,0.00035503467106567384
NCT01927081,Self-management Interventions for Advanced Breast Cancer,0.00030533755944829767,0.00031000508808415057
NCT01990430,Behavioural Changes in Breast Cancer Patients,0.0004334795231504036,0.00033946523770031375
NCT01959490,Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,0.00030586299425634263,0.0003558255894126742
NCT01901146,Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer,0.0003365383297641425,0.0005504631827241912
NCT01901094,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,0.000320418498538601,0.0003869458811120392
NCT01926964,Adjuvant Treatment Recommendation and Oncotype DXÂ® in Early Breast Cancer,0.0003709664263197719,0.00034665000045058336
NCT01926886,A Study of Subcutaneous At Home Administration of Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer,0.0003302769615836223,0.0003293416768328209
NCT01928186,"FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer",0.00033286019763814184,0.0003493591126013016
NCT01928615,A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer,0.00033432128227572986,0.0003555956287778247
NCT01928589,Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer,0.0003479328949506781,0.00030657077042540196
NCT01945476,Effect of Midazolam Premedication Before Induction on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Surgery Due to Breast Cancer,0.0002992815047018862,0.0003531977521234713
NCT01913067,Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC,0.0002975094835278953,0.0003459818541553517
NCT01913990,Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.,0.0003346666060748072,0.00024521232544344007
NCT01907438,Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells,0.00025545444823910546,0.00023398913714770266
NCT01907880,The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer,0.0002782322603091768,0.0002510441581940589
NCT01907529,A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer,0.000289051294817315,0.00030962362007947857
NCT01943695,Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer,0.00036398186416595915,0.0003622689646688347
NCT01943032,Discordant Hormonal Status of Breast Cancer.,0.0003341833448530096,0.0003363932801020299
NCT01966471,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,0.00028005339418069725,0.0002962772982885185
NCT01948128,Effects of Vitamin D in Patients With Breast Cancer,0.0004327581417931717,0.0002682664083518503
NCT01948726,Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer,0.0004696797834353051,0.0004274055864372034
NCT01998906,A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer,0.00030986168618863703,0.000285921873699208
NCT01965522,Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer,0.00027813905486688133,0.0003284711847125218
NCT01965483,Phase 2 Study of Adjuvant Radiotherapy in Breast Cancer Using a Once a Week Hypofractionated Regimen,0.0003247876120763999,0.0003033463870745857
NCT01929811,NeoMET Study in Neoadjuvant Treatment of Breast Cancer,0.0004126569226256081,0.0003055090841658628
NCT01993576,ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.,0.00025594195624483194,0.000310396441484936
NCT01993498,Breast Cancer Toxicity,0.0004710931319453771,0.0002925048656059096
NCT01991340,H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer,0.0003356245915839613,0.000371612830274581
NCT01912612,Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients With Chronic Pain,0.0003333928913190889,0.0003696538232669324
NCT01912963,"Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",0.0002987738352772034,0.00044033311221618383
NCT01940497,SCHEARLY Study: A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,0.0002989107445327614,0.0002773903678228766
NCT01940107,Domiciliary Physiotherapy in Women Undergoing Treatment for Breast Cancer Radiation,0.00031623042442050463,0.000243052014428148
NCT01972984,Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients,0.00032131187238064685,0.0003616375834315448
NCT01973660,PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer,0.00025600229556495176,0.00029985864387488555
NCT01936064,The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients,0.00037990818745917653,0.00035698814451381317
NCT01975363,Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer,0.0002943027995565235,0.00028384549303563664
NCT01935739,Discordant HER2/Neu Status of Breast Cancer.,0.00033351631448908073,0.00033608037524357915
NCT01925651,Clinical Trial of The Use of Bolus in Post Mastectomy Irradiation in Breast Cancer,0.00026336735489700184,0.0003446841262760661
NCT01949376,Mild Cognitive Impairment in Breast Cancer Patients,0.0004312917988989582,0.0003801362693053357
NCT01961128,RPFNA Assessment of Exercise Effect in Breast Cancer,0.0003456348123262276,0.00027238031298331246
NCT01961544,Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer,0.0003248776386696236,0.0003522830931223686
NCT01941784,Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy,0.00031999137339118765,0.00035230735721999366
NCT01983501,A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,0.00035289013849093987,0.0004280624726526176
NCT01934478,Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer,0.00028856274893934773,0.00037704529818433
NCT01905046,Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer,0.000287773513800858,0.0003289562964115802
NCT01905592,"A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",0.00029515064712519863,0.00033142782256369893
NCT01970670,Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer,0.00028128164484872876,0.00023620845487374475
NCT01904331,Breast Cancer Long-term Outcome of Cardiac Dysfunction,0.0003349261574389133,0.00029450679234605226
NCT01904266,Paravertebral Blocks for Breast Cancer Surgery,0.0003538084323495754,0.0003210556132934439
NCT01904903,Cardiac Safety Study in Patients With HER2 + Breast Cancer,0.0003987793372573064,0.000358265769442183
NCT01931709,FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer,0.0003429241939677343,0.0003546932147501871
NCT01931943,A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer,0.00037543487526129086,0.00039330878613218375
NCT01931163,NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer,0.0003364870052782127,0.0003270894248788336
NCT01942759,The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer,0.000254281339395278,0.0002558244651691214
NCT01942980,Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer,0.00026082488386064786,0.0003372218430899681
NCT01964391,A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer,0.00027654146054222837,0.0002737335028512214
NCT01917578,Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction,0.0002913273294945123,0.00027451838381639107
NCT01988870,IORT (Intra-operative Radiation Therapy) in Early Stage Breast Cancer,0.00036254549751307537,0.00035408165803491173
NCT01985841,Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer,0.00028044948579117513,0.0003457692910416928
NCT01985724,"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer",0.00025117382562721437,0.00022997377749695748
NCT01985945,Yoga for Breast Cancer,0.0004703711272459319,0.00031765043750935714
NCT01985971,F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer,0.00032285282211681716,0.00023782680778209174
NCT01984866,CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.,0.0003028471618777328,0.00021623737745463643
NCT01939054,Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients,0.0003272600528550924,0.00025067734575401655
NCT01939483,A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases,0.0003532005567715685,0.00033202149796698205
NCT01938651,Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer,0.00025970197335738036,0.00026440039462089453
NCT01938157,Diffusion Weighted MR Imaging of the Breasts in Women at High Risk of Breast Cancer: A Pilot Study,0.00028444744954437493,0.00026871310264073355
NCT01953003,Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,0.00034648448052978446,0.0003909925902089451
NCT01953588,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,0.00031467257385969804,0.0003626315817867087
NCT01953445,Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer,0.00031694708405216447,0.0004118082733832334
NCT01916837,Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer,0.00025588637792928155,0.000370907814366004
NCT01916317,Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer,0.0002511944149676132,0.0003652803785475595
NCT02652975,Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium,0.00027873230389247305,0.00032199406893408943
NCT02615054,Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors,0.0002477411322037573,0.0002856881970599967
NCT02615678,Acupuncture for CIPN in Breast Cancer Patients,0.00043326574200189884,0.00045412272893850114
NCT02694029,Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer,0.0002473174708248312,0.00024180988888382015
NCT02630368,A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX),0.00037543487526129086,0.00034711258718181983
NCT02626507,Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,0.00033007238895804247,0.00037372734762285907
NCT02692755,Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer,0.00034474414913313224,0.0003440301592275616
NCT02605915,Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Participants With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer,0.0002572921323915512,0.0003317994685261158
NCT02619292,Mindful Movement for Breast Cancer Survivors,0.0004688313334521008,0.00029095100033575363
NCT02619162,Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics,0.00035380489347521465,0.00028796007824170595
NCT02619669,Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer,0.0003112945970210132,0.000298907377605636
NCT02651142,"A Randomized, Controlled Trial of Sentinel Lymph Node Biopsy With or Without Para-Sentinel Lymph Node Dissection in Breast Cancer",0.00024305813109835083,0.00018406971343239308
NCT02651844,Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.,0.00031429740890987103,0.0004113792417999083
NCT02651519,Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation,0.0003084399645498228,0.0003103420006563432
NCT02649101,Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer,0.00029297734132828506,0.0002726298030446585
NCT02611544,Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors,0.00025963829149822754,0.0002444806587692831
NCT02696759,Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer,0.0002667236582077249,0.00019449891360674327
NCT02696707,An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer,0.00033498024350155184,0.0003091165094314427
NCT02680236,Art Therapy for Pain Relief in Breast Cancer Patients,0.00035146627049892376,0.00030742379168303914
NCT02654119,"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",0.0003242087491465528,0.00040984318143828336
NCT02672189,Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms,0.0003151580527104628,0.00032361688067716757
NCT02628613,Neoadjuvant Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Epirubicin for TEKT4 Variation Breast Cancer Patients,0.0003098095156772611,0.0003780676628871838
NCT02612012,Axillary Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes,0.00026154600955290977,0.00031395423686850704
NCT02639832,A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.,0.00026975446190534886,0.0003201533201246823
NCT02644382,Improving Surgical Decision-making in Young Women With Breast Cancer,0.00035371122771402905,0.0002786427043391759
NCT02669576,Mind-Body Medicine Day Care Clinic in Breast Cancer Patients Undergoing Endocrine Therapy,0.00031821024923582206,0.00030101365713058355
NCT02669745,The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients,0.00033271185716264725,0.0003598847780863843
NCT02688257,Assessing Treatment Response in Breast Cancer With Functional Imaging,0.000311266933964673,0.00036967730965986275
NCT02688725,Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer Patients,0.0003171020339531328,0.000321081341972342
NCT02616133,HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program,0.0004752138787630337,0.0002857171903512913
NCT02664103,Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer,0.0003445052133079005,0.0003844697112253303
NCT02664662,The Validation of Tailored Rehabilitated Education in Breast Cancer Survivors After Surgery,0.0003551674500420325,0.00031097661540988486
NCT02647216,Mindfulness for Breast Cancer,0.0004705417050958934,0.00032411945979724617
NCT02661932,Fertility Preservation in Breast Cancer Patients,0.0004312917988989582,0.00037618522117921667
NCT02671097,"Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate",0.0002645264370594992,0.0002806196827889467
NCT02663973,Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III,0.0002578522824531414,0.0003963672691264134
NCT02620735,Smart-phone Health Coaching Intervention to Promote Maintenance of Exercise in Breast Cancer Survivors:Protocol,0.00026105414596671136,0.0003038119331891127
NCT02620280,Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1,0.0003586243966269314,0.00033642536343990724
NCT02685111,"Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)",0.00030776486502475785,0.00022083629157214883
NCT02685306,A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer,0.00029964939449747226,0.0003495589527000211
NCT02621437,Impact of Osteopathy on Pain After Breast Cancer Surgery,0.0002938444452361703,0.0003313815694263578
NCT02613923,A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer,0.00026043340688773056,0.00029244829112258047
NCT02613026,Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer,0.00038106536062260967,0.0003953806055916755
NCT02610426,Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer,0.0003105760502195308,0.0003593290316157542
NCT02610920,Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection,0.00023752751190580411,0.0002531338947503923
NCT02610439,Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer,0.0002961556394797889,0.0003357464766672652
NCT02610413,Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer,0.00029213725809846235,0.00031756424801161087
NCT02610621,Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy,0.00029889350546251527,0.0002798396469620151
NCT02666378,Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer,0.0002870928169927677,0.0003027200165498312
NCT02666261,A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany,0.0003232627134799389,0.0003570038950498772
NCT02666079,Randomised Trial of LightPath Imaging in Breast Cancer Surgery,0.00035814922115894217,0.0002914222685907108
NCT02679586,Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy,0.00028946782689781515,0.00030540894510763323
NCT02679755,"Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer",0.00028827023812585283,0.0003887830113899968
NCT02679638,Factors and Perceptions Affecting Treatment Choices of Breast Cancer Patients,0.0003799811370420863,0.00033806178772121287
NCT02674204,STOP Heart Disease in Breast Cancer Survivors Trial,0.0004686810990771227,0.00037016503103180423
NCT02689921,NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer,0.00033852473528889844,0.00029879682208025623
NCT02627248,Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery,0.0002924580110194596,0.0003037347021391971
NCT02627703,(Oncotype DXÂ®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer,0.0002467352735938574,0.0002794649144277163
NCT02691624,Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation,0.00033189744538269134,0.0002944774623060838
NCT02601794,A Study of Delivering a Mindfulness App Intervention to Accompany Supportive Care Among Women With Breast Cancer,0.00029599541851557166,0.00027016411833869045
NCT02636582,Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer,0.00035216246657165256,0.00031878822444045214
NCT02670577,Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry,0.0003078377315808029,0.000373713180958525
NCT02670668,Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer,0.00034070539698454074,0.0003617215610208439
NCT02625441,"Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer",0.00029258680044790485,0.00032278120695486856
NCT02625935,Prospective Observational Study Evaluating Treatment Decision Impact of ProsignaÂ® in Early Stage Breast Cancer Patients,0.00034962811031909007,0.00031516881145792316
NCT02653105,Women at Risk of Breast Cancer and OLFM4,0.0008984903380354321,0.0002776398953410848
NCT02653755,The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer,0.00027696869816364424,0.0003310475205685972
NCT02690636,Conventional Versus Hypofractionated Radiotherapy in Node Positive Breast Cancer,0.0002637034939729705,0.00019552986594573152
NCT02690116,Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors,0.00025362200754097794,0.00030001547519662705
NCT02698891,Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer,0.00028273767967381633,0.00031635927168779737
NCT02650193,A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.,0.0003241378260579967,0.00030397546434587463
NCT02646735,Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients,0.0003250744702955439,0.00033286305284911216
NCT02632045,Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,0.00034182610126749183,0.0003235770120699306
NCT02676986,Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer,0.0003492120013494027,0.0003988123312449301
NCT02676531,Walking Meditation Exercise in Breast Cancer Patients,0.0003176853702071196,0.00037206623172833655
NCT02614794,Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer,0.0003540118601114408,0.00033314288744069334
NCT02600923,Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate,0.0002901395229501621,0.00040040875573550585
NCT02600442,Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers,0.0002746309890920633,0.00037628778604103516
NCT02600299,Effectiveness of a Psycho-educational Group (PEG) Intervention on Supportive Care and Survivorship Issues in Early-stage Breast Cancer Survivors Who Have Received Systemic Treatment,0.000267246961408284,0.00036057131969492793
NCT02617264,Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery,0.00029926825328524537,0.00030144965215667574
NCT02657343,"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",0.0002721295809370938,0.0003293820485058257
NCT02657889,Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer,0.0003281218616643933,0.00037059187184066924
NCT02604030,"Surgical Intervention and Physiotherapy in Breast Cancer: Effects in Scapular Kinematics, Pain and Upper Limb Function",0.0002507562119275347,0.00022415273424875693
NCT02677714,99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer,0.0003563493468213224,0.00029559413119143753
NCT02677857,Developing a Healthy Lifestyle in Breast Cancer Survivors,0.0008984903380354321,0.0002857128659994983
NCT02668666,Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,0.0002585167652335738,0.0003229032341339953
NCT02699983,Virtual Weight Loss Program in Maintaining Weight in African American Breast Cancer Survivors,0.00033418139480196105,0.0002557870784836959
NCT02681965,A Mail and Video-based Weight Loss Trial in Breast Cancer Survivors,0.0003350328940584663,0.0002773073083128678
NCT02681562,"Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients",0.0003171527625522091,0.0004042451012764361
NCT02681640,uPAR PET/CT for Preoperative Staging of Breast Cancer Patients,0.00043640747286960245,0.00035975709919783093
NCT02681523,ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.,0.00027952271925135497,0.0003141790983668489
NCT02681120,Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer,0.00024619308682432455,0.00026062618703688676
NCT02681107,APBI: 27Gy in 5 Fractions for Early Breast Cancer,0.0004688252076136453,0.0002943504343683998
NCT02609321,Efficacy of Thoracic Paravertebral Block in the Reduction of Acute Post-surgical Pain in Patients With Breast Cancer,0.0002993104632743789,0.0002718424643052691
NCT02673918,The Breast Cancer Online Rehabilitation Program,0.0003387502960543562,0.0002743629005417463
NCT02658461,An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC),0.0002760191934389274,0.00028066135135008214
NCT02658812,Talimogene Laherparepvec (T-VEC) for Breast Cancer Local Recurrence,0.0004729345411728429,0.00035845922924648187
NCT02658708,Bright Light on Fatigue in Women Being Treated for Breast Cancer,0.00033771646346454203,0.00033568378218224815
NCT02622711,Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer,0.0002559805787537484,0.00020714958626847594
NCT02606110,Pilot Study Investigating the Use of the ReBuilder to Treat Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer,0.0003717660859845739,0.0005561293848808224
NCT02683083,"Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients",0.0003302784876281996,0.0003932610007351051
NCT02648802,Cavity Shaving in Breast Conserving Surgery for Breast Cancer Patients,0.00035205152668716413,0.00029850273108302324
NCT02662335,Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors,0.00047038596881714107,0.0002804557678361523
